[
  {
    "objectID": "hei_total_score.html",
    "href": "hei_total_score.html",
    "title": "HEI Total Score",
    "section": "",
    "text": "Human Body Data Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\n\nHuman Body Data Variable\nN\nOverall\nN = 1501\n\nHEI Total Score (Using A Score Cutoff Of 50)\n\np-value2,3\n\n\n&lt;50\nN = 441\n≥50\nN = 1061\n\n\n\n\nSite_Collection\n150\n\n\n\n\n\n\n0.191\n\n\n    AUTH\n\n\n32 (21%)\n11 (25%)\n21 (20%)\n\n\n\n\n    CBG\n\n\n17 (11%)\n3 (6.8%)\n14 (13%)\n\n\n\n\n    ICL\n\n\n24 (16%)\n3 (6.8%)\n21 (20%)\n\n\n\n\n    TEAGASC\n\n\n49 (33%)\n17 (39%)\n32 (30%)\n\n\n\n\n    UVEG\n\n\n28 (19%)\n10 (23%)\n18 (17%)\n\n\n\n\ngender\n150\n\n\n\n\n\n\n0.048*\n\n\n    Female\n\n\n98 (65%)\n34 (77%)\n64 (60%)\n\n\n\n\n    Male\n\n\n52 (35%)\n10 (23%)\n42 (40%)\n\n\n\n\nage_value\n150\n1.96 (1.70, 2.30)\n2.00 (1.70, 2.30)\n1.91 (1.70, 2.30)\n0.742\n\n\nrisk_group_cardiovascular\n150\n\n\n\n\n\n\n0.710\n\n\n    I\n\n\n57 (38%)\n18 (41%)\n39 (37%)\n\n\n\n\n    II\n\n\n15 (10%)\n3 (6.8%)\n12 (11%)\n\n\n\n\n    III\n\n\n3 (2.0%)\n0 (0%)\n3 (2.8%)\n\n\n\n\n    Normal\n\n\n75 (50%)\n23 (52%)\n52 (49%)\n\n\n\n\nai\n150\n-58 (-84, -31)\n-57 (-77, -26)\n-62 (-85, -31)\n0.641\n\n\nae\n150\n-77 (-85, -64)\n-76 (-85, -61)\n-77 (-85, -64)\n0.890\n\n\npe\n150\n-30 (-37, -19)\n-31 (-36, -19)\n-29 (-38, -19)\n0.678\n\n\nans_activity\n150\n108 (93, 126)\n104 (94, 133)\n110 (92, 125)\n0.926\n\n\nans_balance\n150\n66 (35, 102)\n58 (38, 91)\n71 (34, 103)\n0.165\n\n\nstress_resilience\n150\n108 (91, 131)\n106 (93, 136)\n108 (89, 128)\n0.474\n\n\nstress_index\n150\n92 (75, 108)\n96 (70, 109)\n92 (76, 108)\n0.874\n\n\nfatigue_index\n150\n87 (68, 103)\n85 (65, 98)\n88 (69, 105)\n0.414\n\n\nmean_hrt\n150\n71 (64, 79)\n71 (63, 80)\n71 (64, 78)\n0.828\n\n\nelectro_cardiac_stability\n150\n109 (97, 128)\n109 (96, 128)\n109 (97, 124)\n0.874\n\n\nectopic_beat\n150\n0.0 (0.0, 1.0)\n0.0 (0.0, 1.5)\n0.0 (0.0, 1.0)\n0.635\n\n\nsdnn\n150\n35 (26, 47)\n35 (26, 55)\n35 (25, 46)\n0.469\n\n\npsi\n150\n44 (23, 74)\n50 (21, 76)\n44 (23, 68)\n0.877\n\n\ntp\n150\n903 (464, 1,812)\n768 (512, 2,114)\n996 (464, 1,740)\n0.959\n\n\nvlf\n150\n295 (165, 705)\n272 (160, 685)\n303 (169, 705)\n0.681\n\n\nlf\n150\n276 (139, 542)\n289 (148, 632)\n262 (121, 513)\n0.471\n\n\nhf\n150\n183 (97, 395)\n222 (85, 404)\n176 (101, 395)\n0.746\n\n\nlfnorm\n150\n56 (41, 75)\n55 (41, 73)\n57 (42, 75)\n0.977\n\n\nhfnorm\n150\n44 (25, 59)\n45 (27, 59)\n43 (25, 58)\n0.977\n\n\nlf_hf_ratio\n150\n1.26 (0.70, 2.95)\n1.23 (0.69, 2.78)\n1.30 (0.73, 2.95)\n0.982\n\n\nrmssd\n150\n26 (18, 38)\n27 (18, 43)\n26 (17, 36)\n0.363\n\n\napen\n150\n0.98 (0.81, 1.08)\n0.98 (0.87, 1.07)\n0.98 (0.79, 1.09)\n0.749\n\n\nsrd\n150\n0.98 (0.90, 1.07)\n0.97 (0.91, 1.03)\n0.98 (0.90, 1.08)\n0.732\n\n\ntsrd\n150\n119 (89, 152)\n117 (92, 154)\n120 (88, 146)\n0.544\n\n\ntp_ln\n150\n6.81 (6.14, 7.50)\n6.64 (6.23, 7.66)\n6.90 (6.14, 7.46)\n0.956\n\n\nvlf_ln\n150\n5.69 (5.10, 6.56)\n5.60 (5.08, 6.53)\n5.71 (5.13, 6.56)\n0.680\n\n\nlf_ln\n150\n5.62 (4.94, 6.30)\n5.67 (4.99, 6.45)\n5.57 (4.80, 6.24)\n0.464\n\n\nhf_ln\n150\n5.21 (4.57, 5.98)\n5.40 (4.44, 6.00)\n5.17 (4.61, 5.98)\n0.741\n\n\nage\n150\n51 (43, 58)\n51 (45, 58)\n51 (43, 58)\n0.798\n\n\ntbw\n150\n39 (35, 48)\n37 (32, 43)\n40 (35, 49)\n0.022*\n\n\nicw\n150\n24.5 (21.3, 29.6)\n23.1 (20.0, 26.7)\n25.2 (21.9, 30.6)\n0.030*\n\n\necw\n150\n14.9 (13.0, 18.2)\n14.3 (12.2, 16.8)\n15.5 (13.7, 18.4)\n0.018*\n\n\nprotein\n150\n10.60 (9.20, 12.70)\n10.00 (8.65, 11.60)\n10.90 (9.40, 13.20)\n0.029*\n\n\nminerals\n150\n3.83 (3.26, 4.58)\n3.57 (3.17, 4.20)\n3.89 (3.37, 4.68)\n0.014*\n\n\nbfm\n150\n33 (26, 43)\n32 (25, 38)\n35 (27, 45)\n0.131\n\n\nslm\n150\n51 (45, 61)\n48 (41, 56)\n52 (45, 63)\n0.025*\n\n\nffm\n150\n54 (47, 65)\n51 (44, 59)\n55 (48, 67)\n0.024*\n\n\nsmm\n150\n30 (26, 37)\n28 (24, 33)\n31 (27, 38)\n0.031*\n\n\nbmi\n150\n30.6 (28.5, 35.2)\n29.6 (27.7, 33.6)\n31.4 (28.9, 35.7)\n0.052\n\n\npbf\n150\n39 (33, 44)\n40 (33, 44)\n39 (33, 44)\n0.856\n\n\nlean_mass_of_right_arm\n150\n3.02 (2.45, 3.77)\n2.77 (2.24, 3.36)\n3.07 (2.62, 3.84)\n0.018*\n\n\nlean_mass_percent_of_right_arm\n150\n109 (102, 117)\n109 (102, 118)\n109 (102, 116)\n0.880\n\n\nlean_mass_of_left_arm\n150\n2.97 (2.45, 3.71)\n2.79 (2.28, 3.28)\n3.08 (2.59, 3.81)\n0.032*\n\n\nlean_mass_percent_of_left_arm\n150\n109 (101, 116)\n110 (101, 116)\n109 (100, 116)\n0.532\n\n\nlean_mass_of_trunk\n150\n24.3 (20.9, 28.8)\n23.3 (20.0, 26.5)\n25.3 (22.1, 29.8)\n0.025*\n\n\nlean_mass_percent_of_trunk\n150\n103.7 (99.7, 108.0)\n104.4 (99.9, 109.1)\n103.4 (99.7, 107.9)\n0.446\n\n\nlean_mass_of_right_leg\n150\n7.90 (6.62, 9.80)\n7.43 (6.30, 9.13)\n8.17 (6.95, 10.09)\n0.015*\n\n\nlean_mass_percent_of_right_leg\n150\n97 (92, 103)\n95 (91, 101)\n98 (93, 103)\n0.193\n\n\nlean_mass_of_left_leg\n150\n7.88 (6.63, 9.81)\n7.45 (6.32, 9.18)\n8.12 (6.95, 10.02)\n0.016*\n\n\nlean_mass_percent_of_left_leg\n150\n97 (92, 103)\n96 (90, 101)\n98 (93, 104)\n0.255\n\n\ntbw_of_right_arm\n150\n2.34 (1.91, 2.94)\n2.16 (1.75, 2.61)\n2.39 (2.04, 2.98)\n0.018*\n\n\ntbw_of_left_arm\n150\n2.32 (1.91, 2.89)\n2.17 (1.78, 2.55)\n2.40 (2.01, 2.96)\n0.031*\n\n\ntbw_of_trunk\n150\n18.9 (16.3, 22.5)\n18.2 (15.6, 20.7)\n19.7 (17.2, 23.3)\n0.023*\n\n\ntbw_of_right_leg\n150\n6.18 (5.15, 7.65)\n5.79 (4.91, 7.10)\n6.37 (5.42, 7.85)\n0.015*\n\n\ntbw_of_left_leg\n150\n6.13 (5.16, 7.66)\n5.83 (4.91, 7.15)\n6.34 (5.42, 7.83)\n0.016*\n\n\nicw_of_right_arm\n150\n1.46 (1.19, 1.82)\n1.34 (1.09, 1.63)\n1.48 (1.27, 1.86)\n0.020*\n\n\nicw_of_left_arm\n150\n1.43 (1.18, 1.79)\n1.35 (1.11, 1.58)\n1.48 (1.25, 1.84)\n0.036*\n\n\nicw_of_trunk\n150\n11.75 (10.10, 13.90)\n11.20 (9.70, 12.65)\n12.10 (10.70, 14.10)\n0.029*\n\n\nicw_of_right_leg\n150\n3.80 (3.21, 4.73)\n3.60 (3.06, 4.41)\n3.91 (3.35, 4.84)\n0.018*\n\n\nicw_of_left_leg\n150\n3.81 (3.20, 4.73)\n3.57 (3.07, 4.44)\n3.89 (3.34, 4.83)\n0.018*\n\n\necw_of_right_arm\n150\n0.88 (0.72, 1.12)\n0.82 (0.66, 0.99)\n0.91 (0.76, 1.14)\n0.015*\n\n\necw_of_left_arm\n150\n0.88 (0.72, 1.09)\n0.83 (0.68, 0.97)\n0.91 (0.75, 1.13)\n0.028*\n\n\necw_of_trunk\n150\n7.20 (6.20, 8.60)\n6.90 (5.95, 8.00)\n7.50 (6.40, 8.90)\n0.018*\n\n\necw_of_right_leg\n150\n2.39 (1.98, 2.91)\n2.23 (1.86, 2.64)\n2.46 (2.03, 2.99)\n0.017*\n\n\necw_of_left_leg\n150\n2.38 (2.00, 2.91)\n2.24 (1.85, 2.67)\n2.44 (2.05, 2.96)\n0.017*\n\n\necw_tbw_ratio\n150\n0.381 (0.377, 0.386)\n0.379 (0.375, 0.384)\n0.382 (0.377, 0.387)\n0.074\n\n\necw_tbw_ratio_of_right_arm\n150\n0.378 (0.375, 0.381)\n0.378 (0.374, 0.381)\n0.378 (0.376, 0.381)\n0.575\n\n\necw_tbw_ratio_of_left_arm\n150\n0.380 (0.377, 0.382)\n0.379 (0.377, 0.382)\n0.380 (0.377, 0.382)\n0.270\n\n\necw_tbw_ratio_of_trunk\n150\n0.382 (0.377, 0.386)\n0.379 (0.376, 0.384)\n0.383 (0.377, 0.386)\n0.097\n\n\necw_tbw_ratio_of_right_leg\n150\n0.382 (0.376, 0.388)\n0.379 (0.374, 0.386)\n0.383 (0.377, 0.388)\n0.061\n\n\necw_tbw_ratio_of_left_leg\n150\n0.382 (0.377, 0.388)\n0.381 (0.375, 0.386)\n0.383 (0.377, 0.388)\n0.059\n\n\nbfm_of_right_arm\n150\n2.70 (1.90, 3.90)\n2.40 (1.80, 3.35)\n3.00 (2.00, 4.30)\n0.185\n\n\nbfm_percent_of_right_arm\n150\n319 (232, 530)\n283 (205, 396)\n335 (250, 559)\n0.068\n\n\nbfm_of_left_arm\n150\n2.70 (1.90, 4.00)\n2.50 (1.80, 3.40)\n3.00 (2.00, 4.40)\n0.159\n\n\nbfm_percent_of_left_arm\n150\n323 (239, 538)\n284 (209, 403)\n340 (251, 565)\n0.059\n\n\nbfm_of_trunk\n150\n17.5 (13.6, 22.0)\n16.2 (13.0, 19.7)\n17.9 (14.0, 22.3)\n0.146\n\n\nbfm_percent_of_trunk\n150\n340 (284, 454)\n322 (269, 394)\n352 (293, 468)\n0.085\n\n\nbfm_of_right_leg\n150\n4.65 (3.60, 6.00)\n4.10 (3.55, 5.35)\n4.80 (3.70, 6.10)\n0.155\n\n\nbfm_percent_of_right_leg\n150\n208 (175, 277)\n190 (165, 229)\n214 (181, 290)\n0.046*\n\n\nbfm_of_left_leg\n150\n4.60 (3.60, 6.00)\n4.10 (3.50, 5.35)\n4.80 (3.70, 6.10)\n0.154\n\n\nbfm_percent_of_left_leg\n150\n208 (176, 277)\n190 (164, 229)\n214 (181, 289)\n0.046*\n\n\ninbody_score\n150\n66 (59, 71)\n68 (62, 72)\n66 (57, 71)\n0.221\n\n\ntarget_weight\n150\n69 (61, 78)\n66 (57, 76)\n70 (62, 81)\n0.037*\n\n\nweight_control\n150\n-20 (-30, -13)\n-17 (-23, -12)\n-21 (-31, -13)\n0.110\n\n\nbfm_control\n150\n-20 (-30, -13)\n-17 (-23, -12)\n-21 (-31, -14)\n0.108\n\n\nffm_control\n150\n\n\n\n\n\n\n0.458\n\n\n    0\n\n\n141 (94%)\n41 (93%)\n100 (94%)\n\n\n\n\n    0.2\n\n\n2 (1.3%)\n0 (0%)\n2 (1.9%)\n\n\n\n\n    0.3\n\n\n1 (0.7%)\n0 (0%)\n1 (0.9%)\n\n\n\n\n    0.4\n\n\n1 (0.7%)\n1 (2.3%)\n0 (0%)\n\n\n\n\n    0.8\n\n\n2 (1.3%)\n1 (2.3%)\n1 (0.9%)\n\n\n\n\n    2\n\n\n1 (0.7%)\n0 (0%)\n1 (0.9%)\n\n\n\n\n    3.7\n\n\n1 (0.7%)\n1 (2.3%)\n0 (0%)\n\n\n\n\n    6.3\n\n\n1 (0.7%)\n0 (0%)\n1 (0.9%)\n\n\n\n\nbmr\n150\n1,534 (1,386, 1,766)\n1,474 (1,314, 1,642)\n1,564 (1,405, 1,816)\n0.025*\n\n\nwhr\n150\n0.99 (0.93, 1.04)\n0.97 (0.94, 1.02)\n1.00 (0.93, 1.05)\n0.259\n\n\nvfa\n150\n165 (123, 214)\n153 (117, 197)\n179 (128, 214)\n0.181\n\n\nobesity_degree\n150\n145 (132, 165)\n140 (130, 163)\n147 (133, 165)\n0.186\n\n\nbcm\n150\n35 (31, 42)\n33 (29, 38)\n36 (31, 44)\n0.030*\n\n\nac\n150\n35.9 (33.9, 39.4)\n35.1 (33.3, 38.3)\n36.2 (34.2, 39.5)\n0.153\n\n\namc\n150\n29.6 (27.8, 32.3)\n29.4 (27.4, 32.3)\n29.8 (28.0, 32.3)\n0.212\n\n\nbmc\n150\n3.17 (2.74, 3.78)\n2.96 (2.64, 3.53)\n3.24 (2.79, 3.88)\n0.019*\n\n\ntbw_ffm_ratio\n150\n73.30 (73.10, 73.50)\n73.30 (73.10, 73.50)\n73.30 (73.10, 73.50)\n0.676\n\n\nffmi\n150\n19.80 (17.70, 21.40)\n18.90 (17.30, 21.05)\n20.00 (18.20, 21.50)\n0.080\n\n\nfmi\n150\n12.1 (9.3, 15.0)\n11.3 (9.5, 14.8)\n12.3 (9.3, 15.1)\n0.489\n\n\nkhz_ra_5_phase_angle\n150\n2.60 (2.20, 2.80)\n2.60 (2.20, 2.80)\n2.60 (2.20, 2.70)\n0.816\n\n\nkhz_la_5_phase_angle\n150\n2.40 (2.10, 2.70)\n2.50 (2.10, 2.65)\n2.40 (2.10, 2.70)\n0.942\n\n\nkhz_tr_5_phase_angle\n150\n3.35 (2.80, 3.80)\n3.40 (2.70, 4.00)\n3.30 (2.90, 3.80)\n0.686\n\n\nkhz_rl_5_phase_angle\n150\n2.60 (2.40, 2.90)\n2.70 (2.40, 2.90)\n2.60 (2.30, 2.90)\n0.562\n\n\nkhz_ll_5_phase_angle\n150\n2.60 (2.30, 2.80)\n2.70 (2.30, 2.90)\n2.50 (2.30, 2.80)\n0.399\n\n\nkhz_ra_50_phase_angle\n150\n5.20 (4.90, 5.60)\n5.10 (4.85, 5.55)\n5.20 (4.90, 5.60)\n0.532\n\n\nkhz_la_50_phase_angle\n150\n5.00 (4.70, 5.40)\n5.05 (4.70, 5.50)\n5.00 (4.70, 5.40)\n0.928\n\n\nkhz_tr_50_phase_angle\n150\n7.40 (6.80, 8.10)\n7.20 (6.75, 8.10)\n7.40 (6.80, 8.10)\n0.666\n\n\nkhz_rl_50_phase_angle\n150\n5.70 (5.20, 6.30)\n5.90 (5.30, 6.45)\n5.70 (5.20, 6.20)\n0.236\n\n\nkhz_ll_50_phase_angle\n150\n5.60 (5.20, 6.20)\n5.75 (5.20, 6.40)\n5.60 (5.20, 6.00)\n0.335\n\n\nkhz_ra_250_phase_angle\n150\n4.80 (4.50, 5.00)\n4.80 (4.50, 5.00)\n4.75 (4.50, 5.10)\n0.668\n\n\nkhz_la_250_phase_angle\n150\n4.50 (4.30, 4.80)\n4.50 (4.30, 4.80)\n4.50 (4.30, 4.80)\n0.872\n\n\nkhz_tr_250_phase_angle\n150\n7.60 (7.00, 8.30)\n7.70 (7.15, 8.30)\n7.60 (6.80, 8.20)\n0.366\n\n\nkhz_rl_250_phase_angle\n150\n4.40 (4.10, 4.60)\n4.50 (4.20, 4.70)\n4.40 (4.10, 4.60)\n0.368\n\n\nkhz_ll_250_phase_angle\n150\n4.60 (4.30, 4.80)\n4.70 (4.35, 4.90)\n4.50 (4.30, 4.80)\n0.255\n\n\nKhz_50_whole_body_phase_angle\n150\n5.50 (5.10, 6.00)\n5.55 (5.00, 6.00)\n5.50 (5.10, 5.90)\n0.890\n\n\nmeasured_circumference_of_neck\n150\n39.4 (37.0, 42.5)\n38.3 (36.1, 41.7)\n39.8 (37.4, 42.9)\n0.112\n\n\nmeasured_circumference_of_chest\n150\n106 (101, 114)\n104 (98, 112)\n106 (102, 115)\n0.087\n\n\nmeasured_circumference_of_abdomen\n150\n106 (96, 120)\n100 (95, 112)\n107 (97, 122)\n0.067\n\n\nmeasured_circumference_of_hip\n150\n107 (103, 115)\n106 (101, 111)\n108 (104, 116)\n0.066\n\n\nmeasured_circumference_of_right_arm\n150\n36.1 (34.0, 39.7)\n35.2 (33.4, 38.7)\n36.3 (34.5, 39.8)\n0.144\n\n\nmeasured_circumference_of_left_arm\n150\n35.9 (33.9, 39.4)\n35.1 (33.3, 38.3)\n36.2 (34.2, 39.5)\n0.153\n\n\nmeasured_circumference_of_right_thigh\n150\n58.7 (55.8, 62.5)\n57.9 (54.8, 60.8)\n59.6 (56.1, 63.2)\n0.040*\n\n\nmeasured_circumference_of_left_thigh\n150\n58.7 (55.5, 62.5)\n57.6 (54.9, 60.8)\n59.2 (56.2, 62.9)\n0.049*\n\n\ninbody_type\n150\n\n\n\n\n\n\n\n\n\n\n    970\n\n\n150 (100%)\n44 (100%)\n106 (100%)\n\n\n\n\nsmi\n150\n8.00 (7.10, 8.80)\n7.60 (6.90, 8.45)\n8.10 (7.20, 8.90)\n0.025*\n\n\nsmi_t_score\n150\n0.30 (-0.30, 1.20)\n0.20 (-0.40, 1.20)\n0.40 (-0.30, 1.20)\n0.550\n\n\nsmi_z_score\n150\n0.30 (-0.40, 1.20)\n0.15 (-0.45, 1.15)\n0.30 (-0.40, 1.20)\n0.518\n\n\nwhole_body_ecw_tbw_ratio_t_score\n150\n1.10 (0.30, 2.10)\n0.80 (0.10, 1.60)\n1.20 (0.60, 2.20)\n0.017*\n\n\nwhole_body_ecw_tbw_ratio_z_score\n150\n0.25 (-0.40, 1.00)\n0.05 (-0.70, 0.70)\n0.40 (-0.30, 1.20)\n0.022*\n\n\nvfa_t_score\n150\n2.45 (1.30, 3.80)\n1.90 (1.10, 3.10)\n2.60 (1.40, 4.00)\n0.051\n\n\nvfa_z_score\n150\n1.30 (0.40, 2.40)\n1.00 (0.40, 1.90)\n1.45 (0.50, 2.60)\n0.088\n\n\nbmi_t_score\n150\n1.10 (0.60, 2.20)\n0.90 (0.45, 1.90)\n1.30 (0.70, 2.40)\n0.135\n\n\nbmi_z_score\n150\n0.70 (0.10, 1.70)\n0.50 (0.05, 1.60)\n0.80 (0.20, 1.80)\n0.184\n\n\nsubcutaneous_fat\n150\n\n\n\n\n\n\n\n\n\n\n    0\n\n\n150 (100%)\n44 (100%)\n106 (100%)\n\n\n\n\narms_legs_fat_ratio\n150\n15 (11, 20)\n13 (11, 17)\n15 (11, 21)\n0.163\n\n\nvisceral_fat\n150\n\n\n\n\n\n\n\n\n\n\n    0\n\n\n150 (100%)\n44 (100%)\n106 (100%)\n\n\n\n\nabdominal_fat\n150\n\n\n\n\n\n\n\n\n\n\n    0\n\n\n150 (100%)\n44 (100%)\n106 (100%)\n\n\n\n\nv_s_ratio\n150\n\n\n\n\n\n\n\n\n\n\n    0\n\n\n150 (100%)\n44 (100%)\n106 (100%)\n\n\n\n\nsfa\n150\n\n\n\n\n\n\n\n\n\n\n    0\n\n\n150 (100%)\n44 (100%)\n106 (100%)\n\n\n\n\nwhtr\n150\n0.63 (0.58, 0.70)\n0.61 (0.57, 0.69)\n0.64 (0.59, 0.71)\n0.395\n\n\nbai\n150\n31.4 (28.4, 35.7)\n31.3 (28.6, 35.7)\n31.5 (28.2, 35.4)\n0.707\n\n\nabsi\n150\n0.081 (0.079, 0.084)\n0.081 (0.079, 0.083)\n0.082 (0.078, 0.084)\n0.728\n\n\nconicity_index\n150\n1.35 (1.28, 1.40)\n1.33 (1.29, 1.38)\n1.35 (1.28, 1.41)\n0.286\n\n\nsvr\n150\n0.18 (0.14, 0.24)\n0.18 (0.15, 0.23)\n0.18 (0.13, 0.24)\n0.959\n\n\nkhz_50_ab_impedance\n150\n\n\n\n\n\n\n\n\n\n\n    0\n\n\n150 (100%)\n44 (100%)\n106 (100%)\n\n\n\n\nkhz_250_ab_impedance\n150\n\n\n\n\n\n\n\n\n\n\n    0\n\n\n150 (100%)\n44 (100%)\n106 (100%)\n\n\n\n\nwc\n150\n106 (96, 120)\n100 (95, 112)\n107 (97, 122)\n0.067\n\n\nangle_r\n150\n\n\n\n\n\n\n\n\n\n\n    0\n\n\n150 (100%)\n44 (100%)\n106 (100%)\n\n\n\n\nangle_l\n150\n\n\n\n\n\n\n\n\n\n\n    0\n\n\n150 (100%)\n44 (100%)\n106 (100%)\n\n\n\n\nsmm_wt_ratio\n150\n33.7 (30.8, 37.2)\n33.2 (31.2, 37.1)\n34.0 (30.6, 37.3)\n0.793\n\n\nbfm_percent_of_whole_body\n150\n335 (266, 435)\n307 (263, 418)\n353 (269, 444)\n0.303\n\n\necm_bcm_ratio\n150\n0.538 (0.529, 0.548)\n0.535 (0.526, 0.546)\n0.541 (0.531, 0.550)\n0.078\n\n\ntbw_wt_ratio\n150\n45 (41, 49)\n44 (41, 49)\n45 (41, 49)\n0.864\n\n\nbcm_t_score\n150\n0.20 (-0.50, 1.00)\n-0.10 (-0.50, 1.10)\n0.20 (-0.50, 0.80)\n0.747\n\n\nbcm_z_score\n150\n0.45 (-0.30, 1.30)\n0.25 (-0.30, 1.35)\n0.55 (-0.30, 1.30)\n0.545\n\n\nffmi_t_score\n150\n0.50 (-0.40, 1.30)\n0.50 (-0.45, 1.30)\n0.50 (-0.30, 1.30)\n0.874\n\n\nffmi_z_score\n150\n0.55 (-0.40, 1.30)\n0.45 (-0.50, 1.35)\n0.60 (-0.40, 1.30)\n0.827\n\n\nfmi_t_score\n150\n1.30 (0.70, 2.60)\n1.10 (0.50, 1.75)\n1.40 (0.80, 2.80)\n0.076\n\n\nfmi_z_score\n150\n0.80 (0.10, 1.90)\n0.50 (0.10, 1.35)\n0.90 (0.30, 2.00)\n0.167\n\n\npbf_t_score\n150\n1.40 (0.80, 2.00)\n1.15 (0.60, 1.65)\n1.40 (0.90, 2.10)\n0.052\n\n\npbf_z_score\n150\n0.90 (0.30, 1.60)\n0.70 (0.30, 1.10)\n0.90 (0.30, 1.70)\n0.121\n\n\nweight_t_score\n150\n1.10 (0.30, 2.20)\n0.85 (0.20, 1.65)\n1.25 (0.40, 2.30)\n0.114\n\n\nweight_z_score\n150\n0.60 (0.00, 1.70)\n0.35 (-0.20, 1.30)\n0.90 (0.10, 1.80)\n0.120\n\n\nwhr_t_score\n150\n1.10 (0.30, 1.70)\n0.90 (0.40, 1.50)\n1.10 (0.30, 1.80)\n0.317\n\n\nwhr_z_score\n150\n0.55 (-0.10, 1.10)\n0.40 (0.00, 0.90)\n0.60 (-0.20, 1.30)\n0.436\n\n\nkhz_whole_body_phase_angle_t_score\n150\n-0.70 (-1.50, -0.10)\n-0.45 (-1.40, 0.20)\n-0.80 (-1.60, -0.10)\n0.116\n\n\nkhz_whole_body_phase_angle_z_score\n150\n-0.10 (-1.00, 0.60)\n-0.10 (-0.70, 0.70)\n-0.15 (-1.00, 0.50)\n0.289\n\n\ntbw_wt_ratio_t_score\n150\n-1.40 (-2.00, -0.80)\n-1.15 (-1.60, -0.60)\n-1.40 (-2.10, -0.90)\n0.042*\n\n\ntbw_wt_ratio_z_score\n150\n-0.90 (-1.60, -0.30)\n-0.70 (-1.10, -0.30)\n-0.90 (-1.70, -0.30)\n0.132\n\n\nsmm_wt_ratio_t_score\n150\n-1.40 (-2.00, -0.80)\n-1.15 (-1.70, -0.65)\n-1.50 (-2.20, -1.00)\n0.032*\n\n\nsmm_wt_ratio_z_score\n150\n-0.90 (-1.60, -0.30)\n-0.70 (-1.15, -0.30)\n-0.95 (-1.70, -0.30)\n0.120\n\n\necm_bcm_ratio_t_score\n150\n1.00 (0.10, 1.80)\n0.45 (-0.25, 1.25)\n1.10 (0.20, 2.10)\n0.014*\n\n\necm_bcm_ratio_z_score\n150\n0.20 (-0.50, 1.00)\n-0.10 (-0.85, 0.65)\n0.35 (-0.40, 1.30)\n0.020*\n\n\nr_ht_ratio\n150\n335 (283, 380)\n356 (306, 400)\n325 (275, 368)\n0.009**\n\n\nxc_ht_ratio\n150\n32.3 (28.5, 35.8)\n33.1 (31.0, 38.1)\n31.7 (27.5, 35.1)\n0.025*\n\n\n\nP-values are unadjusted.\n\n\n1 n (%); Median (Q1, Q3)\n\n\n2 Fisher’s exact test; Pearson’s Chi-squared test; Wilcoxon rank sum test; NA\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nBiochemical Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\n\nBiochemical Variable\nN\nOverall\nN = 1501\n\nHEI Total Score (Using A Score Cutoff Of 50)\n\np-value2,3\n\n\n&lt;50\nN = 441\n≥50\nN = 1061\n\n\n\n\nCHOL\n150\n203 (184, 233)\n207 (189, 239)\n202 (182, 231)\n0.324\n\n\nLDL\n150\n139 (113, 158)\n144 (118, 168)\n136 (110, 157)\n0.100\n\n\nLDL_Detected\n150\n147 (98%)\n44 (100%)\n103 (97%)\n0.556\n\n\nHbA1c_Perc\n150\n5.60 (5.35, 5.90)\n5.70 (5.33, 5.95)\n5.57 (5.36, 5.90)\n0.788\n\n\nHbA1c_Perc_Detected\n150\n148 (99%)\n44 (100%)\n104 (98%)\n&gt;0.999\n\n\nUREA\n150\n29 (24, 34)\n28 (22, 32)\n29 (25, 34)\n0.166\n\n\nUREA_Detected\n150\n\n\n\n\n\n\n\n\n\n\n    Yes\n\n\n150 (100%)\n44 (100%)\n106 (100%)\n\n\n\n\nCREA\n150\n0.79 (0.70, 0.90)\n0.79 (0.67, 0.90)\n0.79 (0.70, 0.91)\n0.418\n\n\nOH_Vit_D3\n150\n23 (19, 27)\n23 (20, 28)\n23 (19, 27)\n0.928\n\n\nOH_Vit_D3_Detected\n150\n103 (69%)\n30 (68%)\n73 (69%)\n0.934\n\n\nALB\n150\n4.40 (4.10, 4.69)\n4.34 (4.20, 4.70)\n4.40 (4.00, 4.60)\n0.411\n\n\nALB_Detected\n150\n149 (99%)\n44 (100%)\n105 (99%)\n&gt;0.999\n\n\nTBIL\n150\n0.55 (0.41, 0.75)\n0.52 (0.40, 0.73)\n0.57 (0.41, 0.76)\n0.449\n\n\nTBIL_Detected\n150\n146 (97%)\n43 (98%)\n103 (97%)\n&gt;0.999\n\n\nNa\n150\n140.00 (139.00, 142.00)\n140.00 (138.20, 141.90)\n141.00 (139.00, 142.00)\n0.124\n\n\nK\n150\n4.45 (4.20, 4.70)\n4.56 (4.20, 4.77)\n4.40 (4.20, 4.65)\n0.111\n\n\nK_Detected\n150\n148 (99%)\n44 (100%)\n104 (98%)\n&gt;0.999\n\n\nCRP\n150\n0.29 (0.12, 0.91)\n0.24 (0.10, 0.91)\n0.34 (0.13, 0.91)\n0.427\n\n\nCRP_Detected\n150\n\n\n\n\n\n\n\n\n\n\n    Yes\n\n\n150 (100%)\n44 (100%)\n106 (100%)\n\n\n\n\nWBC\n150\n6.21 (5.17, 7.66)\n6.68 (5.49, 7.82)\n5.96 (4.93, 7.61)\n0.309\n\n\nRBC\n150\n4.74 (4.47, 5.02)\n4.64 (4.28, 4.87)\n4.75 (4.51, 5.05)\n0.031*\n\n\nHCT_Perc\n150\n42.7 (40.0, 44.6)\n42.2 (39.8, 44.0)\n43.0 (40.1, 45.0)\n0.137\n\n\nHGB\n150\n14.10 (13.10, 15.10)\n13.80 (13.15, 14.40)\n14.20 (13.10, 15.30)\n0.076\n\n\nNEU_Perc\n150\n57 (51, 62)\n57 (52, 64)\n57 (50, 61)\n0.719\n\n\nLYM_Perc\n150\n32 (28, 37)\n30 (27, 35)\n32 (28, 37)\n0.417\n\n\nMONO_Perc\n150\n7.29 (5.90, 9.10)\n6.97 (5.85, 9.14)\n7.34 (5.97, 9.09)\n0.644\n\n\nBASO_Perc\n150\n0.80 (0.60, 1.28)\n0.76 (0.60, 1.05)\n0.89 (0.58, 1.33)\n0.373\n\n\nBASO_Perc_Detected\n150\n139 (93%)\n42 (95%)\n97 (92%)\n0.509\n\n\nEOS_Perc\n150\n2.80 (1.63, 3.91)\n3.16 (1.63, 4.21)\n2.73 (1.63, 3.77)\n0.700\n\n\nEOS_Perc_Detected\n150\n148 (99%)\n44 (100%)\n104 (98%)\n&gt;0.999\n\n\nMVC\n150\n90.1 (86.5, 93.0)\n91.0 (87.6, 93.2)\n89.7 (86.0, 92.7)\n0.112\n\n\nMCH\n150\n30.00 (29.00, 31.00)\n30.25 (29.00, 31.00)\n30.00 (28.80, 31.00)\n0.341\n\n\nMCHC\n150\n33.30 (32.50, 34.10)\n33.10 (32.35, 34.05)\n33.45 (32.50, 34.10)\n0.393\n\n\nRDW_CV_Perc\n150\n13.00 (12.30, 13.70)\n13.10 (12.15, 13.95)\n12.90 (12.40, 13.70)\n0.825\n\n\nNEU\n150\n3.45 (2.74, 4.52)\n3.61 (2.96, 4.67)\n3.40 (2.72, 4.44)\n0.348\n\n\nLYM\n150\n1.92 (1.55, 2.38)\n2.03 (1.66, 2.37)\n1.91 (1.52, 2.40)\n0.510\n\n\nMONO\n150\n0.45 (0.39, 0.56)\n0.48 (0.39, 0.56)\n0.45 (0.39, 0.56)\n0.716\n\n\nBASO\n150\n0.050 (0.040, 0.080)\n0.055 (0.040, 0.070)\n0.050 (0.040, 0.080)\n0.607\n\n\nBASO_Detected\n150\n139 (93%)\n42 (95%)\n97 (92%)\n0.509\n\n\nEOS\n150\n0.17 (0.10, 0.24)\n0.18 (0.11, 0.27)\n0.17 (0.10, 0.23)\n0.437\n\n\nEOS_Detected\n150\n148 (99%)\n44 (100%)\n104 (98%)\n&gt;0.999\n\n\nPLT\n150\n265 (228, 301)\n291 (261, 324)\n257 (224, 290)\n0.001**\n\n\nSGOT\n150\n23 (19, 27)\n23 (19, 26)\n23 (20, 28)\n0.442\n\n\nSGOT_Detected\n150\n126 (84%)\n41 (93%)\n85 (80%)\n0.048*\n\n\nSGPT\n150\n28 (21, 35)\n28 (21, 34)\n28 (20, 38)\n0.542\n\n\nALP\n150\n71 (56, 86)\n70 (52, 88)\n71 (56, 82)\n0.851\n\n\nALP_Detected\n150\n149 (99%)\n44 (100%)\n105 (99%)\n&gt;0.999\n\n\nALT_AST_Ratio\n150\n1.19 (0.93, 1.53)\n1.20 (0.94, 1.44)\n1.19 (0.93, 1.58)\n0.634\n\n\nALT_AST_Ratio_Detected\n150\n126 (84%)\n41 (93%)\n85 (80%)\n0.048*\n\n\nAISI\n150\n223 (139, 308)\n261 (157, 337)\n211 (132, 289)\n0.068\n\n\ndNLR\n150\n1.31 (1.02, 1.65)\n1.30 (1.06, 1.74)\n1.32 (1.01, 1.58)\n0.706\n\n\nEBR\n150\n3.00 (2.00, 4.75)\n3.67 (2.28, 5.34)\n2.71 (2.00, 4.40)\n0.152\n\n\nEBR_Detected\n150\n138 (92%)\n42 (95%)\n96 (91%)\n0.510\n\n\nLMR\n150\n4.28 (3.43, 5.44)\n4.54 (3.36, 5.44)\n4.21 (3.43, 5.44)\n0.933\n\n\nMLR\n150\n0.23 (0.18, 0.29)\n0.22 (0.18, 0.30)\n0.24 (0.18, 0.29)\n0.933\n\n\nNLR\n150\n1.81 (1.35, 2.26)\n1.85 (1.52, 2.33)\n1.78 (1.33, 2.25)\n0.572\n\n\nPLR\n150\n134 (109, 166)\n148 (118, 168)\n130 (102, 165)\n0.100\n\n\nSII\n150\n463 (337, 619)\n525 (369, 682)\n431 (306, 563)\n0.034*\n\n\n\nUnits are various: mg/dL, ng/mL, g/dL, mmol/L, 10^3/μL, 10^6/μL, %, 10^9/L and U/L. P-values are unadjusted.\n\n\n1 Median (Q1, Q3); n (%)\n\n\n2 Wilcoxon rank sum test; Fisher’s exact test; NA; Pearson’s Chi-squared test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nMedication Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\nMedication Variable\nN\n\nHEI Total Score (Using A Score Cutoff Of 50)\n\np-value2,3\n\n\n&lt;50\nN = 441\n≥50\nN = 1061\n\n\n\n\nAntihypertensives\n150\n\n\n\n\n0.480\n\n\n    No\n\n\n33 (75%)\n85 (80%)\n\n\n\n\n    Yes\n\n\n11 (25%)\n21 (20%)\n\n\n\n\nHyperlipidemias\n150\n\n\n\n\n0.664\n\n\n    No\n\n\n37 (84%)\n92 (87%)\n\n\n\n\n    Yes\n\n\n7 (16%)\n14 (13%)\n\n\n\n\nAntidepressants\n150\n\n\n\n\n0.553\n\n\n    No\n\n\n39 (89%)\n97 (92%)\n\n\n\n\n    Yes\n\n\n5 (11%)\n9 (8.5%)\n\n\n\n\n\nP-values are unadjusted.\n\n\n1 n (%)\n\n\n2 Pearson’s Chi-squared test; Fisher’s exact test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nDietary Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\nDietary Variable\nN\n\nHEI Total Score (Using A Score Cutoff Of 50)\n\np-value2,3\n\n\n&lt;50\nN = 441\n≥50\nN = 1061\n\n\n\n\nMEDAS_Score\n150\n6.00 (5.00, 7.00)\n6.00 (5.00, 7.00)\n0.820\n\n\nDaily_EI\n150\n1,377 (1,369, 1,388)\n1,423 (1,175, 1,647)\n0.572\n\n\nTotal_DII\n150\n2.28 (2.28, 2.31)\n2.32 (1.83, 2.66)\n0.712\n\n\n\nP-values are unadjusted.\n\n\n1 Median (Q1, Q3)\n\n\n2 Wilcoxon rank sum test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nActivity Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\nActivity Variable\nN\n\nHEI Total Score (Using A Score Cutoff Of 50)\n\np-value2,3\n\n\n&lt;50\nN = 421\n≥50\nN = 1021\n\n\n\n\nSteps\n144\n7,161 (4,624, 8,962)\n7,184 (5,160, 9,561)\n0.425\n\n\nSleep\n144\n5.89 (4.83, 6.82)\n5.71 (4.67, 6.92)\n0.794\n\n\nSedentary\n144\n9.70 (8.18, 11.38)\n10.27 (8.90, 11.64)\n0.136\n\n\nLight\n144\n2.37 (1.82, 2.76)\n2.29 (1.97, 2.88)\n0.845\n\n\nModerate\n144\n1.92 (1.52, 2.37)\n1.92 (1.40, 2.46)\n0.862\n\n\nVigorous\n144\n0.01 (0.00, 0.03)\n0.01 (0.00, 0.03)\n0.686\n\n\n\nP-values are unadjusted.\n\n\n1 Median (Q1, Q3)\n\n\n2 Wilcoxon rank sum test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSmoking Status (Timepoint 1)\n\n\n\n\n\n\n\n\n\nSmoking Status Variable\nN\n\nHEI Total Score (Using A Score Cutoff Of 50)\n\np-value2,3\n\n\n&lt;50\nN = 441\n≥50\nN = 1041\n\n\n\n\nSmoking_Status\n148\n\n\n\n\n0.155\n\n\n    Current smoker\n\n\n11 (25%)\n22 (21%)\n\n\n\n\n    Former smoker\n\n\n9 (20%)\n38 (37%)\n\n\n\n\n    Never smoked\n\n\n24 (55%)\n44 (42%)\n\n\n\n\n\nP-values are unadjusted.\n\n\n1 n (%)\n\n\n2 Pearson’s Chi-squared test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSugar & Amino Acid Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\nSugar & Amino Acid Variables\nN\n\nHEI Total Score (Using A Score Cutoff Of 50)\n\np-value2,3\n\n\n&lt;50\nN = 441\n≥50\nN = 1061\n\n\n\n\nAnhydroglucitol\n150\n93 (75, 117)\n99 (76, 128)\n0.590\n\n\nGlucose\n150\n5,538 (4,317, 7,304)\n7,258 (5,669, 8,017)\n0.002**\n\n\nMannose\n150\n40 (26, 55)\n55 (37, 68)\n&lt;0.001***\n\n\nFructose\n150\n8 (5, 24)\n25 (7, 32)\n&lt;0.001***\n\n\nValine\n150\n181 (120, 266)\n248 (179, 318)\n0.001**\n\n\nLeucine\n150\n177 (123, 226)\n208 (171, 266)\n0.006**\n\n\nIsoleucine\n150\n53 (35, 74)\n63 (47, 85)\n0.006**\n\n\nGlutamine\n150\n460 (335, 615)\n619 (450, 718)\n0.002**\n\n\nGlutamic_Acid\n150\n41 (24, 75)\n68 (42, 99)\n0.002**\n\n\nPhenylalanine\n150\n62 (45, 76)\n69 (61, 80)\n0.029*\n\n\nTyrosine\n150\n56 (42, 70)\n70 (56, 88)\n0.001**\n\n\nTryptophan\n150\n42 (31, 55)\n53 (41, 63)\n0.005**\n\n\nGlutamine_To_Glutamic_Acid_Ratio\n150\n11 (7, 20)\n9 (6, 14)\n0.095\n\n\nBCAA_To_AAA_Ratio\n150\n2.67 (2.33, 2.98)\n2.69 (2.36, 3.00)\n0.396\n\n\n\nUnits are in μΜ. P-values are unadjusted.\n\n\n1 Median (Q1, Q3)\n\n\n2 Wilcoxon rank sum test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nAcylCarnitines Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\nAcylCarnitines Variable\nN\n\nHEI Total Score (Using A Score Cutoff Of 50)\n\np-value2,3\n\n\n&lt;50\nN = 441\n≥50\nN = 1061\n\n\n\n\nAcetylcarnitine\n150\n8.1 (5.6, 12.1)\n10.9 (7.8, 13.7)\n0.015*\n\n\nPropionylcarnitine\n150\n0.49 (0.42, 0.72)\n0.60 (0.44, 0.76)\n0.200\n\n\nButyrylcarnitine\n150\n0.09 (0.06, 0.12)\n0.09 (0.06, 0.14)\n0.105\n\n\nValerylcarnitine\n150\n0.055 (0.035, 0.069)\n0.056 (0.036, 0.071)\n0.452\n\n\nHexanoylcarnitine\n150\n0.06 (0.04, 0.08)\n0.06 (0.04, 0.07)\n0.939\n\n\nOctanoylcarnitine\n150\n0.13 (0.09, 0.20)\n0.14 (0.09, 0.19)\n0.777\n\n\nDecanoylcarnitine\n150\n0.26 (0.17, 0.33)\n0.25 (0.18, 0.36)\n0.846\n\n\nLauroylcarnitine\n150\n0.05 (0.03, 0.06)\n0.04 (0.03, 0.06)\n0.530\n\n\nMyristoylcarnitine\n150\n0.019 (0.012, 0.024)\n0.019 (0.015, 0.026)\n0.178\n\n\nPalmitoylcarnitine\n150\n0.09 (0.08, 0.11)\n0.10 (0.08, 0.12)\n0.161\n\n\nStearoylcarnitine\n150\n0.017 (0.012, 0.023)\n0.020 (0.013, 0.026)\n0.089\n\n\nLinoleoylcarnitine\n150\n0.07 (0.04, 0.09)\n0.07 (0.05, 0.09)\n0.536\n\n\nOleoylcarnitine\n150\n0.11 (0.09, 0.18)\n0.13 (0.11, 0.18)\n0.059\n\n\n\nUnits are in μΜ. P-values are unadjusted.\n\n\n1 Median (Q1, Q3)\n\n\n2 Wilcoxon rank sum test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nHILIC Urine Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\nHILIC Urine Variable\nN\n\nHEI Total Score (Using A Score Cutoff Of 50)\n\np-value2,3\n\n\n&lt;50\nN = 441\n≥50\nN = 1051\n\n\n\n\n2_Hydroxyisovalericacid\n149\n2,998 (2,485, 4,292)\n3,166 (2,399, 4,889)\n0.965\n\n\n2_Hydroxyisovalericacid_Detected\n149\n32 (73%)\n92 (88%)\n0.026*\n\n\n3_Methylhistidine\n149\n305,564 (206,938, 751,360)\n331,539 (167,853, 690,537)\n0.703\n\n\n3_Methylhistidine_Detected\n149\n43 (98%)\n97 (92%)\n0.282\n\n\nAcetylcarnitine\n149\n2,267,427 (956,752, 4,708,700)\n1,702,376 (1,067,740, 3,312,019)\n0.319\n\n\nAdenine\n149\n26,701 (20,982, 40,521)\n24,233 (17,125, 35,744)\n0.182\n\n\nAdenine_Detected\n149\n19 (43%)\n40 (38%)\n0.562\n\n\nAlanine\n149\n37,001 (20,799, 76,520)\n37,722 (23,155, 66,012)\n0.945\n\n\nAlanine_Detected\n149\n\n\n\n\n\n\n\n\n    Yes\n\n\n44 (100%)\n105 (100%)\n\n\n\n\nAllantoin\n149\n8,863 (5,696, 15,171)\n9,008 (5,596, 14,651)\n0.965\n\n\nAscorbic_Acid\n149\n1,588 (1,325, 2,277)\n1,681 (1,338, 2,209)\n0.587\n\n\nAscorbic_Acid_Detected\n149\n\n\n\n\n\n\n\n\n    Yes\n\n\n44 (100%)\n105 (100%)\n\n\n\n\nAsparagine\n149\n5,637 (4,057, 15,347)\n5,886 (4,417, 11,189)\n0.827\n\n\nBenzoic_Acid\n149\n1,029 (495, 1,828)\n1,033 (549, 1,970)\n0.685\n\n\nBenzoic_Acid_Detected\n149\n25 (57%)\n45 (43%)\n0.119\n\n\nBetaine\n149\n941,830 (667,519, 2,275,528)\n1,009,388 (784,961, 1,849,974)\n0.631\n\n\nCaffeine\n149\n34,714 (14,367, 55,849)\n19,918 (7,730, 39,214)\n0.075\n\n\nCaffeine_Detected\n149\n\n\n\n\n\n\n\n\n    Yes\n\n\n44 (100%)\n105 (100%)\n\n\n\n\nCholine\n149\n210,795 (147,473, 365,597)\n225,679 (145,919, 363,628)\n0.853\n\n\nCotinine\n149\n140,339 (1,587, 341,980)\n55,053 (1,009, 268,890)\n0.443\n\n\nCotinine_Detected\n149\n25 (57%)\n62 (59%)\n0.801\n\n\nCreatine\n149\n675,284 (294,815, 1,549,661)\n471,766 (277,150, 1,375,904)\n0.491\n\n\nCreatinine\n149\n47,159,126 (40,609,537, 60,768,979)\n48,216,574 (41,841,106, 57,427,410)\n0.757\n\n\nCytosine\n149\n15,813 (11,044, 37,239)\n19,003 (12,456, 40,507)\n0.383\n\n\nCytosine_Detected\n149\n35 (80%)\n85 (81%)\n0.843\n\n\nDimethylamine\n149\n36,360 (30,142, 56,999)\n36,021 (29,136, 45,706)\n0.640\n\n\nGlutamic_Acid\n149\n665 (509, 934)\n632 (500, 1,013)\n0.433\n\n\nGlutamic_Acid_Detected\n149\n22 (50%)\n55 (52%)\n0.791\n\n\nGlutamine\n149\n215,300 (159,782, 360,410)\n208,258 (155,981, 331,455)\n0.716\n\n\nGuanine\n149\n1,916 (989, 3,053)\n1,660 (882, 2,774)\n0.386\n\n\nGuanine_Detected\n149\n42 (95%)\n99 (94%)\n&gt;0.999\n\n\nHippuric_Acid\n149\n118,298 (51,530, 158,367)\n74,615 (38,568, 114,718)\n0.006**\n\n\nHistamine\n149\n3,213 (2,155, 9,324)\n2,676 (2,013, 5,389)\n0.370\n\n\nHistamine_Detected\n149\n26 (59%)\n76 (72%)\n0.111\n\n\nHypotaurine\n149\n248 (211, 523)\n240 (183, 367)\n0.269\n\n\nHypotaurine_Detected\n149\n12 (27%)\n35 (33%)\n0.468\n\n\nHypoxanthine\n149\n94,131 (60,731, 135,227)\n82,641 (57,173, 121,022)\n0.136\n\n\nHypoxanthine_Detected\n149\n\n\n\n\n\n\n\n\n    Yes\n\n\n44 (100%)\n105 (100%)\n\n\n\n\nIndole_3_Lactic_Acid\n149\n2,697 (2,239, 3,466)\n2,751 (2,175, 3,341)\n0.962\n\n\nInosine\n149\n1,664 (1,127, 2,412)\n1,134 (710, 2,529)\n0.102\n\n\nInosine_Detected\n149\n43 (98%)\n102 (97%)\n&gt;0.999\n\n\nKynurenate\n149\n21,070 (15,678, 30,356)\n15,983 (11,094, 24,714)\n0.064\n\n\nLactose\n149\n1,649 (957, 5,920)\n1,770 (978, 6,271)\n0.679\n\n\nLysine\n149\n16,086 (11,012, 65,765)\n17,020 (10,156, 50,796)\n0.526\n\n\nLysine_Detected\n149\n38 (86%)\n87 (83%)\n0.595\n\n\nMannitol\n149\n1,127 (629, 3,146)\n1,808 (779, 3,390)\n0.236\n\n\nMannitol_Detected\n149\n40 (91%)\n95 (90%)\n&gt;0.999\n\n\nMethylamine\n149\n6,031 (4,413, 9,840)\n6,386 (4,467, 8,616)\n0.919\n\n\nMethylamine_Detected\n149\n43 (98%)\n105 (100%)\n0.295\n\n\nMonoisoamylamine\n149\n16,825 (11,116, 26,177)\n15,044 (11,073, 24,795)\n0.604\n\n\nMonoisoamylamine_Detected\n149\n40 (91%)\n102 (97%)\n0.196\n\n\nNicotinamide\n149\n1,863 (1,337, 2,436)\n1,949 (1,383, 2,574)\n0.528\n\n\nNicotinamide_Detected\n149\n42 (95%)\n105 (100%)\n0.086\n\n\nPantothenate\n149\n9,763 (5,786, 32,048)\n9,043 (4,342, 17,750)\n0.309\n\n\nPhenylalanine\n149\n42,289 (29,069, 72,869)\n47,823 (28,761, 80,404)\n0.652\n\n\nPyridoxine\n149\n34,477 (25,488, 72,219)\n32,820 (24,484, 63,323)\n0.631\n\n\nPyridoxine_Detected\n149\n18 (41%)\n38 (36%)\n0.587\n\n\nPyroglutamic\n149\n36,898 (23,826, 81,049)\n34,449 (20,881, 62,282)\n0.379\n\n\nPyroglutamic_Detected\n149\n43 (98%)\n97 (92%)\n0.282\n\n\nRivoflavine\n149\n2,385 (701, 6,322)\n1,471 (736, 4,252)\n0.185\n\n\nRivoflavine_Detected\n149\n36 (82%)\n82 (78%)\n0.610\n\n\nSerine\n149\n20,092 (15,145, 57,354)\n20,795 (16,235, 35,660)\n0.856\n\n\nSorbitol\n149\n558 (398, 963)\n750 (457, 1,297)\n0.151\n\n\nSorbitol_Detected\n149\n\n\n\n\n\n\n\n\n    Yes\n\n\n44 (100%)\n105 (100%)\n\n\n\n\nSucrose\n149\n226 (137, 491)\n267 (142, 411)\n0.856\n\n\nSucrose_Detected\n149\n24 (55%)\n53 (50%)\n0.650\n\n\nTaurine\n149\n6,997 (3,601, 15,739)\n9,377 (5,528, 18,043)\n0.163\n\n\nTaurine_Detected\n149\n42 (95%)\n98 (93%)\n&gt;0.999\n\n\nTheobromine\n149\n45,456 (30,933, 87,466)\n50,722 (27,231, 86,481)\n0.919\n\n\nThiamine\n149\n24,817 (9,388, 63,658)\n28,031 (17,646, 56,818)\n0.357\n\n\nThiamine_Detected\n149\n43 (98%)\n103 (98%)\n&gt;0.999\n\n\nThreonine\n149\n15,902 (11,828, 37,950)\n17,580 (12,550, 31,610)\n0.866\n\n\nThreonine_Detected\n149\n\n\n\n\n\n\n\n\n    Yes\n\n\n44 (100%)\n105 (100%)\n\n\n\n\nTrimethylamine\n149\n7,122 (5,571, 13,045)\n6,909 (5,113, 11,807)\n0.531\n\n\nTrimethylamine_Detected\n149\n31 (70%)\n70 (67%)\n0.652\n\n\nTrimethylamine_N_Oxide\n149\n1,929,850 (1,312,246, 3,138,985)\n1,499,565 (1,090,219, 2,444,095)\n0.099\n\n\nTryptamine\n149\n42,037 (21,674, 58,269)\n37,800 (25,094, 61,987)\n0.801\n\n\nTryptamine_Detected\n149\n\n\n\n\n\n\n\n\n    Yes\n\n\n44 (100%)\n105 (100%)\n\n\n\n\nTryptophan\n149\n17,771 (11,594, 31,415)\n17,640 (11,047, 31,330)\n0.863\n\n\nTyrosine\n149\n5,812 (3,443, 10,925)\n6,666 (4,022, 11,894)\n0.491\n\n\nTyrosine_Detected\n149\n42 (95%)\n98 (93%)\n&gt;0.999\n\n\nUracil\n149\n2,894 (2,200, 4,010)\n2,942 (2,082, 3,924)\n0.896\n\n\nUracil_Detected\n149\n\n\n\n\n\n\n\n\n    Yes\n\n\n44 (100%)\n105 (100%)\n\n\n\n\nUric_Acid\n149\n1,329 (717, 2,122)\n1,486 (853, 2,301)\n0.545\n\n\nUric_Acid_Detected\n149\n36 (82%)\n89 (85%)\n0.656\n\n\nValine\n149\n28,944 (19,804, 46,464)\n28,209 (19,125, 43,049)\n0.850\n\n\nValine_Detected\n149\n42 (95%)\n103 (98%)\n0.582\n\n\nXanthine\n149\n16,137 (10,565, 22,181)\n13,240 (9,700, 17,154)\n0.041*\n\n\nXanthine_Detected\n149\n\n\n\n\n\n\n\n\n    Yes\n\n\n44 (100%)\n105 (100%)\n\n\n\n\nA_Ketoglutaric_Acid\n149\n1,077 (650, 2,025)\n768 (555, 1,194)\n0.043*\n\n\nA_Ketoglutaric_Acid_Detected\n149\n44 (100%)\n102 (97%)\n0.555\n\n\nG_Aminobutyric\n149\n396 (319, 810)\n410 (316, 653)\n0.788\n\n\nG_Aminobutyric_Detected\n149\n25 (57%)\n46 (44%)\n0.147\n\n\nLeucine_Isoleucine_Ratio\n149\n34,848 (24,953, 51,397)\n33,026 (22,022, 52,493)\n0.607\n\n\nLeucine_Isoleucine_Ratio_Detected\n149\n42 (95%)\n103 (98%)\n0.582\n\n\n\nUnits are in peak area. P-values are unadjusted.\n\n\n1 Median (Q1, Q3); n (%)\n\n\n2 Wilcoxon rank sum test; Pearson’s Chi-squared test; Fisher’s exact test; NA\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTyrosine–Tryptophan Pathway Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\nTyrosine–Tryptophan Pathway Variable\nN\n\nHEI Total Score (Using A Score Cutoff Of 50)\n\np-value2,3\n\n\n&lt;50\nN = 441\n≥50\nN = 1041\n\n\n\n\n5HIAA\n148\n1.19 (0.98, 1.56)\n1.25 (0.98, 1.63)\n0.503\n\n\n5HIAA_Detected\n148\n44 (100%)\n101 (97%)\n0.555\n\n\n5HIAA_Sulfate\n148\n0.07 (0.05, 0.11)\n0.08 (0.04, 0.12)\n0.983\n\n\n5HIAA_Sulfate_Detected\n148\n44 (100%)\n101 (97%)\n0.555\n\n\nDopamine\n148\n0.07 (0.04, 0.09)\n0.06 (0.05, 0.09)\n0.710\n\n\nDopamine_Detected\n148\n41 (93%)\n97 (93%)\n&gt;0.999\n\n\nHippuric_Acid\n148\n492 (305, 857)\n426 (232, 847)\n0.190\n\n\nHippuric_Acid_Detected\n148\n44 (100%)\n100 (96%)\n0.318\n\n\nHomovanilic_Acid\n148\n1.13 (0.83, 1.62)\n1.37 (0.95, 1.89)\n0.072\n\n\nHomovanilic_Acid_Detected\n148\n44 (100%)\n99 (95%)\n0.322\n\n\nIndole\n148\n1.02 (0.68, 1.54)\n0.84 (0.62, 1.31)\n0.422\n\n\nIndole_Detected\n148\n38 (86%)\n96 (92%)\n0.356\n\n\nIndole3Acetic_Acid\n148\n0.64 (0.29, 1.44)\n0.87 (0.45, 1.49)\n0.150\n\n\nIndole3Acetic_Acid_Detected\n148\n28 (64%)\n58 (56%)\n0.375\n\n\nIndole3Lactic_Acid\n148\n0.23 (0.14, 0.32)\n0.17 (0.12, 0.31)\n0.300\n\n\nIndole3Lactic_Acid_Detected\n148\n32 (73%)\n70 (67%)\n0.515\n\n\nIndoxyl_Sulfate\n148\n42 (24, 57)\n39 (22, 56)\n0.686\n\n\nIndoxyl_Sulfate_Detected\n148\n44 (100%)\n99 (95%)\n0.322\n\n\nKynurenic_Acid\n148\n1.57 (1.13, 2.12)\n1.23 (0.67, 2.03)\n0.163\n\n\nKynurenic_Acid_Detected\n148\n33 (75%)\n75 (72%)\n0.718\n\n\nKynurenine\n148\n0.20 (0.14, 0.41)\n0.31 (0.18, 0.49)\n0.066\n\n\nKynurenine_Detected\n148\n44 (100%)\n101 (97%)\n0.555\n\n\nP_Coumaric_Acid\n148\n0.07 (0.04, 0.10)\n0.06 (0.03, 0.10)\n0.298\n\n\nP_Coumaric_Acid_Detected\n148\n39 (89%)\n96 (92%)\n0.529\n\n\nP_Coumaric_Acid_Sulfate\n148\n0.05 (0.02, 0.10)\n0.03 (0.02, 0.08)\n0.265\n\n\nP_Coumaric_Acid_Sulfate_Detected\n148\n42 (95%)\n94 (90%)\n0.511\n\n\nP_Cresol_Sulfate\n148\n100 (56, 130)\n92 (43, 149)\n0.868\n\n\nP_Cresol_Sulfate_Detected\n148\n42 (95%)\n96 (92%)\n0.724\n\n\nP_Ethylphenol_Sulfate\n148\n25 (17, 45)\n34 (14, 79)\n0.315\n\n\nP_Ethylphenol_Sulfate_Detected\n148\n44 (100%)\n100 (96%)\n0.318\n\n\nP_HBA\n148\n318 (192, 524)\n328 (243, 467)\n0.622\n\n\nP_HBA_Detected\n148\n44 (100%)\n99 (95%)\n0.322\n\n\nP_HBA_Sulfate\n148\n3,443 (1,719, 5,402)\n3,130 (1,702, 6,172)\n0.878\n\n\nP_HBA_Sulfate_Detected\n148\n33 (75%)\n75 (72%)\n0.718\n\n\nP_Hydroxyphenyl_Acetic_Acid\n148\n11 (8, 15)\n9 (6, 14)\n0.522\n\n\nP_Hydroxyphenyl_Acetic_Acid_Detected\n148\n44 (100%)\n101 (97%)\n0.555\n\n\nP_Hydroxyphenyl_Acetic_Acid_Sulfate\n148\n0.44 (0.30, 0.77)\n0.42 (0.22, 0.62)\n0.204\n\n\nP_Hydroxyphenyl_Acetic_Acid_Sulfate_Detected\n148\n37 (84%)\n88 (85%)\n0.936\n\n\nP_Hydroxyphenyllactic_Acid\n148\n0.04 (0.02, 0.06)\n0.04 (0.02, 0.07)\n0.873\n\n\nP_Hydroxyphenyllactic_Acid_Detected\n148\n38 (86%)\n89 (86%)\n0.900\n\n\nP_Hydroxyphenyllactic_Acid_Sulfate\n148\n1.75 (1.37, 2.18)\n1.56 (1.15, 2.01)\n0.044*\n\n\nP_Hydroxyphenyllactic_Acid_Sulfate_Detected\n148\n44 (100%)\n101 (97%)\n0.555\n\n\nP_Hydroxyphenylpropionic_Acid\n148\n0.19 (0.13, 0.31)\n0.18 (0.13, 0.28)\n0.539\n\n\nP_Hydroxyphenylpropionic_Acid_Detected\n148\n26 (59%)\n56 (54%)\n0.557\n\n\nP_Hydroxyphenylpropionic_Acid_Sulfate\n148\n0.005 (0.002, 0.008)\n0.006 (0.003, 0.009)\n0.612\n\n\nP_Hydroxyphenylpropionic_Acid_Sulfate_Detected\n148\n42 (95%)\n93 (89%)\n0.346\n\n\nPhenol_Sulfate\n148\n6 (3, 11)\n6 (3, 13)\n0.695\n\n\nPhenol_Sulfate_Detected\n148\n42 (95%)\n100 (96%)\n&gt;0.999\n\n\nPhenylalanine\n148\n3.76 (2.57, 5.31)\n4.18 (2.78, 6.30)\n0.286\n\n\nPhenylalanine_Detected\n148\n42 (95%)\n99 (95%)\n&gt;0.999\n\n\nTryptophan\n148\n2.99 (2.44, 4.39)\n3.62 (2.44, 4.94)\n0.197\n\n\nTryptophan_Detected\n148\n44 (100%)\n101 (97%)\n0.555\n\n\nTyramine\n148\n0.29 (0.20, 0.34)\n0.30 (0.22, 0.37)\n0.422\n\n\nTyramine_Detected\n148\n44 (100%)\n101 (97%)\n0.555\n\n\nTyrosine\n148\n26 (19, 38)\n29 (21, 46)\n0.218\n\n\nTyrosine_Detected\n148\n44 (100%)\n101 (97%)\n0.555\n\n\n\nUnits are in μg/mmol of creatinine. P-values are unadjusted.\n\n\n1 Median (Q1, Q3); n (%)\n\n\n2 Wilcoxon rank sum test; Fisher’s exact test; Pearson’s Chi-squared test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001",
    "crumbs": [
      "Sections",
      "HEI Total Score"
    ]
  },
  {
    "objectID": "hei_total_score.html#amino-acids-sugars",
    "href": "hei_total_score.html#amino-acids-sugars",
    "title": "HEI Total Score",
    "section": "Amino Acids & Sugars",
    "text": "Amino Acids & Sugars\n\nSmooths\n \n\n\n\n\n\n\n\n\n\n\n\n(a) Anhydroglucitol (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Glucose (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Mannose (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(d) Fructose (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(e) Valine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(f) Leucine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(g) Isoleucine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(h) Glutamine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(i) Glutamic Acid (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(j) Phenylalanine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(k) Tyrosine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(l) Tryptophan (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(m) Glutamine-to-Glutamic Acid Ratio (after outlier remocal i.e. &gt;40)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(n) BCAA-to-AAA Ratio\n\n\n\n\n\n\n\nFigure 1: Amino Acids $ Sugars in relation to HEI Total Score.\n\n\n\n \n\n\nBoxplots\n \n\n\n\n\n\n\n\n\n\n\n\n(a) Anhydroglucitol (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Glucose (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Mannose (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(d) Fructose (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(e) Valine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(f) Leucine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(g) Isoleucine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(h) Glutamine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(i) Glutamic Acid (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(j) Phenylalanine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(k) Tyrosine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(l) Tryptophan (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(m) Glutamine-to-Glutamic Acid Ratio (after outlier remocal i.e. &gt;40)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(n) BCAA-to-AAA Ratio\n\n\n\n\n\n\n\nFigure 2: Amino Acids $ Sugars in relation to HEI Total Score.",
    "crumbs": [
      "Sections",
      "HEI Total Score"
    ]
  },
  {
    "objectID": "hei_total_score.html#acylcarnitines",
    "href": "hei_total_score.html#acylcarnitines",
    "title": "HEI Total Score",
    "section": "AcylCarnitines",
    "text": "AcylCarnitines\n \n\nSmooths\n \n\n\n\n\n\n\n\n\n\n\n\n(a) Acetylcarnitine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Propionylcarnitine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Butyrylcarnitine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(d) Valerylcarnitine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(e) Hexanoylcarnitine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(f) Octanoylcarnitine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(g) Decanoylcarnitine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(h) Lauroylcarnitine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(i) Myristoylcarnitine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(j) Palmitoylcarnitine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(k) Stearoylcarnitine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(l) Linoleoylcarnitine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(m) Oleoylcarnitine (μΜ)\n\n\n\n\n\n\n\nFigure 3: AcylCarnitines in relation to HEI Total Score.\n\n\n\n \n\n\nBoxplots\n \n\n\n\n\n\n\n\n\n\n\n\n(a) Acetylcarnitine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) Propionylcarnitine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Butyrylcarnitine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(d) Valerylcarnitine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(e) Hexanoylcarnitine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(f) Octanoylcarnitine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(g) Decanoylcarnitine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(h) Lauroylcarnitine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(i) Myristoylcarnitine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(j) Palmitoylcarnitine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(k) Stearoylcarnitine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(l) Linoleoylcarnitine (μΜ)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(m) Oleoylcarnitine (μΜ)\n\n\n\n\n\n\n\nFigure 4: AcylCarnitines in relation to HEI Total Score.",
    "crumbs": [
      "Sections",
      "HEI Total Score"
    ]
  },
  {
    "objectID": "hei_total_score.html#hilic",
    "href": "hei_total_score.html#hilic",
    "title": "HEI Total Score",
    "section": "HILIC",
    "text": "HILIC\n \n\nSmooths\n \n\n\n\n\n\n\n\n\n\n\n\n(a) 2_Hydroxyisovalericacid (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) 3_Methylhistidine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Acetylcarnitine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(d) Adenine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(e) Alanine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(f) Allantoin (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(g) Ascorbic Acid (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(h) Asparagine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(i) Benzoic Acid (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(j) Betaine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(k) Caffeine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(l) Choline (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(m) Cotinine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(n) Creatine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(o) Creatinine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(p) Cytosine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(q) Dimethylamine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(r) Glutamic Acid (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(s) Glutamine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(t) Guanine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(u) Hippuric Acid (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(v) Histamine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(w) Hypotaurine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(x) Hypoxanthine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(y) Indole 3 Lactic Acid (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(z) Inosine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n({) Kynurenate (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(|) Lactose (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(}) Lysine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(~) Mannitol (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Methylamine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Monoisoamylamine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Nicotinamide (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Pantothenate (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Phenylalanine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Pyridoxine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Pyroglutamic (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Riboflavine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Serine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Sorbitol (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Sucrose (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Taurine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Theobromine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Thiamine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Threonine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Trimethylamine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Trimethylamine N Oxide (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Tryptamine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Tryptophan (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Tyrosine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Uracil(peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Uric Acid (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Valine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Xanthine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() A Ketoglutaric Acid (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() G Aminobutyric (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Leucine-to-Isoleucine Ratio\n\n\n\n\n\n\n\nFigure 5: HILIC Panel in relation to HEI Total Score.\n\n\n\n \n\n\nBoxplots\n \n\n\n\n\n\n\n\n\n\n\n\n(a) 2_Hydroxyisovalericacid (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(b) 3_Methylhistidine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Acetylcarnitine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(d) Adenine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(e) Alanine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(f) Allantoin (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(g) Ascorbic Acid (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(h) Asparagine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(i) Benzoic Acid (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(j) Betaine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(k) Caffeine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(l) Choline (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(m) Cotinine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(n) Creatine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(o) Creatinine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(p) Cytosine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(q) Dimethylamine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(r) Glutamic Acid (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(s) Glutamine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(t) Guanine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(u) Hippuric Acid (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(v) Histamine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(w) Hypotaurine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(x) Hypoxanthine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(y) Indole 3 Lactic Acid (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(z) Inosine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n({) Kynurenate (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(|) Lactose (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(}) Lysine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n(~) Mannitol (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Methylamine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Monoisoamylamine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Nicotinamide (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Pantothenate (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Phenylalanine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Pyridoxine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Pyroglutamic (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Riboflavine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Serine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Sorbitol (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Sucrose (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Taurine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Theobromine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Thiamine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Threonine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Trimethylamine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Trimethylamine N Oxide (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Tryptamine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Tryptophan (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Tyrosine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Uracil(peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Uric Acid (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Valine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Xanthine (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() A Ketoglutaric Acid (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() G Aminobutyric (peak area)\n\n\n\n\n\n\n\n\n\n\n\n\n\n() Leucine-to-Isoleucine Ratio\n\n\n\n\n\n\n\nFigure 6: HILIC Panel in relation to HEI Total Score.",
    "crumbs": [
      "Sections",
      "HEI Total Score"
    ]
  },
  {
    "objectID": "modeling2.html",
    "href": "modeling2.html",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "",
    "text": "We constructed a Metabolic Syndrome Index from the available data. The modeling process was iterative, incorporating distinct data blocks based on a predetermined priority order. At each step, we used ordinal regression with penalization and an iterative forward-selection approach. Variables were only added to the model if they significantly improved predictive power, conditional on the variables already present. We assessed this conditional value using likelihood ratio testing as well as relative explained variation, applying in addition the False Discovery Rate (FDR) correction to account for multiple comparisons.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#overall-logic-behind-the-priority-order",
    "href": "modeling2.html#overall-logic-behind-the-priority-order",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "🧭 Overall logic behind the priority order",
    "text": "🧭 Overall logic behind the priority order\nThe goal is to build models that progress from broad, upstream, easily interpretable determinants of MetS to fine-grained, mechanistic, or exploratory markers.\nSo the ordering reflects a conceptual causal and interpretability hierarchy, not statistical performance:\n\nFrom distal → proximal → mechanistic → exploratory\n\nThis mirrors how we reason biologically and clinically:\n\nWho is at risk? (demographics, behavior)\nWhat modifiable exposures or interventions exist? (diet, medication)\nWhat physiological manifestations are measurable in routine care? (clinical biochemistry)\nWhat molecular signatures explain underlying pathways? (targeted metabolites → untargeted omics)",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#demographics",
    "href": "modeling2.html#demographics",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "1️⃣ Demographics",
    "text": "1️⃣ Demographics\nExamples: age, sex, ethnicity, socioeconomic status, education, family history\n\nWhy first:\n\nThese are fundamental, non-modifiable determinants that shape all downstream biology and behaviors.\nThey act as baseline confounders or stratifiers for almost every other dataset (e.g., age and sex affect biochemistry, metabolomics, and disease risk).\nCollected reliably, at low cost, and are always available.\nThey provide context for interpreting later findings (e.g., age-related differences in metabolites).\n\n\n\nPriority rationale:\n\nAlways start here to define baseline risk and to adjust all subsequent models.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#dietary-indices-lifestyle-factors",
    "href": "modeling2.html#dietary-indices-lifestyle-factors",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "2️⃣ Dietary indices / lifestyle factors",
    "text": "2️⃣ Dietary indices / lifestyle factors\nExamples: Healthy Eating Index, Mediterranean Diet Score, physical activity questionnaires, smoking, alcohol, sleep questionnaires\n\nWhy second:\n\nRepresent modifiable exposures that directly influence metabolic health.\nThey often precede disease onset and affect biomarkers downstream (lipids, glucose, metabolites).\nThey connect public-health interventions to molecular outcomes.\nEven if self-reported, they capture long-term habits not seen in blood/metabolite snapshots.\n\n\n\nPriority rationale:\n\nKey upstream, modifiable factors that influence nearly every physiological pathway related to MetS.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#medications",
    "href": "modeling2.html#medications",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "3️⃣ Medications",
    "text": "3️⃣ Medications\nExamples: antihypertensives, statins, metformin, GLP-1 agonists, etc.\n\nWhy third:\n\nStrongly influence downstream biochemical and metabolomic readouts.\nRepresent clinical interventions that modify the phenotype of interest.\nMust be accounted for to distinguish disease biology from drug effects.\nOften act as confounders or effect modifiers in biomarker analyses.\n\n\n\nPriority rationale:\n\nCritical to adjust for before interpreting any biological signal — they change metabolic readouts directly.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#device-data",
    "href": "modeling2.html#device-data",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "4️⃣ Device data",
    "text": "4️⃣ Device data\nExamples: objectively measured activity, step count, energy expenditure, sleep metrics, heart rate variability\n\nWhy fourth:\n\nProvide objective, continuous measures of lifestyle and physiology, complementing self-reported behaviors.\nReflect real-time metabolic demand and stress, bridging behavior and physiology.\nMore proximal than lifestyle but still modifiable and behavioral in nature.\nIncreasingly reliable with modern wearables, but still variable across devices and populations.\n\n\n\nPriority rationale:\n\nObjective bridge between behavior and physiology; still upstream of biochemical consequences.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#clinical-blood-biochemistry",
    "href": "modeling2.html#clinical-blood-biochemistry",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "5️⃣ Clinical blood biochemistry",
    "text": "5️⃣ Clinical blood biochemistry\nExamples: glucose, insulin, HbA1c, triglycerides, HDL, LDL, CRP, liver enzymes\n\nWhy fifth:\n\nReflect established diagnostic and mechanistic markers of metabolic syndrome components (dyslipidemia, insulin resistance, inflammation).\nRoutinely measured, standardized, and directly interpretable.\nRepresent proximal physiological consequences of earlier exposures.\nProvide the foundation for defining MetS itself (waist circumference, TG, HDL, glucose, blood pressure).\n\n\n\nPriority rationale:\n\nDirectly linked to the clinical phenotype; serve as both outcomes and mediators of upstream factors.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#targeted-metabolites",
    "href": "modeling2.html#targeted-metabolites",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "6️⃣ Targeted metabolites",
    "text": "6️⃣ Targeted metabolites\nExamples: amino acids, sugars, acylcarnitines, bile acids, short-chain fatty acids\n\nWhy sixth:\n\nCapture specific biochemical pathways involved in energy metabolism, insulin signaling, fatty acid oxidation.\nProvide mechanistic insight beyond routine biochemistry.\nOften measurable with targeted LC-MS/MS → quantitative, interpretable, reproducible.\nReflect early molecular perturbations before clinical changes become apparent.\nRequire domain expertise for interpretation; not as standardized across labs as clinical chemistry.\n\n\n\nPriority rationale:\n\nMechanistic layer connecting clinical phenotypes to molecular dysregulation; interpretable but downstream of physiology.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#urine-data",
    "href": "modeling2.html#urine-data",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "7️⃣ Urine data",
    "text": "7️⃣ Urine data\nExamples: creatinine, albumin, electrolytes, urinary metabolites\n\nWhy seventh:\n\nReflects systemic metabolic waste and renal function — downstream consequence of blood biochemistry.\nUseful for normalization (e.g., creatinine) or secondary pathways (oxidative stress, kidney involvement).\nMore variable due to hydration, timing, diet; less directly interpretable mechanistically than plasma markers.\n\n\n\nPriority rationale:\n\nSecondary biofluid — complementary but less directly connected to primary metabolic processes measured in blood.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#untargeted-metabolomics-other-omics",
    "href": "modeling2.html#untargeted-metabolomics-other-omics",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "8️⃣ Untargeted metabolomics / other omics",
    "text": "8️⃣ Untargeted metabolomics / other omics\nExamples: untargeted LC-MS, NMR, transcriptomics, proteomics, microbiome, methylomics\n\nWhy last:\n\nHigh-dimensional, exploratory, and hypothesis-generating.\nContain potentially novel biomarkers, but also high noise and platform bias.\nHarder to interpret mechanistically without context from previous levels.\nUseful after upstream and targeted layers are understood or adjusted for.\nOften correlate with clinical and targeted data, so entering them last avoids overshadowing interpretable effects.\n\n\n\nPriority rationale:\n\nDeep, hypothesis-generating molecular layer — biologically valuable but least interpretable and most context-dependent.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#conceptual-summary-causal-and-interpretive-hierarchy",
    "href": "modeling2.html#conceptual-summary-causal-and-interpretive-hierarchy",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "🧩 Conceptual summary — causal and interpretive hierarchy",
    "text": "🧩 Conceptual summary — causal and interpretive hierarchy\n\n\n\n\n\n\n\n\n\nLevel\nBlock\nRole in the MetS pathway\nTypical use in modeling\n\n\n\n\n1\nDemographics\nBaseline determinants, confounders\nAlways adjust first\n\n\n2\nDiet/lifestyle\nModifiable exposures\nCausal/behavioral drivers\n\n\n3\nMedications\nClinical interventions\nConfounders/effect modifiers\n\n\n4\nDevice data\nObjective behavior, physiology\nBridge between behavior & biology\n\n\n5\nClinical labs\nPhysiological biomarkers\nCore diagnostic information\n\n\n6\nTargeted metabolites\nMechanistic biomarkers\nLink pathways to phenotype\n\n\n7\nUrine\nSecondary metabolic output\nComplementary / kidney status\n\n\n8\nUntargeted omics\nExploratory molecular layer\nDiscover novel mechanisms",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#summary-rationale",
    "href": "modeling2.html#summary-rationale",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "✅ Summary rationale",
    "text": "✅ Summary rationale\n\nWe start with who the person is (demographics), then what they do (diet & lifestyle), what’s done to them (medications), what their body does in real life (device data), how their physiology currently looks (clinical biochemistry), what’s happening mechanistically (targeted metabolites), what’s being excreted (urine), and finally what’s observable at the most granular molecular level (untargeted omics).\n\n\n\n⚖️ Practical Note\n\nThis order emphasizes parsimony and interpretability first, then mechanistic depth.\nStatistically, the analysis can be implemented as hierarchical modeling or block-wise regression (adding predictors in blocks and testing incremental R², likelihood ratio tests, or predictive accuracy).\nIf the aim is prediction only (not interpretation), sometimes statistical learning SL algorithms can integrate all blocks simultaneously i.e. partial least squares and variants, least absolute shrinkage and selection operator (lasso) — at the expense of losing the interpretative clarity of the priority approach. However, even if prediction is the sole goal, the question is how much more the predictive performance is improved by including all available data into a model.\nMost SL algorithms that can be applied to small size data or high-dimensional data do not account for potential non-linear associations with a response variable, as well as not accounting for interactions among predictor variables. The priority approach here can handle those issues but in a less automatic manner.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#dietary-indices-lifestyle-factors-1",
    "href": "modeling2.html#dietary-indices-lifestyle-factors-1",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "Dietary Indices / Lifestyle Factors",
    "text": "Dietary Indices / Lifestyle Factors\n\nRedundancy Analysis\n\n\n\n\n\nrow\nlist of remaining predictors\n\n\n\n\n1\nHEI_Total_Score\n\n\n2\nTotal_DII\n\n\n3\nMEDAS_Score\n\n\n4\nSmoking_Status\n\n\n5\nSleep\n\n\n6\nSedentary\n\n\n7\nLight\n\n\n8\nModerate\n\n\n9\nVigorous\n\n\n10\nDaily_EI\n\n\n11\nHEI_Total_Score_AdjEI\n\n\n\n\n\nwhere Daily_EI id the daily energy intake in kcal and HEI_Total_Score_AdjEI is the HEI_Total_Score adjusted for the Daily_EI.\n\n\nLRT\nModel: MetS ~ Gender + rcs(xDietaryLifestyle,3) + Gender:rcs(xDietaryLifestyle,3) where xDietaryLifestyle is a predictor from the above list, rcs(xDietaryLifestyle,3) means that when xDietaryLifestyle is continuous, it is transformed using restricted cubic splines with 3 degrees of freedom in order to account for potential non-linear associations, and : means that the variables are also interacting.\nResults: None of the potential predictors show added value as the FDR adjusted p-values are higher than the chosen threshold of 15%. All three predictors show similar performance, but MEDAS_Score shows an interaction with Gender that would pass the FDR test. The HEI_Total_Score has a distribution that is largely bimodal, and hence it is not considered a representative measure. As a result, we keep only the MEDAS_Score in the model.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nrow\nvarName\nchisq\ndf\nanova_pval\ninteractions_pval\nFDR_pval\nvarTransform\n\n\n\n\n1\nMEDAS_Score\n23.0018\n5\n0.0451\n0.009632\n0.1804\nrcs\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nFigure 2: Interaction of MEDAS Score and Gender for differentiating the MetS index. The red horizontal line corresponds to the median MetS index value of 58.67 which separates the index into higher (&gt;58.67) and lower (&lt;58.67) risk regions\n\n\n\n\n\n\n\n1. Relationship is Nonlinear\n\nThere isn’t a simple “higher score = better metabolic health” pattern.\nInstead, both curves show a bend (lowest/highest MetS risk) around MEDAS scores of 7, suggesting a sweet spot of dietary adherence or worsening depending on Gender.\n\n\n\n2. Gender Differences\nFemales (red line):\n\nShow a stronger protective effect around MEDAS score 7, with a significant drop in metabolic syndrome index.\nAt both very low (1–3) and very high MEDAS scores (&gt;9), the MetS index appears higher again—suggesting either insufficient diet quality or possibly extreme dietary restriction does not confer additional benefit.\n\nMales (blue line):\n\nThe curve is flatter overall—meaning the Mediterranean diet adherence may have less pronounced impact on metabolic risk compared to females in this dataset.\nThere’s still a mild upward tip around MEDAS 7, but not as sharp as in females.\n\n\n\n3. Possible Interpretation of the “U-shaped” Pattern\n\nModerate adherence to Mediterranean diet appears most beneficial.\nVery low adherence = poor diet → higher MetS risk\nVery high adherence might reflect individuals already at high risk making compensatory dietary changes, or reduced metabolic benefit after a certain point (diminishing returns).\nThe Mediterranean diet appears most metabolically protective at moderate adherence levels (MEDAS 6–7).\nFemales show a stronger improvement in metabolic health with optimal MEDAS scores compared to males.\nBoth very low and very high adherence are associated with higher metabolic risk, indicating a nonlinear, possibly U-shaped relationship.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#medications-1",
    "href": "modeling2.html#medications-1",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "Medications",
    "text": "Medications\n\nRedundancy Analysis\nAll three variables remain.\n\n\n\n\n\nrow\nlist of remaining predictors\n\n\n\n\n1\nAntihypertensives\n\n\n2\nHyperlipidemias\n\n\n3\nAntidepressants\n\n\n\n\n\n\n\nLRT\nModel: MetS ~ Gender + rcs(MEDAS_Score,3) + Gender:rcs(MEDAS_Score,3) + xMedication where xMedication is a predictor from the above list, rcs(X,3) means that for each X as above and continuous, X is transformed using restricted cubic splines with 3 degrees of freedom in order to account for potential non-linear associations, and : means that the variables are also interacting.\nResults:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nrow\nvarName\nchisq\ndf\nanova_pval\nvarTransform\nFDR_pval\n\n\n\n\n1\nAntihypertensives\n31.8885\n6\n0.0152\nAsIs\n0.0456\n\n\n2\nAntidepressants\n29.7248\n6\n0.0533\nAsIs\n0.0799\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nFigure 3: Antihypertensives in differentiating the MetS index. The red horizontal line corresponds to the median MetS index value of 58.67 which separates the index into higher (&gt;58.67) and lower (&lt;58.67) risk regions.\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nFigure 4: Antidepressants in differentiating the MetS index. The red horizontal line corresponds to the median MetS index value of 58.67 which separates the index into higher (&gt;58.67) and lower (&lt;58.67) risk regions.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#device-data-1",
    "href": "modeling2.html#device-data-1",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "Device Data",
    "text": "Device Data\nBy device data we mean the human body measurements as seen in the Data Processing & EDA page. Also a shorter list of those measurements was finally selected for potential inclusion into the model (the list was based on better measurement interpretation reasons).\n\nRedundancy Analysis\n\n\n\n\n\nrow\nlist of remaining predictors\n\n\n\n\n1\nSite_Collection\n\n\n2\nae\n\n\n3\npe\n\n\n4\nans_balance\n\n\n5\nfatigue_index\n\n\n6\nrisk_group_cardiovascular\n\n\n7\nage\n\n\n8\nsmm\n\n\n9\nwhr\n\n\n10\ntbw_ffm_ratio\n\n\n11\nbcm_t_score\n\n\n12\nkhz_whole_body_phase_angle_z_score\n\n\n\n\n\n\n\nLRT\nModel: MetS ~ Gender + rcs(MEDAS_Score,3) + Gender:rcs(MEDAS_Score,3) + Antihypertensives + Antidepressants + rcs(xDevice,3) + Gender:rcs(xDevice,3) where xDevice is a predictor from the above list, rcs(X,3) means that for each X as above and continuous, X is transformed using restricted cubic splines with 3 degrees of freedom in order to account for potential non-linear associations, and : means that the variables are also interacting.\nResults:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nrow\nvarName\nchisq\ndf\nvarTransform\nanova_pval\nanova_pval_interactions\nFDR_pval\n\n\n\n\n1\nsmm\n63.6400\n11\nrcs\n0.0000\n0.0100\n0.0000\n\n\n2\nbcm_t_score\n63.6681\n11\nrcs\n0.0000\n0.0830\n0.0000\n\n\n3\nwhr\n54.5978\n11\nrcs\n0.0012\n0.8559\n0.0048\n\n\n4\nfatigue_index\n46.4206\n11\nrcs\n0.0243\n0.2061\n0.0729\n\n\n5\nSite_Collection\n50.9868\n15\nAsIs\n0.0529\n0.0575\n0.1270\n\n\n\n\n\nFrom the above table we can also see that smm, bcm_t_score and Site_Collection seem to interact with Gender in differentiating the MetS index. Examples are shown below.\n \n\n\n\n\n\n\n\n\nFigure 5: Interaction of Gender and Site Collection for differentiating the MetS index.\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nFigure 6: Interaction of Gender and Skeletal Muscle Mass for differentiating the MetS index. See Figure 34 for comparison to the adjusted case without Gender differentiation.\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nFigure 7: Interaction of Gender and Body Cell Mass (t-score) for differentiating the MetS index.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#biochemical-data",
    "href": "modeling2.html#biochemical-data",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "Biochemical Data",
    "text": "Biochemical Data\n\nRedundancy Analysis\n\n\n\n\n\nrow\nlist of remaining predictors\n\n\n\n\n1\nCHOL\n\n\n2\nLDL\n\n\n3\nHbA1c_Perc\n\n\n4\nUREA\n\n\n5\nCREA\n\n\n6\nOH_Vit_D3\n\n\n7\nALB\n\n\n8\nTBIL\n\n\n9\nNa\n\n\n10\nK\n\n\n11\nCRP\n\n\n12\nRBC\n\n\n13\nMVC\n\n\n14\nMCHC\n\n\n15\nRDW_CV_Perc\n\n\n16\nMONO\n\n\n17\nEOS\n\n\n18\nSGOT\n\n\n19\nSGPT\n\n\n20\nALP\n\n\n21\nAISI\n\n\n22\nEBR\n\n\n23\nLMR\n\n\n24\nPLR\n\n\n\n\n\n\n\nrexVar\nThe following predictors are not considered as they use measurements that define the MetS: TRIG, HDL, GLU, TG_HDL_C_Index, CHOL_HDL_Ratio, TyG_Index and Atherogenic_Index.\nModel: MetS ~ Gender + rcs(MEDAS_Score,3) + Gender:rcs(MEDAS_Score,3) + Antihypertensives + Antidepressants + rcs(bcm_t_score,3) + rcs(whr,3) + rcs(smm,3) + rcs(fatigue_index,3) + Site_Collection + Gender:rcs(bcm_t_score,3) + Gender:rcs(smm,3) + Gender:Site_Collection + rcs(xBiochem,3) + xBiochem_Detected + rcs(xBiochem,3):xBiochem_Detected + gender:rcs(xBiochem,3) + rcs(xBiochem,3):Antihypertensives + rcs(xBiochem,3):Antidepressants + rcs(xBiochem,3):rcs(MEDAS_Score,3) + rcs(xBiochem,3):rcs(bcm_t_score,3) + rcs(xBiochem,3):rcs(whr,3) + rcs(xBiochem,3):rcs(smm,3) + rcs(xBiochem,3):rcs(fatigue_index,3) + rcs(xBiochem,3):Site_Collection where xBiochem is a predictor from the above list, xBiochem_Detected is the corresponding LOD related indicator, rcs(X,3) means that for each X as above and continuous, X is transformed using restricted cubic splines with 3 degrees of freedom in order to account for potential non-linear associations, and : means that the variables are also interacting.\nNote that the indicator columns of type xBiochem_Detected do not play much of role in the biochemical data since they contain non-detection cases at an average rate of 5%.\nResults:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nrow\nvarName\ndf\npval_partialR2\nvarTransform\nrowname\nREV\nLower\nUpper\nFDR_pval_partialR2\n\n\n\n\n1\nHbA1c_Perc\n17.2171\n0.0000\nrcs\nxBiochem\n0.2066\n0.0710\n0.3409\n0.0000\n\n\n2\nTBIL\n18.4097\n0.0000\nrcs\nxBiochem\n0.0978\n0.0301\n0.2663\n0.0000\n\n\n3\nSGPT\n17.1463\n0.0037\nrcs\nxBiochem\n0.0992\n0.0268\n0.2430\n0.0045\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nFigure 8: Percentage of Total Hemoglobin in differentiating the MetS index. The red horizontal line corresponds to the median MetS index value of 58.67 which separates the index into higher (&gt;58.67) and lower (&lt;58.67) risk regions. See Figure 31 for comparison to the adjusted case.\n\n\n\n\n\n\n\nU-Shaped Relationship\n\nAt lower hemoglobin levels, the MetS index is higher, indicating poorer metabolic health.\nAs hemoglobin rises to a moderate range (~5.0–5.3 mg/dL), the MetS index appears to reach a low point, reflecting better metabolic health.\nBeyond this point, as hemoglobin increases further, the MetS index rises again, suggesting worsening metabolic health.\n\n➡ This indicates that both low and high hemoglobin levels may be associated with increased cardiometabolic risk, while a mid-range value represents a healthier metabolic profile.\n\n\n🧬 Physiological Interpretation\n\nLow hemoglobin may reflect anemia, inflammation, nutrient deficiencies, or chronic illness—all linked to metabolic dysfunction.\nHigh hemoglobin can reflect:\n\nIncreased blood viscosity (thicker blood),\nHypoxia or sleep apnea (common in obesity),\nInsulin resistance and oxidative stress,\nElevated erythropoietin signaling due to metabolic stress.\n\n\nThe plot suggests a U-shaped relationship, where metabolic syndrome risk is lowest at mid-range hemoglobin levels and increases at both lower and higher extremes. This may point to hemoglobin as a marker of metabolic balance, inflammation, and oxidative stress.\n\n\n\n\n\n\n\n\n\nFigure 9: Total Bilirubin in differentiating the MetS index. The red horizontal line corresponds to the median MetS index value of 58.67 which separates the index into higher (&gt;58.67) and lower (&lt;58.67) risk regions.\n\n\n\n\n\n\nSlight Inverse Trend\n\nAt low bilirubin levels, the MetS index appears slightly higher.\nAs bilirubin increases, the MetS index trends slightly lower, particularly beyond ~0.8 mg/dL.\n\nHowever, the effect is small and relatively flat overall, as shown by the non-linear curve (blue) being close to flat.\n\n\n\n🧪 Physiological Interpretation\nBilirubin is both a waste product and an endogenous antioxidant.\n\nHigher bilirubin levels (within normal range) are associated with:\n\nLower oxidative stress\nReduced inflammation\nLower risk of cardiovascular disease, diabetes, and metabolic syndrome (supported by multiple epidemiological studies)\n\nLow bilirubin may reflect reduced antioxidant capacity and increased oxidative stress, contributing to metabolic syndrome.\n\n\nThe slight downward trend in this plot supports the idea that bilirubin may be protective against metabolic dysfunction.\n\n\nThere is a modest inverse association between bilirubin and metabolic syndrome risk.\nHigher bilirubin levels (within physiological range) are associated with slightly better metabolic health.\nThe relationship is weak compared to other biochemical measurements examined here, indicating bilirubin is likely a secondary or supporting biomarker, not a primary driver.\n\n\n\n🔍 Bilirubin’s Effect Seems To Increase When Included in the Model\nEven though the raw (unadjusted) relationship between bilirubin and the Metabolic Syndrome Index appears weak and slightly negative, bilirubin is likely correlated with other variables that mask its true protective effect in the unadjusted plot.\nOnce it is included in a multivariable model that adjusts for those confounding factors, its true independent contribution becomes clearer and stronger.\n\n\n✅ Possible Explanations:\n\n\n\n\n\n\n\nMechanism\nWhat it Means\n\n\n\n\nConfounding suppression\nOther markers (like inflammation, triglycerides, glucose) may be masking bilirubin’s protective effect in the raw scatterplot. Adjusting for them reveals bilirubin’s true signal.\n\n\nNegative correlation with harmful markers\nBilirubin may be inversely correlated with oxidative stress, insulin resistance, or liver fat — so once those factors are controlled, bilirubin’s protective role is more visible.\n\n\nNonlinear effects accounted for in the model\nThe model may capture subtle nonlinear relationships (e.g., U-shaped or threshold effects) that aren’t obvious from a simple scatter.\n\n\nMultimarker synergy\nBilirubin may act as part of a protective metabolic signature that only shows significance in combination with other variables.\n\n\n\nBilirubin is a strong endogenous antioxidant. Numerous studies show that higher bilirubin (within physiological range) is protective against diabetes, cardiovascular disease, and metabolic syndrome. Its effect is often underestimated in unadjusted observations but becomes apparent when controlling for inflammation, obesity markers, or liver function.\n\nAlthough total bilirubin appears only weakly associated with metabolic syndrome when viewed alone, the multivariable model reveals that it has a meaningful independent protective effect when controlling for other metabolic factors.\n\n\n\n\n\n\n\n\n\n\nFigure 10: Serum Glutamic-Pyruvic Transaminase in differentiating the MetS index. The red horizontal line corresponds to the median MetS index value of 58.67 which separates the index into higher (&gt;58.67) and lower (&lt;58.67) risk regions.\n\n\n\n\n\n\nClear Positive Association\n\nAs ALT levels increase (even modestly), the MetS index rises.\nThe log transform compresses the scale, meaning that each step along the x-axis represents a multiplicative increase in ALT (e.g., doubling or tripling), not a linear unit.\nDespite the compression, the blue trend line still shows a steady upward slope, suggesting that even incremental log-transformed increases in ALT are associated with increased metabolic syndrome risk.\n\nALT is a biomarker of liver health. Elevated ALT is linked to:\n\nNon-alcoholic fatty liver disease (NAFLD)\nInsulin resistance\nVisceral fat accumulation\nChronic inflammation\n\nThese are core drivers of metabolic syndrome.\n➡ Thus, rising ALT—even in the subclinical range—reflects worsening metabolic dysfunction.\n\nHigher ALT levels (log-transformed) are strongly associated with increasing metabolic syndrome severity.\nThe relationship persists even after accounting for nonlinear scaling—suggesting ALT is a robust indicator of metabolic stress.\nThis supports the role of liver dysfunction as a central mechanism in the development of metabolic syndrome.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#amino-acids-sugars-data",
    "href": "modeling2.html#amino-acids-sugars-data",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "Amino Acids & Sugars Data",
    "text": "Amino Acids & Sugars Data\n\nRedundancy Analysis\n\n\n\n\n\nrow\nlist of remaining predictors\n\n\n\n\n1\nAnhydroglucitol\n\n\n2\nGlucose\n\n\n3\nMannose\n\n\n4\nFructose\n\n\n5\nValine\n\n\n6\nIsoleucine\n\n\n7\nGlutamine\n\n\n8\nPhenylalanine\n\n\n9\nTyrosine\n\n\n10\nTryptophan\n\n\n11\nGlutamine_To_Glutamic_Acid_Ratio\n\n\n\n\n\n\n\nrexVar\nThe Upper rexVar threshold is changed here to 10% from 20% that was used with the biochemical data, in order to give a larger opportunity to metabolites to enter into the model.\nModel: MetS ~ gender + rcs(MEDAS_Score,3) + Antihypertensives + Antidepressants + gender:rcs(MEDAS_Score,3) + rcs(bcm_t_score,3) + rcs(whr,3) + rcs(smm,3) + rcs(fatigue_index,3) + Site_Collection + gender:rcs(bcm_t_score,3) + gender:rcs(smm,3) + gender:Site_Collection + rcs(HbA1c_Perc,3) + rcs(SGPT,3) + rcs(TBIL,3) + rcs(xAAS,3) + rcs(xAAS,3):Site_Collection + rcs(xAAS,3):gender + rcs(xAAS,3):Antihypertensives + rcs(xAAS,3):Antidepressants + rcs(xAAS,3):rcs(MEDAS_Score,3) + rcs(xAAS,3):rcs(smm,3) + rcs(xAAS,3):rcs(bcm_t_score,3) + rcs(xAAS,3):rcs(whr,3) + rcs(xAAS,3):rcs(fatigue_index,3) + rcs(xAAS,3):rcs(HbA1c_Perc,3) + rcs(xAAS,3):rcs(SGPT,3) + rcs(xAAS,3):rcs(TBIL,3) where xAAS is a predictor from the above list and rcs means that potential non-linear associations are taken into account, and : denotes interaction.\nResults:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nrow\nvarName\ndf\npval_partialR2\nvarTransform\nrowname\nREV\nLower\nUpper\nFDR_pval_partialR2\n\n\n\n\n1\nAnhydroglucitol\n28.2136\n0.0038\nrcs\nxAAS\n0.0454\n0.0275\n0.1146\n0.0038\n\n\n2\nGlucose\n30.1713\n0.0000\nrcs\nxAAS\n0.0659\n0.0306\n0.1266\n0.0000\n\n\n3\nGlutamine_To_Glutamic_Acid_Ratio\n24.5132\nNA\nrcs\nxAAS\n0.0423\n0.0091\n0.1079\nNA\n\n\n\n\n\n \nBelow is some information on Anhydroglucitol:\n1,5-Anhydroglucitol (1,5-AG) is a naturally occurring carbohydrate (a polyol, or sugar alcohol) that circulates in the blood. It is derived mainly from dietary sources and is normally maintained at a stable level in the bloodstream.\n\n\nMetabolic Role\n\n1,5-AG closely resembles glucose in structure.\nUnder normal physiological conditions, the kidneys reabsorb it almost completely.\nWhen blood glucose levels become elevated (especially above the renal threshold ~180 mg/dL), glucose spills into the urine and competes with 1,5-AG for reabsorption.\nThis leads to decreased levels of 1,5-AG in the blood.\n\n\n\nClinical Significance\nBecause of this competition, 1,5-AG acts as a biomarker for short-term glycemic control (reflecting glucose spikes over the previous 1–2 weeks). Low 1,5-AG levels indicate frequent hyperglycemic episodes.\n\n\n\n\n\n\n\nFeature\nDetail\n\n\n\n\nChemical class\nMonosaccharide derivative (polyol)\n\n\nSource\nPrimarily dietary; minimally produced by the body\n\n\nMetabolic behavior\nReabsorbed by kidneys unless high glucose is present\n\n\nClinical use\nMarker for short-term glycemic control (postprandial glucose spikes)\n\n\nTest name\nGlycoMark® test in clinical practice\n\n\n\n1,5-Anhydroglucitol is useful in diabetes management as it helps detect hyperglycemia that may not be reflected in HbA1c values.\nAnhydroglucitol is a glucose-like blood metabolite used as a sensitive indicator of recent high blood sugar excursions.\n \n\n\n\n\n\n\n\n\nFigure 11: Relationship between 1,5-Anhydroglucitol levels (x-axis) and blood glucose levels (y-axis), separated by metabolic syndrome (MetS) risk groups. The median MetS index value of 58.67 separates the index into higher (&gt;58.67) and lower (&lt;58.67) risk regions. Red = Higher MetS risk and * Green = Lower MetS risk. See Figure 32 for comparison to the adjusted case for Anhydroglucitol.\n\n\n\n\n\n\n1. Inverse relationship overall\n\nAs Anhydroglucitol increases, glucose levels tend to decrease, especially in the lower-risk group (green line).\nThis aligns with clinical understanding: higher 1,5-AG indicates better short-term glycemic control.\n\n\n\n2. Stronger association in the lower-risk group\n\nThe green curve (lower MetS risk) shows a clear drop in glucose as Anhydroglucitol rises.\nIndividuals with good metabolic health maintain both higher Anhydroglucitol and lower glucose.\n\n\n\n3. Higher-risk group shows less benefit\n\nThe red curve (higher MetS risk) shows a flatter or even U-shaped pattern: even when Anhydroglucitol rises, glucose eventually increases again.\nThis suggests metabolic dysregulation: 1,5-AG loses its protective correlation in those at higher risk.\nLow Anhydroglucitol = poor glycemic control and likely metabolic dysfunction.\nHigh Anhydroglucitol is protective, but only in those without advanced metabolic syndrome.\nIn those at higher risk, the regulatory relationship between 1,5-AG and glucose appears impaired—possibly due to renal threshold changes or chronic hyperglycemia.\n\n\nHigher 1,5-Anhydroglucitol is associated with lower glucose levels and better metabolic health. However, in people with higher metabolic syndrome risk, this relationship weakens, suggesting underlying metabolic damage that interferes with normal glucose buffering and renal reabsorption mechanisms.\n \n\n\n\n\n\n\n\n\nFigure 12: Relationship between Glutamine To Glutamic Acid Ratio and Metabolic Syndrome (MetS) Risk. The median MetS index value of 58.67 separates the index into higher (&gt;58.67) and lower (&lt;58.67) risk regions.\n\n\n\n\n\nU-Shaped Relationship\n\nAt low ratios (closer to 1.0), the MetS index is high, indicating poor metabolic health.\nAs the ratio increases toward approximately 2.5–3.0, the MetS index declines, suggesting improved metabolic health.\nBeyond ~3.0, the trend curves upward slightly, suggesting that extremely high ratios may be associated with increasing metabolic risk again.\n\n▶ Optimal metabolic health appears around a glutamine/glutamic acid ratio of ~2.5–3.0.\n\nGlutamine is anti-inflammatory and associated with better insulin sensitivity.\nGlutamic acid (glutamate) is linked to oxidative stress, inflammation, and metabolic dysfunction.\nTherefore, a higher ratio generally reflects a healthier metabolic state—up to a point.\n\n🔸 Low ratio = high glutamic acid = metabolic stress and insulin resistance. 🔸 Moderate ratio = optimal balance = better metabolic health. 🔸 Very high ratio = possibly reflects abnormal amino acid metabolism or compensatory stress response.\nThe optimal metabolic profile occurs at a balanced glutamine-to-glutamic acid ratio (around 2.5–3.0). Very low or very high ratios are associated with higher metabolic syndrome risk.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#acylcarnitines-data",
    "href": "modeling2.html#acylcarnitines-data",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "AcylCarnitines Data",
    "text": "AcylCarnitines Data\n\nRedundancy Analysis\n\n\n\n\n\nrow\nlist of remaining predictors\n\n\n\n\n1\nAcetylcarnitine\n\n\n2\nPropionylcarnitine\n\n\n3\nButyrylcarnitine\n\n\n4\nValerylcarnitine\n\n\n5\nLauroylcarnitine\n\n\n6\nStearoylcarnitine\n\n\n7\nLinoleoylcarnitine\n\n\n8\nOleoylcarnitine\n\n\n\n\n\n\n\nrexVar\nThe Upper rexVar threshold is changed here to 10% from 20% that was used with the biochemical data, in order to give a larger opportunity to metabolites to enter into the model.\nModel: MetS ~ gender + rcs(MEDAS_Score,3) + Antihypertensives + Antidepressants + gender:rcs(MEDAS_Score,3) + rcs(bcm_t_score,3) + rcs(whr,3) + rcs(smm,3) + rcs(fatigue_index,3) + Site_Collection + gender:rcs(bcm_t_score,3) + gender:rcs(smm,3) + gender:Site_Collection + rcs(HbA1c_Perc,3) + rcs(log(SGPT),3) + rcs(log(TBIL),3) + rcs(Anhydroglucitol,3) + rcs(Glucose,3) + rcs(log(Glutamine_To_Glutamic_Acid_Ratio),3) + rcs(xAcylCar,3) + rcs(xAcylCar,3):gender + rcs(xAcylCar,3):rcs(MEDAS_Score,3) + rcs(xAcylCar,3):Antihypertensives + rcs(xAcylCar,3):Antidepressants + rcs(xAcylCar,3):rcs(bcm_t_score,3) + rcs(xAcylCar,3):rcs(whr,3) + rcs(xAcylCar,3):rcs(smm,3) + rcs(xAcylCar,3):rcs(fatigue_index,3) + rcs(xAcylCar,3):Site_Collection + rcs(xAcylCar,3):rcs(HbA1c_Perc,3) + rcs(xAcylCar,3):rcs(log(SGPT),3) + rcs(xAcylCar,3):rcs(log(TBIL),3) + rcs(xAcylCar,3):rcs(Anhydroglucitol,3) + rcs(xAcylCar,3):rcs(Glucose,3) + rcs(xAcylCar,3):rcs(log(Glutamine_To_Glutamic_Acid_Ratio),3) where xAAS is a predictor from the above list and rcs means that potential non-linear associations are taken into account, and : denotes interaction.\nResults:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nrow\nvarName\ndf\npval_partialR2\nvarTransform\nrowname\nREV\nLower\nUpper\nFDR_pval_partialR2\n\n\n\n\n1\nPropionylcarnitine\n25.1347\n0\nrcs\nxAcylCar\n0.0468\n0.0125\n0.1004\n0\n\n\n2\nLauroylcarnitine\n20.9980\n0\nrcs\nxAcylCar\n0.0085\n0.0038\n0.1204\n0\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nFigure 13: Relationship between Propionylcarnitine (μΜ) and Metabolic Syndrome (MetS) Risk. The median MetS index value of 58.67 separates the index into higher (&gt;58.67) and lower (&lt;58.67) risk regions.\n\n\n\n\n\n\n\n1. U-Shaped (Curvilinear) Relationship\nThe fitted blue line exhibits a slight U-shaped curve, suggesting a non-linear association between Propionylcarnitine and the MetS Index:\n\nLow Concentrations: At very low concentrations of Propionylcarnitine (left side, e.g., \\(\\text{log}(\\mu\\text{M}) \\approx 0.2\\) to \\(0.5\\)), the MetS Index is relatively high.\nIntermediate Concentrations: The MetS Index reaches its lowest point (the bottom of the “U”) around the intermediate Propionylcarnitine concentration (\\(\\text{log}(\\mu\\text{M}) \\approx 0.6\\) to \\(0.8\\)).\nHigh Concentrations: At very high concentrations of Propionylcarnitine (right side, e.g., \\(\\text{log}(\\mu\\text{M}) \\approx 1.2\\) to \\(1.6\\)), the MetS Index rises again.\n\n\n\n2. Risk Regions Defined by the Red Line\nThe red line is at the median MetS Index value of \\(58.67\\), separating the risk regions:\n\nMetS Index \\(&gt;\\) 58.67 (Higher Risk): This area is above the red line.\nMetS Index \\(&lt;\\) 58.67 (Lower Risk): This area is below the red line.\n\nThe fitted blue curve is mostly below the red line in the intermediate concentration range, indicating that individuals with intermediate Propionylcarnitine levels generally have a MetS Index below the median risk threshold. Conversely, individuals at the lowest and highest extremes of Propionylcarnitine concentration have fitted MetS Index values that approach or cross above the risk threshold (red line), suggesting a potential increase in Metabolic Syndrome risk at these extremes.\nThe plot suggests that the lowest risk for Metabolic Syndrome (lowest MetS Index) is found at intermediate levels of Propionylcarnitine, with risk potentially increasing at both very low and very high concentrations, following a slight U-shaped pattern.\nPropionylcarnitine (C3) is a short-chain acylcarnitine derived from the breakdown of certain amino acids (specifically valine, methionine, threonine, and isoleucine), as well as odd-chain fatty acids.\n\n\n3. Marker of Impaired Amino Acid Catabolism\nThe primary biological inferred context of elevated Propionylcarnitine (C3) in the context of MetS and related conditions (like insulin resistance) is that it signals a potential bottleneck in the mitochondrial catabolism of Branched-Chain Amino Acids (BCAAs) and other amino acids.\n\nPropionyl-CoA, an intermediate in the BCAA breakdown pathway, is esterified with carnitine to form Propionylcarnitine (C3) to prevent the accumulation of Propionyl-CoA, which would otherwise inhibit the Krebs cycle.\nHigh levels of C3, often alongside other acylcarnitines, suggest that the capacity of the mitochondria to handle this metabolic load is overwhelmed, a classic sign of mitochondrial dysfunction and insulin resistance.\n\n\n\n4. Association with Insulin Resistance and MetS Risk\nNumerous studies have found that higher serum Propionylcarnitine concentrations are positively correlated with an increased risk of MetS and its components, including:\n\nIncreased body fat and BMI.\nDyslipidemia (high triglycerides, low HDL).\nHigher risk of insulin resistance and cardiovascular disease.\n\n\n\n5. Contrast with Long-Chain Acylcarnitines\nWhile long-chain acylcarnitines (like Palmitoylcarnitine) primarily reflect impaired fatty acid oxidation, Propionylcarnitine (C3) specifically highlights a disorder in amino acid-derived carbon flux into the Krebs cycle, making it a distinct and important biomarker for the metabolic stress underlying MetS.\n\n \n\n\n\n\n\n\n\n\nFigure 14: Relationship between Lauroylcarnitine (μΜ) and Metabolic Syndrome (MetS) Risk. The median MetS index value of 58.67 separates the index into higher (&gt;58.67) and lower (&lt;58.67) risk regions.\n\n\n\n\n\n\n\n1. Inverted U-Shaped (Curvilinear) Relationship\nThe fitted blue line shows a slightly inverted U-shaped curve, indicating that risk is lower at extreme concentrations:\n\nLow Concentrations (Left Side): At the lowest Lauroylcarnitine concentrations (e.g., \\(\\text{log10}(\\mu\\text{M}) \\approx 0.003\\) to \\(0.01\\)), the MetS Index is relatively low.\nIntermediate Concentrations (Peak): The MetS Index reaches its highest predicted value (the peak of the inverted “U”) around the intermediate Lauroylcarnitine concentration (\\(\\text{log10}(\\mu\\text{M}) \\approx 0.03\\) to \\(0.1\\)).\nHigh Concentrations (Right Side): At the highest concentrations of Lauroylcarnitine (e.g., \\(\\text{log10}(\\mu\\text{M}) \\approx 0.3\\) to \\(1.0\\)), the MetS Index decreases again.\n\n\n\n2. Risk Regions Defined by the Red Line\nThe red line is at the median MetS Index value of \\(58.67\\), separating the risk regions:\n\nMetS Index \\(\\ge\\) 58.67 (Higher Risk): This area is above the red line.\nMetS Index \\(&lt;\\) 58.67 (Lower Risk): This area is below the red line.\n\nThe fitted blue curve is close but not above the red line for a significant range of the intermediate concentration (roughly \\(\\text{log10}(\\mu\\text{M}) \\approx 0.01\\) to \\(0.3\\)), indicating that individuals with intermediate Lauroylcarnitine levels generally have a MetS risk. Conversely, individuals at the lowest and highest extremes of Lauroylcarnitine concentration have fitted MetS Index values that drop to or are below the risk threshold, suggesting a potential decrease in Metabolic Syndrome risk at these extremes.\n\n\n3. Biological Context (Inferred)\nLauroylcarnitine is an acylcarnitine involved in fatty acid \\(\\beta\\)-oxidation. Elevated acylcarnitines, particularly medium- and long-chain forms, are often observed when fatty acid oxidation is incomplete, typically due to mitochondrial dysfunction and insulin resistance, which are central to Metabolic Syndrome.\nThe inverted U-shape suggests that MetS risk is highest when Lauroylcarnitine is at a moderate concentration, which could represent a state of significant but compensated metabolic stress. Risk decreases at the extremes (very low or very high), potentially due to different underlying physiological states.\nThe previous two plots, the inverted U-shaped curve of Lauroylcarnitine, and the likely positive or U-shaped curve for Propionylcarnitine, both relate to Metabolic Syndrome (MetS) through the lens of mitochondrial dysfunction and impaired substrate metabolism.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#urine-hydrophilic-interaction-liquid-chromatography-hilic-data",
    "href": "modeling2.html#urine-hydrophilic-interaction-liquid-chromatography-hilic-data",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "Urine Hydrophilic Interaction Liquid Chromatography (HILIC) Data",
    "text": "Urine Hydrophilic Interaction Liquid Chromatography (HILIC) Data\n\nRedundancy Analysis\n\n\n\n\n\nrow\nlist of remaining predictors\n\n\n\n\n1\nMethylhistidine\n\n\n2\nAcetylcarnitine\n\n\n3\nAdenine\n\n\n4\nAllantoin\n\n\n5\nAscorbic_Acid\n\n\n6\nBenzoic_Acid\n\n\n7\nBetaine\n\n\n8\nCaffeine\n\n\n9\nCotinine\n\n\n10\nCreatine\n\n\n11\nCytosine\n\n\n12\nGuanine\n\n\n13\nHippuric_Acid\n\n\n14\nHistamine\n\n\n15\nHypoxanthine\n\n\n16\nInosine\n\n\n17\nKynurenate\n\n\n18\nLactose\n\n\n19\nLysine\n\n\n20\nMethylamine\n\n\n21\nNicotinamide\n\n\n22\nPantothenate\n\n\n23\nPyridoxine\n\n\n24\nRiboflavine\n\n\n25\nSorbitol\n\n\n26\nSucrose\n\n\n27\nTaurine\n\n\n28\nTheobromine\n\n\n29\nThiamine\n\n\n30\nTrimethylamine\n\n\n31\nTrimethylamine_N_Oxide\n\n\n32\nTryptamine\n\n\n33\nUracil\n\n\n34\nXanthine\n\n\n35\nA_Ketoglutaric_Acid\n\n\n36\nG_Aminobutyric\n\n\n\n\n\n\n\nrexVar\nThe Upper rexVar threshold is changed here to 10% from 20% that was used with the biochemical data, in order to give a larger opportunity to metabolites to enter into the model.\nModel: MetS ~ gender + rcs(MEDAS_Score,3) + Antihypertensives + Antidepressants + gender:rcs(MEDAS_Score,3) + rcs(bcm_t_score,3) + rcs(whr,3) + rcs(smm,3) + rcs(fatigue_index,3) + Site_Collection + gender:rcs(bcm_t_score,3) + gender:rcs(smm,3) + gender:Site_Collection + rcs(HbA1c_Perc,3) + rcs(log(SGPT),3) + rcs(log(TBIL),3) + rcs(Anhydroglucitol,3) + rcs(Glucose,3) + rcs(log(Glutamine_To_Glutamic_Acid_Ratio),3) + rcs(Propionylcarnitine,3) + rcs(log(Lauroylcarnitine),3) + rcs(log(xHilic),3) + rcs(log(xHilic),3):gender + rcs(log(xHilic),3):rcs(MEDAS_Score,3) + rcs(log(xHilic),3):Antihypertensives + rcs(log(xHilic),3):Antidepressants + rcs(log(xHilic),3):rcs(bcm_t_score,3) + rcs(log(xHilic),3):rcs(whr,3) + rcs(log(xHilic),3):rcs(smm,3) + rcs(log(xHilic),3):rcs(fatigue_index,3) + rcs(log(xHilic),3):Site_Collection + rcs(log(xHilic),3):rcs(HbA1c_Perc,3) + rcs(log(xHilic),3):rcs(log(SGPT),3) + rcs(log(xHilic),3):rcs(log(TBIL),3) + rcs(log(xHilic),3):rcs(Anhydroglucitol,3) + rcs(log(xHilic),3):rcs(Glucose,3) + rcs(log(xHilic),3):rcs(log(Glutamine_To_Glutamic_Acid_Ratio),3) + rcs(log(xHilic),3):rcs(Propionylcarnitine,3) + rcs(log(xHilic),3):rcs(log(Lauroylcarnitine),3) where xHilic is a predictor from the above list and rcs means that potential non-linear associations are taken into account, and : denotes interaction.\nResults:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nrow\nvarName\ndf\npval_partialR2\nvarTransform\nrowname\nREV\nLower\nUpper\nFDR_pval_partialR2\n\n\n\n\n1\nRiboflavine\n26.9323\n0\nrcs\nxHilic\n0.0381\n0.0179\n0.1069\n0\n\n\n2\nUracil\n28.0276\n0\nrcs\nxHilic\n0.0282\n0.0139\n0.1089\n0\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nFigure 15: Relationship between Riboflavine (peak area) and Metabolic Syndrome (MetS) Risk. The median MetS index value of 58.67 separates the index into higher (&gt;58.67) and lower (&lt;58.67) risk regions.\n\n\n\n\n\nConnection to metabolic syndrome (MetS)\n\nConnection suggested by various studies, largely focusing on the role of Riboflavin (Vitamin \\(B_2\\)) and its coenzymes in metabolic pathways implicated in MetS:\nEnergy Metabolism and Insulin Resistance: Riboflavin and its flavocoenzymes are central to mitochondrial function and energy production. Dysfunction in these pathways is a hallmark of insulin resistance, a core component of Metabolic Syndrome.\nInflammation: Some research suggests that riboflavin supplementation may help reduce obesity-related inflammation, which is a major contributor to insulin resistance and the development of MetS and type 2 diabetes.\nAssociation with MetS Risk: Studies have explored the correlation between riboflavin levels (e.g., in serum) and the risk of developing Metabolic Syndrome, with some finding an association.\nFat Metabolism: Riboflavin is essential for enzymes involved in fatty acid oxidation. Impairment in riboflavin-dependent enzymes can lead to a MADD (Multiple Acyl-CoA Dehydrogenase Deficiency) profile, reflecting disturbed fatty acid metabolism.\n\nRiboflavin (or its metabolites) is a major polar molecule in urine, often analyzed by HILIC, and its metabolism is strongly linked to the fundamental biological processes (like energy production and redox status) that are dysfunctional in Metabolic Syndrome.\nReferences\n1, 2, 3, 4, 5, 6, 7, 8, 9,10\n \n\n\n\n\n\n\n\n\nFigure 16: Relationship between Uracil (peak area) and Metabolic Syndrome (MetS) Risk. The median MetS index value of 58.67 separates the index into higher (&gt;58.67) and lower (&lt;58.67) risk regions.\n\n\n\n\n\nConnection to metabolic syndrome (MetS)\nWhile Uracil itself isn’t a widely recognized primary biomarker for MetS like blood glucose or lipids, alterations in its related metabolic pathway (pyrimidine metabolism) are relevant to the underlying pathology of MetS:\n\nNucleic Acid Metabolism: Uracil and pyrimidine metabolites are essential for cell proliferation and repair. Dysregulation of nucleotide synthesis is often observed in conditions of metabolic stress or disease.\nUric Acid Precursor: Although Uracil is a pyrimidine, its metabolism can be related to purine metabolism, which leads to uric acid production. High uric acid levels (hyperuricemia) are a recognized component and risk factor associated with MetS and insulin resistance.\nBiomarker Potential: In the context of large-scale metabolomic screening, Uracil, along with a panel of other metabolites (including amino acids and lipids), may contribute to a “molecular signature” in urine that can help discriminate between healthy individuals and those with MetS. Changes in these polar metabolites are used to gain insight into system-wide metabolic disruptions caused by the syndrome.\n\nReferences\n1, 2",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#urine-tyrosinetryptophan-pathway-data",
    "href": "modeling2.html#urine-tyrosinetryptophan-pathway-data",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "Urine Tyrosine–Tryptophan Pathway Data",
    "text": "Urine Tyrosine–Tryptophan Pathway Data\n\nRedundancy Analysis\n\n\n\n\n\nrow\nlist of remaining predictors\n\n\n\n\n1\nHIAA\n\n\n2\nHIAA_Sulfate\n\n\n3\nDopamine\n\n\n4\nHippuric_Acid\n\n\n5\nHomovanilic_Acid\n\n\n6\nIndole\n\n\n7\nIndole3Acetic_Acid\n\n\n8\nIndoxyl_Sulfate\n\n\n9\nKynurenic_Acid\n\n\n10\nKynurenine\n\n\n11\nP_Coumaric_Acid\n\n\n12\nP_Coumaric_Acid_Sulfate\n\n\n13\nP_Cresol_Sulfate\n\n\n14\nP_Ethylphenol_Sulfate\n\n\n15\nP_HBA\n\n\n16\nP_HBA_Sulfate\n\n\n17\nP_Hydroxyphenyl_Acetic_Acid\n\n\n18\nP_Hydroxyphenyl_Acetic_Acid_Sulfate\n\n\n19\nP_Hydroxyphenyllactic_Acid\n\n\n20\nP_Hydroxyphenyllactic_Acid_Sulfate\n\n\n21\nP_Hydroxyphenylpropionic_Acid_Sulfate\n\n\n22\nPhenol_Sulfate\n\n\n23\nPhenylalanine\n\n\n24\nTyramine\n\n\n\n\n\n\n\nrexVar\nThe Upper rexVar threshold is changed here to 10% from 20% that was used with the biochemical data, in order to give a larger opportunity to metabolites to enter into the model.\nModel: MetS ~ gender + rcs(MEDAS_Score,3) + Antihypertensives + Antidepressants + gender:rcs(MEDAS_Score,3) + rcs(bcm_t_score,3) + rcs(whr,3) + rcs(smm,3) + rcs(fatigue_index,3) + Site_Collection + gender:rcs(bcm_t_score,3) + gender:rcs(smm,3) + gender:Site_Collection + rcs(HbA1c_Perc,3) + rcs(log(SGPT),3) + rcs(log(TBIL),3) + rcs(Anhydroglucitol,3) + rcs(Glucose,3) + rcs(log(Glutamine_To_Glutamic_Acid_Ratio),3) + rcs(Propionylcarnitine,3) + rcs(log(Lauroylcarnitine),3) + rcs(log(Riboflavine),3) + rcs(log(Uracil),3) + rcs(log(xTyroTrypto),3) + xTyroTrypto_Detected + rcs(log(xTyroTrypto),3):xTyroTrypto_Detected + rcs(log(xTyroTrypto),3):gender + rcs(log(xTyroTrypto),3):rcs(MEDAS_Score,3) + rcs(log(xTyroTrypto),3):Antihypertensives + rcs(log(xTyroTrypto),3):Antidepressants + rcs(log(xTyroTrypto),3):rcs(bcm_t_score,3) + rcs(log(xTyroTrypto),3):rcs(whr,3) + rcs(log(xTyroTrypto),3):rcs(smm,3) + rcs(log(xTyroTrypto),3):rcs(fatigue_index,3) + rcs(log(xTyroTrypto),3):Site_Collection + rcs(log(xTyroTrypto),3):rcs(HbA1c_Perc,3) + rcs(log(xTyroTrypto),3):rcs(log(SGPT),3) + rcs(log(xTyroTrypto),3):rcs(log(TBIL),3) + rcs(log(xTyroTrypto),3):rcs(Anhydroglucitol,3) + rcs(log(xTyroTrypto),3):rcs(log(Glutamine_To_Glutamic_Acid_Ratio),3) + rcs(log(xTyroTrypto),3):rcs(Propionylcarnitine,3) + rcs(log(xTyroTrypto),3):rcs(log(Lauroylcarnitine),3) + rcs(log(xTyroTrypto),3):rcs(Glucose,3) + rcs(log(xTyroTrypto),3):rcs(log(Riboflavine),3) + rcs(log(xTyroTrypto),3):rcs(log(Uracil),3) where xTyroTrypto is a predictor from the above list, rcs means that potential non-linear associations are taken into account and : denotes interaction.\nResults:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nrow\nvarName\ndf\npval_partialR2\nvarTransform\nrowname\nREV\nLower\nUpper\nFDR_pval_partialR2\n\n\n\n\n1\nHIAA\n32.0768\n0\nrcs\nxTyroTrypto\n0.0995\n0.0492\n0.1604\n0\n\n\n6\nIndole3Lactic_Acid\n29.5786\n0\nrcs\nxTyroTrypto\n0.0940\n0.0403\n0.1652\n0\n\n\n5\nIndole3Acetic_Acid\n29.8645\n0\nrcs\nxTyroTrypto\n0.0822\n0.0378\n0.1683\n0\n\n\n4\nIndole\n30.7003\n0\nrcs\nxTyroTrypto\n0.0779\n0.0290\n0.1698\n0\n\n\n3\nHippuric_Acid\n28.9300\n0\nrcs\nxTyroTrypto\n0.0559\n0.0154\n0.1188\n0\n\n\n9\nP_Coumaric_Acid_Sulfate\n28.8463\n0\nrcs\nxTyroTrypto\n0.0475\n0.0088\n0.1058\n0\n\n\n2\nDopamine\n24.9307\n0\nrcs\nxTyroTrypto\n0.0464\n0.0089\n0.1267\n0\n\n\n7\nKynurenic_Acid\n27.1583\n0\nrcs\nxTyroTrypto\n0.0438\n0.0184\n0.1170\n0\n\n\n8\nP_Coumaric_Acid\n22.7229\n0\nrcs\nxTyroTrypto\n0.0376\n0.0090\n0.1029\n0\n\n\n10\nP_HBA_Sulfate\n29.0542\n0\nrcs\nxTyroTrypto\n0.0334\n0.0177\n0.1005\n0\n\n\n11\nP_Hydroxyphenyl_Acetic_Acid\n30.9906\n0\nrcs\nxTyroTrypto\n0.0154\n0.0078\n0.1073\n0\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nFigure 17: Relationship between 5HIAA (μg/mmol of creatinine) and Metabolic Syndrome (MetS) Risk. The median MetS index value of 58.67 separates the index into higher (&gt;58.67) and lower (&lt;58.67) risk regions.\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nFigure 18: Relationship between Hippuric Acid (μg/mmol of creatinine) and Metabolic Syndrome (MetS) Risk. The median MetS index value of 58.67 separates the index into higher (&gt;58.67) and lower (&lt;58.67) risk regions. See Figure 33 for comparison to the adjusted case.\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nFigure 19: Relationship between Indole (μg/mmol of creatinine) and Metabolic Syndrome (MetS) Risk. The median MetS index value of 58.67 separates the index into higher (&gt;58.67) and lower (&lt;58.67) risk regions.\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nFigure 20: Relationship between Indole3Lactic Acid (μg/mmol of creatinine) and Metabolic Syndrome (MetS) Risk. The median MetS index value of 58.67 separates the index into higher (&gt;58.67) and lower (&lt;58.67) risk regions.\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nFigure 21: Relationship between P-Coumaric Acid Sulfate (μg/mmol of creatinine) and Metabolic Syndrome (MetS) Risk. The median MetS index value of 58.67 separates the index into higher (&gt;58.67) and lower (&lt;58.67) risk regions.\n\n\n\n\n\nThese urine metabolites indicate some strength on key disruptions in two major interconnected pathways: the Tryptophan Metabolism (Kynurenine and Indole Pathways) and Gut Microbiota Metabolism.\nMetS seems to be associated with a systemic change in how the body and its resident bacteria process the amino acid Tryptophan and other dietary compounds, leading to altered levels of neuroactive, anti-inflammatory, and pro-inflammatory molecules.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#tryptophan-metabolism-inflammation",
    "href": "modeling2.html#tryptophan-metabolism-inflammation",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "1. Tryptophan Metabolism & Inflammation",
    "text": "1. Tryptophan Metabolism & Inflammation\nThe essential amino acid Tryptophan is metabolized down three main pathways in the body. The metabolites listed reflect imbalances in two of these pathways, which are often dysregulated in MetS due to chronic low-grade inflammation and immune activation—hallmarks of the condition.\n\n\n\n\n\n\n\n\nMetabolite\nPathway\nRole & Link to MetS\n\n\n\n\n5-HIAA (5-Hydroxyindoleacetic Acid)\nSerotonin Pathway\nThe main breakdown product of the neurotransmitter Serotonin. Serotonin is largely produced in the gut. Altered 5-HIAA levels can indicate changes in serotonin turnover, which impacts gut motility, mood, and appetite regulation—all factors relevant to MetS development.\n\n\nKynurenic Acid\nKynurenine Pathway\nThis is the major route for Tryptophan catabolism. An overactive Kynurenine pathway, often driven by inflammation (e.g., from inflammatory cytokines), can deplete Tryptophan available for the Serotonin pathway. Kynurenic Acid is often considered neuroprotective and its levels relative to other metabolites can serve as a marker of the body’s inflammatory status.\n\n\nDopamine\nCatecholamine Metabolism\nWhile not a Tryptophan metabolite, Dopamine is a crucial neurotransmitter. Changes in urinary Dopamine levels can reflect alterations in the autonomic nervous system and neuroendocrine regulation, which are closely tied to blood pressure (hypertension) and energy balance—core components of MetS.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#gut-microbiota-derived-metabolites",
    "href": "modeling2.html#gut-microbiota-derived-metabolites",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "2. Gut Microbiota-Derived Metabolites",
    "text": "2. Gut Microbiota-Derived Metabolites\nA large portion of the listed metabolites are produced directly or indirectly by the gut microbiota (the bacteria living in your intestines) from undigested dietary compounds, especially Tryptophan and polyphenols. An altered gut bacterial community, known as dysbiosis, is strongly linked to MetS.\n\n\n\n\n\n\n\n\nMetabolite\nPrimary Source\nLink to MetS\n\n\n\n\nIndole & Indole-3-Acetic Acid (IAA), Indole-3-Lactic Acid\nTryptophan breakdown by gut bacteria\nThese Indole derivatives are powerful signaling molecules. They activate host receptors (like the Aryl Hydrocarbon Receptor, AhR) which are essential for maintaining the gut barrier integrity and regulating the immune system. Low levels of beneficial indoles (often seen in dysbiosis) are linked to a “leaky gut,” systemic inflammation, and insulin resistance.\n\n\nHippuric Acid\nPolyphenols (from fruits, vegetables, coffee) breakdown by gut bacteria\nA major marker of the health and diversity of the gut microbiome. It’s the final host-processed form of compounds produced by bacteria. A low level can be an indicator of poor gut bacterial function or low dietary intake of polyphenols, both associated with poor metabolic health.\n\n\nP-Coumaric Acid, P-Coumaric Acid Sulfate, P-HBA Sulfate, P-Hydroxyphenyl Acetic Acid\nTyrosine and Polyphenol breakdown by gut bacteria\nThese are common products of microbial degradation of aromatic amino acids (like Tyrosine) and dietary polyphenols. Their altered urinary levels reflect a change in the efficiency or type of microbial fermentation occurring in the gut, another sign of dysbiosis in MetS patients.\n\n\n\nThe combined changes in these urinary metabolites provide a non-invasive “fingerprint” of metabolic health that points to systemic inflammation, dysregulation of neurotransmitter precursors, and, most importantly, dysfunctional gut microbiota activity as central features of Metabolic Syndrome.\nThe plots display the relationship between the Metabolic Syndrome (MetS) Index (Y-axis) and the urinary concentration of five metabolites (X-axis, \\(\\text{log}\\) scale). The blue line represents the trend (Local Polynomial Regression, or LOESS), and the red line represents the median MetS Index.\nBy analyzing the trend line we can determine the correlation.\n\n1. Metabolites Showing a Negative Correlation\nA negative correlation means that as the metabolite level increases, the MetS Index decreases (i.e., a better metabolic state). This supports the idea that these metabolites are important in differentiating MetS, as a high concentration suggests a healthy metabolic profile.\n\n\n\n\n\n\n\n\n\nMetabolite\nTrend (Blue Line)\nSupport for Differentiation?\nInterpretation in MetS\n\n\n\n\nHippuric Acid\nDecreases steadily as the X-value increases.\nYES\nHigh levels are associated with high gut microbiota diversity/activity (polyphenol breakdown), suggesting a healthy gut-host interaction. Low levels are linked to MetS.\n\n\nP-Coumaric Acid Sulfate\nDecreases steadily as the X-value increases.\nYES\nHigh levels reflect robust gut microbiota processing of dietary phenolics. Low levels suggest dysbiosis or poor diet/absorption.\n\n\nIndole3Lactic Acid\nDecreases steadily as the X-value increases.\nYES\nA product of Tryptophan metabolism by gut bacteria. High levels may indicate a healthy Tryptophan-microbiota axis and beneficial signaling.\n\n\n\n\n\n2. Metabolites Showing a Non-Linear or Inverse Relationship\nThese metabolites show a more complex or non-linear relationship with the MetS Index.\n\n\n\n\n\n\n\n\n\nMetabolite\nTrend (Blue Line)\nSupport for Differentiation?\nInterpretation in MetS\n\n\n\n\n5HIAA\nStarts high, peaks around the median \\(\\text{log}\\) value, then decreases.\nPARTIALLY\nThe flat or slightly decreasing portion at lower concentrations and the subsequent decrease suggest that a moderate to high level is associated with a lower MetS Index. The initial increase might reflect complex feedback in Serotonin metabolism.\n\n\nIndole\nForms a “U” shape (concave up). The lowest MetS Index occurs at moderate Indole levels (around \\(1.00 - 2.00\\) \\(\\text{log}\\) scale).\nPARTIALLY\nThis indicates a non-linear effect: very low and very high levels of Indole are associated with a higher MetS Index (worse MetS state). This suggests that homeostasis (a moderate level) of this Tryptophan-derived gut metabolite is optimal for metabolic health.\n\n\n\nThe plots support the functional importance of Hippuric Acid, P-Coumaric Acid Sulfate, and Indole3Lactic Acid in differentiating the metabolic state, as a direct inverse relationship is observed: higher concentration of these gut-derived metabolites correlates with a lower MetS Index.\nThe relationships for 5HIAA and Indole are more complex (non-linear or moderate inverse), suggesting that their role is governed by a regulatory optimum rather than a simple dose-response curve. Nonetheless, they still differentiate the extremes of the MetS Index, supporting their inclusion as relevant potential biomarkers.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#untargeted-metabolomics",
    "href": "modeling2.html#untargeted-metabolomics",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "Untargeted metabolomics",
    "text": "Untargeted metabolomics\nAwaiting data provision.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#selected-predictors",
    "href": "modeling2.html#selected-predictors",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "Selected Predictors",
    "text": "Selected Predictors\nList:\n\n\n\n\n\nrow\npredictor\ntype\n\n\n\n\n1\ngender\ndemographic\n\n\n2\nMEDAS_Score\ndietary\n\n\n3\nAntihypertensives\nmedication\n\n\n4\nAntidepressants\nmedication\n\n\n5\nsmm\ndevice\n\n\n6\nbcm_t_score\ndevice\n\n\n7\nwhr\ndevice\n\n\n8\nfatigue_index\ndevice\n\n\n9\nSite_Collection\ndemographic\n\n\n10\nHbA1c_Perc\nbiochemical\n\n\n11\nTBIL\nbiochemical\n\n\n12\nSGPT\nbiochemical\n\n\n13\nAnhydroglucitol\namino acid & sugar\n\n\n14\nGlucose\namino acid & sugar\n\n\n15\nGlutamine_To_Glutamic_Acid_Ratio\namino acid & sugar\n\n\n16\nPropionylcarnitine\ncarnitines\n\n\n17\nLauroylcarnitine\ncarnitines\n\n\n18\nRiboflavine\nhilic urine\n\n\n19\nUracil\nhilic urine\n\n\n20\nHIAA\ntryptophan-tyrosine urine\n\n\n21\nDopamine\ntryptophan-tyrosine urine\n\n\n22\nHippuric_Acid\ntryptophan-tyrosine urine\n\n\n23\nIndole\ntryptophan-tyrosine urine\n\n\n24\nIndole3Acetic_Acid\ntryptophan-tyrosine urine\n\n\n25\nIndole3Lactic_Acid\ntryptophan-tyrosine urine\n\n\n26\nKynurenic_Acid\ntryptophan-tyrosine urine\n\n\n27\nP_Coumaric_Acid\ntryptophan-tyrosine urine\n\n\n28\nP_Coumaric_Acid_Sulfate\ntryptophan-tyrosine urine\n\n\n29\nP_HBA_Sulfate\ntryptophan-tyrosine urine\n\n\n30\nP_Hydroxyphenyl_Acetic_Acid\ntryptophan-tyrosine urine\n\n\n\n\n\n \nThe predictors selected also show univariate differentiation ability of the MetS score as seen in the Data Processing & EDA page. The only exception is the predictor bcm_t_score which in isolation does not show differentiation whereas when included in the model is does. This seems to occur due to a suppresion effect of the Gender predictor, which effectively increases the predictive validity of bcm_t_score by improving its relationship with the outcome.\nbcm_t_score and the related predictor bcm are associated with Gender as witnessed in the redundancy analysis of the device data. For instance the cumulative R-squared values when modeling Gender using these two related predictors is seen below in parentheses:\ngender ~ bcm (0.573) + bcm_t_score (0.931)\n\n\n\n\n\n\n\n\nFigure 22: Gender differentiation of the bcm at first data collection time.\n\n\n\n\n\n\n\n\n\n\n\n\n\nFigure 23: bcm_t_score differentiation of the MetS index at first data collection time. The relationship is weaker i.e. smaller slope, when compared to the bcm_t_score being split by Gender as below.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n(a) Female\n\n\n\n\n\n\n\n\n\n\n\n(b) Male\n\n\n\n\n\n\n\nFigure 24: bcm_t_score differentiation of the MetS index when grouped by Gender and at first data collection time. Conditional on Gender the association of bcm_t_score with the MetS index becomes stronger as seen by the upward trending regression lines.\n\n\n\n \nPredictors from device data in relation with BMI which is used to define the response MetS\n\n\n\n\n\n\n\n\n\n\n\n(a) Skeletal Muscle Mass\n\n\n\n\n\n\n\n\n\n\n\n(b) Waist-to-Hip Ratio\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Body Cell Mass t-score\n\n\n\n\n\n\n\n\n\n\n\n(d) Fatigue Index\n\n\n\n\n\n\n\nFigure 25: Device predictors in relation to BMI.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#model-performance-assessment",
    "href": "modeling2.html#model-performance-assessment",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "🔍 Model Performance Assessment",
    "text": "🔍 Model Performance Assessment\n\n1. Bias Corrected Calibration (Solid Line)\nThe solid black line indicates the corrected calibration performance:\n\nLow Probability (\\(&lt; 0.4\\)): The solid line is below the ideal line. For example, where the model predicts a probability of \\(0.3\\), the actual probability is only about \\(0.2\\). This means the model overestimates the risk in subjects predicted to have a low likelihood of the event.\nIntermediate Probability (\\(0.4 - 0.7\\)): The solid line closely tracks the ideal line, indicating good calibration in this range.\nHigh Probability (\\(&gt; 0.7\\)): The solid line tends to be above the ideal line (though the curve is sparse here). This suggests the model may underestimate the risk for individuals predicted to have a very high likelihood of the event.\n\n\n\n2. Quantitative Performance Metrics\nThe error metrics provided at the bottom of the plot quantify the calibration quality:\n\n\\(\\mathbf{n=150}\\): The sample size used for the model and calibration.\nMean absolute error (MAE) \\(\\mathbf{= 0.055}\\): On average, the absolute difference between the predicted and actual probability is \\(5.5\\%\\). This is generally considered a good error rate, suggesting strong calibration overall.\nMean squared error (MSE) \\(\\mathbf{= 0.00351}\\): The squared difference between predictions and outcomes. A small value confirms the predictions are close to the actual observations.\n\\(\\mathbf{0.9}\\) Quantile of absolute error \\(\\mathbf{= 0.083}\\): For \\(90\\%\\) of the predictions, the absolute error is \\(8.3\\%\\) or less. This reinforces the view that the model is well-calibrated for the majority of the population.\n\nThe model is generally well-calibrated (low MAE and MSE), especially in the moderate risk range. However, it shows a tendency to be slightly overly pessimistic (overestimate risk) for subjects in the lowest probability range.\n\n\n\n\n\n\n\n\nFigure 28: Quantifying the relative contribution of the various predictors to the total explained variation in MetS.\n\n\n\n\n\nX-axis: Relative Explained Variation: This represents the independent contribution of each predictor (or term) to the total variance explained by the model. Higher values mean the variable is a stronger predictor. Right Y-axis: Percent of Total: This shows the percentage contribution of each variable to the sum of explained variations across all listed variables.\n\n\nTop Predictors and Interpretation\nThe plot clearly shows a distinct hierarchy of importance, with a few variables dominating the explained variation:\n\n\n\n\n\n\n\n\n\n\nRank\nVariable\nRelative Explained Variation\n% of Total\nInterpretation\n\n\n\n\n1\nHbA1c_c_Perc\n0.0429\n~23%\nHemoglobin A1c (HbA1c) is the single most important predictor, explaining over a fifth of the total variation. This strongly links the response variable MetS Index to long-term blood sugar control and diabetes status, which is central to metabolic disease.\n\n\n2\nAnhydroglucitol\n0.0197\n~10%\nThis is the second strongest predictor, explaining about half the variation of HbA1c. Anhydroglucitol is another marker of recent hyperglycemia/glycemic control, further emphasizing the importance of glucose metabolism.\n\n\n3\nHippuric_Acid\n0.016\n~8%\nHippuric acid is a metabolite derived from the gut microbiome and diet. Its high ranking suggests that microbiome-related or dietary factors are significant contributors to the explained variation.\n\n\n\n\n\nKey Metabolic and Clinical Findings\n\nMetabolic Syndrome Markers: Variables directly related to glucose control (HbA1c and Anhydroglucitol) are the top contributors, followed by a liver enzyme (SGPT), which is also linked to metabolic health and non-alcoholic fatty liver disease (NAFLD).\nAmino Acid and Carnitine Metabolism:\n\nThe Glutamine_To_Glutamic_Acid_Ratio and Kynurenic_Acid are moderately important (around 5% each), highlighting the role of amino acid metabolism and the kynurenine pathway.\nPropionylcarnitine (a short-chain acylcarnitine) is present but further down the list, contributing 0.0065 to the variation (about 3%). This is notable because acylcarnitines often serve as markers of mitochondrial dysfunction, but its predictive power is lower than that of the glucose markers.\nLauroylcarnitine (a medium-chain acylcarnitine) has a zero (0) contribution, suggesting that its non-linear relationship (inverted U-shape) is not strong enough to be an important independent predictor in this specific overall model when compared to the other variables.\n\nClinical Interventions: The use of Antihypertensives is also a meaningful predictor (\\(0.0069\\), or 3%), which aligns with the previously seen boxplot showing a higher median MetS Index in the “≥58.67” group, confirming the clinical relevance of hypertension/treatment as a feature of the outcome.\nLeast Important Predictors: Most of the interaction terms (e.g., gender • smm) and certain metabolites (e.g., Dopamine, P_HBA_Sulfate) explain virtually none of the variation (close to \\(0\\)).\n\nIn summary, this plot identifies that glycemic control (HbA1c and Anhydroglucitol) is the dominant factor explaining the variation in the response, overshadowing the contributions of lipid and amino acid metabolites like the acylcarnitines in this particular model.\n\n\n\n\n\n\n\n\nFigure 29: Forest plots of odds ratios of the variables involved in modeling the MetS index.\n\n\n\n\n\nThe above plot is like a Forest Plot which displays the results of the penalized ordinal regression model used to predict the risk of the metabolic event: MetS Index \\(\\ge 58.67\\) (the median or the clinical cut-off for Metabolic Syndrome Index).\nThis plot visually summarizes the Odds Ratios (ORs) for each predictor variable, illustrating their direction and strength of association with the event risk.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "metSyn_index_construction.html",
    "href": "metSyn_index_construction.html",
    "title": "Metabolic Syndrome Index Construction",
    "section": "",
    "text": "The optimization of complex systems, ranging from industrial manufacturing processes to advanced machine learning models and biotechnological experiments, frequently involves multiple performance metrics, referred to as responses (\\(Y_i\\)). These Multi-Response Optimization (MRO) problems present two primary challenges: the metrics are often non-commensurable (measured on different scales, such as minimizing cost and maximizing purity), and they are frequently antagonistic or conflicting (an improvement in one response often degrades at least one other response).(1) In such complex environments, it is impractical and often detrimental to optimize each response variable in isolation. Instead, the objective is to locate a compromise solution—a specific setting of input factors \\(X\\) that yields the ‘most desirable’ combined outcome across all responses.(1) The desirability function (DF) methodology, initially introduced by Harrington (1965) and formalized by Derringer and Suich (DS) in 1980, provides a widely accepted framework for solving this problem.(2) This methodology functions as a dimensionality reduction strategy, transforming the complex multi-objective optimization problem into a simpler, single-objective problem: the maximization of a unified aggregate measure, the Overall Desirability Index (\\(D\\)).(2)\n\n\n\nThe conceptual foundation of desirability is based on transforming a measured or predicted response (\\(\\hat{Y}_i\\)) into a uniform, scale-free desirability score (\\(d_i\\)) confined within the interval [0-1].(3) Here, \\(d_i = 0\\) signifies a completely unacceptable response, and \\(d_i = 1\\) represents an ideal or perfectly desirable outcome.(4) The R package desirability2 explicitly implements the functional forms proposed by Derringer and Suich (1980).5 The DS contribution was critical as it formalized the use of piecewise functions with adjustable exponents (\\(s\\) and \\(t\\)) to model the specific utility requirements for maximization, minimization, and target achievement.(3) The DS methodology remains highly popular due to its intuitive nature and effectiveness in domains such as quality control, engineering, and chemical technology.(1)\n\n\n\nThe desirability2 package, authored by Max Kuhn and part of the tidymodels ecosystem, represents a modern architectural update to implementing the DS framework in R.6 Published on August 22, 2025 (Version 0.2.0), the package focuses on enhanced usability and integration with modern R workflows.(5) The key innovation of desirability2 over predecessor packages lies in its provision of in-line functions that facilitate “easy use within dplyr pipelines”.(5) This architectural alignment with the Tidyverse philosophy means that the multi-response optimization step is no longer treated as a separate, procedural analysis but rather as a routine, seamless data transformation step.(6) For computational statisticians, this enables the desirability calculation to be integrated directly into data cleaning, feature engineering, and model tuning workflows, which significantly enhances the efficiency and reproducibility of the overall analysis.(6) The package supplies the core functions required for analysis, specifically d_max(), d_min() (and the implied target function), and the critical aggregation function d_overall().(7)\n\n\n\n\nThe individual desirability function, \\(d_i(\\hat{Y}_i)\\), maps the predicted or observed response value \\(\\hat{Y}_i\\) to the unit interval $$. The functional form depends entirely on the required optimization criterion for that specific response.\n\n\nThe maximization function is employed when higher values of the response variable are inherently more desirable, such as maximizing product yield, profit, or predictive performance metrics like the Area Under the ROC Curve (AUC).(4) This function requires two parameters defined by the decision-maker (DM): a lower acceptable limit (\\(L_i\\)) below which the response is completely undesirable (\\(d_i=0\\)), and an upper ideal limit (\\(U_i\\)) at which desirability reaches its maximum (\\(d_i=1\\)). The individual desirability function for maximization is defined as:\n\\[\\mathbf{d_{\\max}(\\hat{Y}_i) = \\begin{cases} 0 & \\text{if } \\hat{Y}_i &lt; L_i \\\\ \\left(\\frac{\\hat{Y}_i - L_i}{U_i - L_i}\\right)^s & \\text{if } L_i \\le \\hat{Y}_i \\le U_i \\\\ 1 & \\text{if } \\hat{Y}_i &gt; U_i \\end{cases}}\\]\nWithin the desirability2 package, the function d_max() implements this transformation, where desirability scales non-linearly from 0 at \\(L_i\\) to 1 at \\(U_i\\) and remains 1 for all values exceeding \\(U_i\\).(8)\n\n\n\nThe minimization function is utilized when lower values of the response variable are preferable, such as minimizing cost, error rate (e.g., multinomial log-loss), or the number of components used in a model.(4) Similar to the maximization case, the function requires a lower ideal limit (\\(L_i\\)), where \\(d_i=1\\), and an upper acceptable limit (\\(U_i\\)), above which the response is entirely unacceptable (\\(d_i=0\\)). The individual desirability function for minimization is defined as:\n\\[\\mathbf{d_{\\min}(\\hat{Y}_i) = \\begin{cases} 1 & \\text{if } \\hat{Y}_i &lt; L_i \\\\ \\left(\\frac{U_i - \\hat{Y}_i}{U_i - L_i}\\right)^t & \\text{if } L_i \\le \\hat{Y}_i \\le U_i \\\\ 0 & \\text{if } \\hat{Y}_i &gt; U_i \\end{cases}}\\]\nThe d_min() function in the package handles this transformation, where desirability decreases from 1 towards 0 as the response value approaches the upper limit \\(U_i\\).(7)\n\n\n\nWhen the ideal scenario involves achieving a specific value (\\(T_i\\)) within a defined range, a two-sided transformation is required. This applies when deviations in either direction from the target (e.g., product strength or purity) reduce desirability.(3) The target value (\\(T_i\\)) must fall between the lower (\\(L_i\\)) and upper (\\(U_i\\)) acceptable limits (\\(L_i \\le T_i \\le U_i\\)). This function combines aspects of minimization for values above the target and maximization for values below the target, often using two potentially different strictness parameters, \\(s\\) and \\(t\\).\nThe two-sided desirability function is defined as:\n\\[\\mathbf{d_{\\text{target}}(\\hat{Y}_i) = \\begin{cases} 0 & \\text{if } \\hat{Y}_i &lt; L_i \\text{ or } \\hat{Y}_i &gt; U_i \\\\ \\left(\\frac{\\hat{Y}_i - L_i}{T_i - L_i}\\right)^s & \\text{if } L_i \\le \\hat{Y}_i &lt; T_i \\\\ \\left(\\frac{U_i - \\hat{Y}_i}{U_i - T_i}\\right)^t & \\text{if } T_i &lt; \\hat{Y}_i \\le U_i \\\\ 1 & \\text{if } \\hat{Y}_i = T_i \\end{cases}}\\]\nValues outside of [\\(Li\\)​,\\(Ui\\)​] result in \\(d_i​=0\\).(7)\n\n\n\nThe parameters \\(s\\) and \\(t\\), which must be non-negative, are known as the strictness exponents. They are essential components of the DS methodology, as they define the shape of the desirability curve within the acceptable interval \\([L_i, U_i]\\) and, consequently, determine how rapidly the desirability score transitions between 0 and 1.(8) By adjusting these exponents, the decision-maker (DM) can embed non-linear utility preferences into the optimization process, moving beyond a simple linear penalty assessment. If \\(s=1\\) or \\(t=1\\), the function is linear, meaning the desirability score changes proportionally with the response value. If the exponent is greater than one (\\(s&gt;1\\) or \\(t&gt;1\\)), the resulting curve is concave. This shape signifies that desirability scores near 1 are only achieved very close to the ideal boundary (\\(U_i\\) or \\(T_i\\)), heavily penalizing minor deviations and indicating a strong preference for near-ideal results. Conversely, if the exponent is less than one (\\(s&lt;1\\) or \\(t&lt;1\\)), the function is convex. In this case, desirability increases quickly, meaning that even moderately performing values retain a high \\(d_i\\) score, reflecting greater tolerance for variability.(8) The specific choice of these exponents is critical, as the resulting overall optimum is sensitive to the defined utility curve.\n\n\n\n\n\n\n\n\n\n\n\n\nExponent Value\nCurve Shape\nImplication for Penalty Assessment\nDM Preference\n\n\n\n\n\\(s=1\\) or \\(t=1\\)\nLinear\nProportional change in desirability with response value.\nNeutral or standard compromise.\n\n\n\\(s &gt; 1\\) or \\(t &gt; 1\\)\nConcave\nHigh desirability (near 1) is achieved only very close to the ideal point.\nExtreme sensitivity; heavily penalizes minor deviations from the ideal.\n\n\n\\(s &lt; 1\\) or \\(t &lt; 1\\)\nConvex\nDesirability increases quickly, allowing moderate performance to retain high \\(d_i\\).\nTolerance for variability; allows slight penalty for small deviations.\n\n\n\n\n\n\n\n\n\nThe ultimate goal of the desirability function approach is to aggregate the individual desirability scores (\\(d_i\\)) into a single, unified metric known as the Overall Desirability Index, \\(D\\). This index is the objective function that the optimization seeks to maximize, effectively reducing the MRO problem to a single-objective maximization task.(2) Following the framework established by Harrington and utilized by Derringer and Suich, \\(D\\) is defined as the geometric mean of the \\(k\\) individual desirability functions.(1) \\[D = \\left( d_{1} ( Y_{1} ) \\cdot d_{2} ( Y_{2} ) \\cdots d_{k} ( Y_{k} )\\right) ^{1/k}\\]\nHere, \\(k\\) denotes the total number of responses being optimized simultaneously.(4)\n\n\n\nThe use of the geometric mean (multiplicative form) is a defining characteristic of the DS methodology and carries a profound implication for optimization results: the enforcement of the non-compensatory principle.(9) Since \\(D\\) is calculated as the product of all \\(d_i\\) values raised to the \\(1/k\\) power, the entire geometric mean collapses if any single individual desirability score is zero. Mathematically, if \\(d_i = 0\\) for any \\(i\\), then \\(D=0\\).(4) This strictly non-compensatory approach reflects the idea, common in industry and quality control, that the “quality” of a product or process with multiple characteristics is considered “completely unacceptable” if even one characteristic falls outside defined desirable limits. In practical terms, this ensures that the final optimal solution represents a true compromise where all responses achieve at least a minimally acceptable level (i.e., \\(d_i &gt; 0\\)). Superior performance in one area cannot compensate for a failure (i.e., \\(d_i=0\\)) in another.12 This is a key distinction from alternative additive scoring methods, which often allow high scores on a few variables to mask poor performance on others.(9) The calculation relies on the individual desirability values being non-negative 11, which is structurally guaranteed by the DS functional definitions.\n\n\n\nIn the standard geometric mean formula, all \\(k\\) responses are treated equally. However, in many MRO scenarios, the Decision Maker requires certain responses to carry more importance than others. This is accommodated by incorporating objective importance weights (\\(w_i\\)) into the geometric mean calculation.(9) The generalized, weighted geometric mean formula is defined as: \\[ D_w = \\left( d_{1}^{w_1} ( Y_{1} ) \\cdot d_{2}^{w_2} ( Y_{2} ) \\cdots d_{k}^{w_k} ( Y_{k} )\\right) ^{1/\\sum w_i} \\]\nThe use of weights provides crucial flexibility, allowing the DM to subjectively define which criteria are “worth more than others”.(10) For example, in optimizing a classification model, the computational budget might dictate that minimizing the number of features (\\(Y_{\\text{features}}\\)) is twice as important as minimizing the prediction error (\\(Y_{\\text{error}}\\)). This priority setting is directly encoded by assigning \\(w_{\\text{features}}=2\\) and \\(w_{\\text{error}}=1\\). The weighted formula maintains the non-compensatory nature of the DF approach while providing control over the relative influence of each response on the overall index \\(D\\).\n\n\n\n\nThe desirability2 package is designed to modernize the application of the DS methodology, making it accessible and efficient for users familiar with the Tidyverse computational environment in R.\n\n\ndesirability2 is architecturally aligned with the tidymodels framework, requiring R version 4.1.0 or newer and relying heavily on core Tidyverse packages.(5) Key dependencies include cli, stats, and tibble, but most critically, dplyr and purrr for streamlined data manipulation and functional programming, along with rlang for handling non-standard evaluation.(5) This architecture provides a substantial improvement over the original R package implementations of desirability functions.(11) The design prioritizes user experience, transforming a typically procedural multi-step analysis into a concise, chainable set of data transformation operations.(6)\n\n\n\nThe defining feature of desirability2 is its support for in-line computation, which is central to its utility within dplyr pipelines.(5) This approach fundamentally changes how MRO is executed within R environments. Instead of requiring external function calls or the management of temporary objects, the calculation and assignment of individual desirability scores (\\(d_i\\)) occur directly within a data manipulation pipe, typically using the mutate() verb. For instance, if a researcher has a table of tuning results (classification_results) containing ROC AUC values, the calculation of its desirability score (roc_d) is seamless:\nclassification_results |&gt; mutate(roc_d = d_max(roc_auc, low = 0.5, high = 1.0)).(6)\nOnce all individual scores are calculated, the overall desirability \\(D\\) is aggregated in the same pipeline using the d_overall() function in conjunction with the dplyr::across() selector. This permits the calculation of the geometric mean across multiple columns defined by a pattern (e.g., all columns ending with _d).8 The final step, ranking the results, is then accomplished immediately within the same pipe using slice_max(D, n = 1), resulting in a concise, readable, and highly auditable workflow that flows logically from raw data to the optimal result.(6) This cohesion dramatically increases the efficiency of managing complex optimization problems and reduces potential coding errors related to intermediate steps.\n\n\n\nThe package is engineered to support modern data analysis challenges, including those involving responses that change over time. For instance, when analyzing predictive metrics derived from time-dependent data (e.g., the time-dependent ROC curve often used in survival analysis), the function definitions accommodate an eval_time parameter.(7) This parameter allows the user to specify a single numeric time point at which the dynamic metrics should be selected for desirability calculation, ensuring consistency with the original data creation process.(5) This adaptability demonstrates that desirability2 is designed to support not just classical experimental design but also advanced computational problems common in machine learning and data science.\nTable 2 highlights the architectural shift achieved by desirability2 compared to legacy implementations.\n\n\n\n\n\n\n\n\n\n\n\n\nFeature\nTraditional DF Packages (e.g., original desirability)\ndesirability2 R Package\nSignificance\n\n\n\n\nComputation Style\nProcedural; required multiple external function calls or custom wrappers.\nFunctional and In-line. (12)\nDirect integration into data transformation pipelines.\n\n\nData Structure Focus\nVector or matrix input; less emphasis on data frame workflow.\nOptimized for tibble and dplyr. (6)\nMaximized compatibility with the tidymodels ecosystem for model tuning.\n\n\nAggregation Method\nSeparate function call applied to pre-calculated score vectors.\nSeamless aggregation via d_overall(across(...)).(6)\nSingle, readable step from individual score calculation to overall ranking.\n\n\nDesign Philosophy\nFocus on mathematical implementation of core functions.\nFocus on user experience (UX) and modern computational efficiency.(6)\nReduces cognitive load and streamlines iterative optimization tasks.\n\n\n\n\n\n\n\nThe desirability function methodology is highly versatile, finding utility in diverse fields that require the negotiation of trade-offs between competing performance indicators.\n\n\nIn computational statistics, particularly within machine learning, desirability functions provide a clear mechanism for balancing model complexity against predictive performance.(6) Optimization often requires selecting hyperparameters that simultaneously maximize a positive metric (e.g., ROC AUC) and minimize negative metrics (e.g., log-loss, model size). For instance, in genetic algorithms used for feature selection, DFs can be used to guide the search process.(12) Kuhn and Johnson (2019) utilized these functions to help select predictors that improved model performance while actively reducing the number of predictors used, effectively balancing the objective of predictive power with the objective of model parsimony.(12) The practical demonstration within the package shows how classification results, including metrics such as multinomial log-loss, ROC AUC, and the number of features, can be ranked. This involves applying d_max() to ROC AUC and d_min() to both log-loss and feature count, and then aggregating these three scale-free scores using the d_overall() function to identify the optimal compromise setting among hundreds of possible model configurations.(6)\n\n\n\nIn industrial and biological sciences, the Desirability Optimization Methodology (DOM) frequently combines desirability functions with Response Surface Methodology (RSM), where the response values (\\(Y_i\\)) are derived from fitted predictive models (\\(\\hat{Y}_i\\)).(3) A compelling example arises in biotechnological systems, specifically the optimization of secondary metabolite production in plants. Research involving Datura stramonium hairy roots required determining optimal elicitation conditions (jasmonate treatments) to maximize the valuable tropane alkaloid, hyoscyamine, while minimizing the inhibition of overall biomass growth.3 These are inherently antagonist responses. The application of DOM successfully addressed this conflict. By maximizing the overall desirability index \\(D\\), the methodology identified an optimal compromise: the application of 0.06 mM jasmonic acid for 24 hours.(3) This treatment resulted in hyoscyamine levels increasing by up to 290% after 24 hours, while biomass growth was only slightly affected (Growth Index, GI = 0.9) 120 hours after elicitation.(3) The efficacy of the geometric mean aggregation is demonstrated here; if the treatment had led to high alkaloid production but completely unacceptable biomass growth (\\(d_{\\text{growth}}=0\\)), the overall index \\(D\\) would have immediately dropped to zero, signaling that the trade-off was a failure. The DF approach guarantees that the selected optimum is a satisfactory compromise across all critical responses.(3)\n\n\n\n\nWhile the DS desirability function is a robust and highly utilized tool for MRO, its application in rigorous scientific contexts necessitates an understanding of its inherent limitations, particularly concerning subjectivity and statistical inference.\n\n\nA principal challenge in applying the DS methodology is the sensitivity of the final optimized solution (the maximum \\(D\\) value) to the initial parameters chosen by the decision-maker. The boundaries (\\(L_i, U_i, T_i\\)) and the shape parameters (\\(s, t\\)) define the DM’s utility function and risk tolerance regarding the variability of the response.(8) The determination of these parameters is inherently subjective.(1) For instance, setting \\(L_i\\) slightly higher for a minimization objective can significantly reduce the overall desirability of numerous acceptable process points. If the chosen exponents reflect an overly strict utility function (e.g., \\(s, t &gt; 1\\)), minor deviations from the ideal target will be heavily penalized, potentially excluding viable operating conditions. Therefore, in any formal research or industrial application, thorough sensitivity analysis across a reasonable range of \\(L_i, U_i\\), and exponents is mandatory to ensure the robustness of the identified optimal solution.\n\n\n\nThe conventional framework of the DS method maximizes the point estimate \\(D\\). When attempting to conduct statistical inference—such as constructing confidence or prediction intervals around the estimated optimal \\(D\\) value—a significant methodological gap emerges.(9) The underlying response models (\\(\\hat{Y}_i\\)) in MRO problems are typically derived from experimental designs (e.g., RSM) and exhibit a complex structure of covariance. The responses are often significantly correlated, and frequently exhibit the antagonism that initially necessitated the MRO analysis.(1) However, traditional, simple methods for calculating intervals around the optimal \\(D\\) often rely on the assumption that the response variables are independent, which is fundamentally antithetical to the nature of the problem.(9) Methods that construct simple confidence intervals by examining the best and worst cases for individual responses fail to incorporate this crucial covariance component.(9) This exclusion means that the resulting intervals for the optimal desirability index \\(D\\) are statistically inadequate and may provide misleading estimates of confidence or uncertainty. The literature recognizes this need for novel inference methods that explicitly account for the complex covariance structure among the fitted response variables to ensure statistically rigorous confidence regions are established around the optimum \\(D\\).(9)\n\n\n\nThe piecewise and potentially non-smooth nature of the DS functions, combined with the aforementioned inference challenges, has spurred the development of alternative desirability frameworks. Other optimization strategies, such as those based on minimizing the estimated distance from an ideal design point (Khuri and Conlon, 1981), offer different theoretical bases.(2) Furthermore, alternative functional forms, such as exponential desirability functions, have been proposed to offer different mechanisms for assessing penalty and utility.(2) More recently, researchers have focused on proposing novel desirability functions that are smooth, nonlinear, and fully differentiable. These characteristics are desirable because they make the objective function \\(D\\) more suitable for application within highly efficient, modern gradient-based optimization algorithms, particularly when searching large, complex response surfaces.(1)\n\n\n\n\nThe desirability2 R package successfully translates the influential Derringer and Suich (1980) framework for Multi-Response Optimization into a modern, computationally efficient software architecture. The core function of the package is to provide highly flexible, exponent-controlled transformations that map multi-scale responses (\\(\\hat{Y}_i\\)) to a uniform desirability score (\\(d_i\\)). The subsequent aggregation via the geometric mean, implemented through the d_overall() function, enforces the essential non-compensatory principle, guaranteeing that any chosen optimal solution satisfies a minimum acceptability criterion for every objective simultaneously. The package’s primary architectural contribution is the seamless integration of these desirability calculations into dplyr pipelines via in-line functions. This enables researchers, especially those working within the tidymodels ecosystem, to treat MRO as a routine and auditable data transformation step, significantly streamlining tasks such as hyperparameter tuning and model ranking. Moving forward, future methodological research must focus on overcoming the known limitations of statistical inference within the DS framework. Specifically, effort should be directed toward integrating advanced inference techniques that can accurately account for the covariance structure among the antagonistic response variables.11 Additionally, the incorporation of smooth and fully differentiable desirability functions into the desirability2 architecture would enhance the package’s compatibility with cutting-edge gradient-based optimization methods, thereby extending its utility to handle even larger and more complex optimization challenges.(1)",
    "crumbs": [
      "Sections",
      "Metabolic Syndrome Index Construction"
    ]
  },
  {
    "objectID": "metSyn_index_construction.html#i.-introduction-to-multi-response-optimization-and-the-desirability-framework",
    "href": "metSyn_index_construction.html#i.-introduction-to-multi-response-optimization-and-the-desirability-framework",
    "title": "Metabolic Syndrome Index Construction",
    "section": "",
    "text": "The optimization of complex systems, ranging from industrial manufacturing processes to advanced machine learning models and biotechnological experiments, frequently involves multiple performance metrics, referred to as responses (\\(Y_i\\)). These Multi-Response Optimization (MRO) problems present two primary challenges: the metrics are often non-commensurable (measured on different scales, such as minimizing cost and maximizing purity), and they are frequently antagonistic or conflicting (an improvement in one response often degrades at least one other response).(1) In such complex environments, it is impractical and often detrimental to optimize each response variable in isolation. Instead, the objective is to locate a compromise solution—a specific setting of input factors \\(X\\) that yields the ‘most desirable’ combined outcome across all responses.(1) The desirability function (DF) methodology, initially introduced by Harrington (1965) and formalized by Derringer and Suich (DS) in 1980, provides a widely accepted framework for solving this problem.(2) This methodology functions as a dimensionality reduction strategy, transforming the complex multi-objective optimization problem into a simpler, single-objective problem: the maximization of a unified aggregate measure, the Overall Desirability Index (\\(D\\)).(2)\n\n\n\nThe conceptual foundation of desirability is based on transforming a measured or predicted response (\\(\\hat{Y}_i\\)) into a uniform, scale-free desirability score (\\(d_i\\)) confined within the interval [0-1].(3) Here, \\(d_i = 0\\) signifies a completely unacceptable response, and \\(d_i = 1\\) represents an ideal or perfectly desirable outcome.(4) The R package desirability2 explicitly implements the functional forms proposed by Derringer and Suich (1980).5 The DS contribution was critical as it formalized the use of piecewise functions with adjustable exponents (\\(s\\) and \\(t\\)) to model the specific utility requirements for maximization, minimization, and target achievement.(3) The DS methodology remains highly popular due to its intuitive nature and effectiveness in domains such as quality control, engineering, and chemical technology.(1)\n\n\n\nThe desirability2 package, authored by Max Kuhn and part of the tidymodels ecosystem, represents a modern architectural update to implementing the DS framework in R.6 Published on August 22, 2025 (Version 0.2.0), the package focuses on enhanced usability and integration with modern R workflows.(5) The key innovation of desirability2 over predecessor packages lies in its provision of in-line functions that facilitate “easy use within dplyr pipelines”.(5) This architectural alignment with the Tidyverse philosophy means that the multi-response optimization step is no longer treated as a separate, procedural analysis but rather as a routine, seamless data transformation step.(6) For computational statisticians, this enables the desirability calculation to be integrated directly into data cleaning, feature engineering, and model tuning workflows, which significantly enhances the efficiency and reproducibility of the overall analysis.(6) The package supplies the core functions required for analysis, specifically d_max(), d_min() (and the implied target function), and the critical aggregation function d_overall().(7)",
    "crumbs": [
      "Sections",
      "Metabolic Syndrome Index Construction"
    ]
  },
  {
    "objectID": "metSyn_index_construction.html#ii.-the-theoretical-framework-of-individual-desirability-d_i",
    "href": "metSyn_index_construction.html#ii.-the-theoretical-framework-of-individual-desirability-d_i",
    "title": "Metabolic Syndrome Index Construction",
    "section": "",
    "text": "The individual desirability function, \\(d_i(\\hat{Y}_i)\\), maps the predicted or observed response value \\(\\hat{Y}_i\\) to the unit interval $$. The functional form depends entirely on the required optimization criterion for that specific response.\n\n\nThe maximization function is employed when higher values of the response variable are inherently more desirable, such as maximizing product yield, profit, or predictive performance metrics like the Area Under the ROC Curve (AUC).(4) This function requires two parameters defined by the decision-maker (DM): a lower acceptable limit (\\(L_i\\)) below which the response is completely undesirable (\\(d_i=0\\)), and an upper ideal limit (\\(U_i\\)) at which desirability reaches its maximum (\\(d_i=1\\)). The individual desirability function for maximization is defined as:\n\\[\\mathbf{d_{\\max}(\\hat{Y}_i) = \\begin{cases} 0 & \\text{if } \\hat{Y}_i &lt; L_i \\\\ \\left(\\frac{\\hat{Y}_i - L_i}{U_i - L_i}\\right)^s & \\text{if } L_i \\le \\hat{Y}_i \\le U_i \\\\ 1 & \\text{if } \\hat{Y}_i &gt; U_i \\end{cases}}\\]\nWithin the desirability2 package, the function d_max() implements this transformation, where desirability scales non-linearly from 0 at \\(L_i\\) to 1 at \\(U_i\\) and remains 1 for all values exceeding \\(U_i\\).(8)\n\n\n\nThe minimization function is utilized when lower values of the response variable are preferable, such as minimizing cost, error rate (e.g., multinomial log-loss), or the number of components used in a model.(4) Similar to the maximization case, the function requires a lower ideal limit (\\(L_i\\)), where \\(d_i=1\\), and an upper acceptable limit (\\(U_i\\)), above which the response is entirely unacceptable (\\(d_i=0\\)). The individual desirability function for minimization is defined as:\n\\[\\mathbf{d_{\\min}(\\hat{Y}_i) = \\begin{cases} 1 & \\text{if } \\hat{Y}_i &lt; L_i \\\\ \\left(\\frac{U_i - \\hat{Y}_i}{U_i - L_i}\\right)^t & \\text{if } L_i \\le \\hat{Y}_i \\le U_i \\\\ 0 & \\text{if } \\hat{Y}_i &gt; U_i \\end{cases}}\\]\nThe d_min() function in the package handles this transformation, where desirability decreases from 1 towards 0 as the response value approaches the upper limit \\(U_i\\).(7)\n\n\n\nWhen the ideal scenario involves achieving a specific value (\\(T_i\\)) within a defined range, a two-sided transformation is required. This applies when deviations in either direction from the target (e.g., product strength or purity) reduce desirability.(3) The target value (\\(T_i\\)) must fall between the lower (\\(L_i\\)) and upper (\\(U_i\\)) acceptable limits (\\(L_i \\le T_i \\le U_i\\)). This function combines aspects of minimization for values above the target and maximization for values below the target, often using two potentially different strictness parameters, \\(s\\) and \\(t\\).\nThe two-sided desirability function is defined as:\n\\[\\mathbf{d_{\\text{target}}(\\hat{Y}_i) = \\begin{cases} 0 & \\text{if } \\hat{Y}_i &lt; L_i \\text{ or } \\hat{Y}_i &gt; U_i \\\\ \\left(\\frac{\\hat{Y}_i - L_i}{T_i - L_i}\\right)^s & \\text{if } L_i \\le \\hat{Y}_i &lt; T_i \\\\ \\left(\\frac{U_i - \\hat{Y}_i}{U_i - T_i}\\right)^t & \\text{if } T_i &lt; \\hat{Y}_i \\le U_i \\\\ 1 & \\text{if } \\hat{Y}_i = T_i \\end{cases}}\\]\nValues outside of [\\(Li\\)​,\\(Ui\\)​] result in \\(d_i​=0\\).(7)\n\n\n\nThe parameters \\(s\\) and \\(t\\), which must be non-negative, are known as the strictness exponents. They are essential components of the DS methodology, as they define the shape of the desirability curve within the acceptable interval \\([L_i, U_i]\\) and, consequently, determine how rapidly the desirability score transitions between 0 and 1.(8) By adjusting these exponents, the decision-maker (DM) can embed non-linear utility preferences into the optimization process, moving beyond a simple linear penalty assessment. If \\(s=1\\) or \\(t=1\\), the function is linear, meaning the desirability score changes proportionally with the response value. If the exponent is greater than one (\\(s&gt;1\\) or \\(t&gt;1\\)), the resulting curve is concave. This shape signifies that desirability scores near 1 are only achieved very close to the ideal boundary (\\(U_i\\) or \\(T_i\\)), heavily penalizing minor deviations and indicating a strong preference for near-ideal results. Conversely, if the exponent is less than one (\\(s&lt;1\\) or \\(t&lt;1\\)), the function is convex. In this case, desirability increases quickly, meaning that even moderately performing values retain a high \\(d_i\\) score, reflecting greater tolerance for variability.(8) The specific choice of these exponents is critical, as the resulting overall optimum is sensitive to the defined utility curve.\n\n\n\n\n\n\n\n\n\n\n\n\nExponent Value\nCurve Shape\nImplication for Penalty Assessment\nDM Preference\n\n\n\n\n\\(s=1\\) or \\(t=1\\)\nLinear\nProportional change in desirability with response value.\nNeutral or standard compromise.\n\n\n\\(s &gt; 1\\) or \\(t &gt; 1\\)\nConcave\nHigh desirability (near 1) is achieved only very close to the ideal point.\nExtreme sensitivity; heavily penalizes minor deviations from the ideal.\n\n\n\\(s &lt; 1\\) or \\(t &lt; 1\\)\nConvex\nDesirability increases quickly, allowing moderate performance to retain high \\(d_i\\).\nTolerance for variability; allows slight penalty for small deviations.",
    "crumbs": [
      "Sections",
      "Metabolic Syndrome Index Construction"
    ]
  },
  {
    "objectID": "metSyn_index_construction.html#iii.-aggregation-and-the-overall-desirability-index-d",
    "href": "metSyn_index_construction.html#iii.-aggregation-and-the-overall-desirability-index-d",
    "title": "Metabolic Syndrome Index Construction",
    "section": "",
    "text": "The ultimate goal of the desirability function approach is to aggregate the individual desirability scores (\\(d_i\\)) into a single, unified metric known as the Overall Desirability Index, \\(D\\). This index is the objective function that the optimization seeks to maximize, effectively reducing the MRO problem to a single-objective maximization task.(2) Following the framework established by Harrington and utilized by Derringer and Suich, \\(D\\) is defined as the geometric mean of the \\(k\\) individual desirability functions.(1) \\[D = \\left( d_{1} ( Y_{1} ) \\cdot d_{2} ( Y_{2} ) \\cdots d_{k} ( Y_{k} )\\right) ^{1/k}\\]\nHere, \\(k\\) denotes the total number of responses being optimized simultaneously.(4)\n\n\n\nThe use of the geometric mean (multiplicative form) is a defining characteristic of the DS methodology and carries a profound implication for optimization results: the enforcement of the non-compensatory principle.(9) Since \\(D\\) is calculated as the product of all \\(d_i\\) values raised to the \\(1/k\\) power, the entire geometric mean collapses if any single individual desirability score is zero. Mathematically, if \\(d_i = 0\\) for any \\(i\\), then \\(D=0\\).(4) This strictly non-compensatory approach reflects the idea, common in industry and quality control, that the “quality” of a product or process with multiple characteristics is considered “completely unacceptable” if even one characteristic falls outside defined desirable limits. In practical terms, this ensures that the final optimal solution represents a true compromise where all responses achieve at least a minimally acceptable level (i.e., \\(d_i &gt; 0\\)). Superior performance in one area cannot compensate for a failure (i.e., \\(d_i=0\\)) in another.12 This is a key distinction from alternative additive scoring methods, which often allow high scores on a few variables to mask poor performance on others.(9) The calculation relies on the individual desirability values being non-negative 11, which is structurally guaranteed by the DS functional definitions.\n\n\n\nIn the standard geometric mean formula, all \\(k\\) responses are treated equally. However, in many MRO scenarios, the Decision Maker requires certain responses to carry more importance than others. This is accommodated by incorporating objective importance weights (\\(w_i\\)) into the geometric mean calculation.(9) The generalized, weighted geometric mean formula is defined as: \\[ D_w = \\left( d_{1}^{w_1} ( Y_{1} ) \\cdot d_{2}^{w_2} ( Y_{2} ) \\cdots d_{k}^{w_k} ( Y_{k} )\\right) ^{1/\\sum w_i} \\]\nThe use of weights provides crucial flexibility, allowing the DM to subjectively define which criteria are “worth more than others”.(10) For example, in optimizing a classification model, the computational budget might dictate that minimizing the number of features (\\(Y_{\\text{features}}\\)) is twice as important as minimizing the prediction error (\\(Y_{\\text{error}}\\)). This priority setting is directly encoded by assigning \\(w_{\\text{features}}=2\\) and \\(w_{\\text{error}}=1\\). The weighted formula maintains the non-compensatory nature of the DF approach while providing control over the relative influence of each response on the overall index \\(D\\).",
    "crumbs": [
      "Sections",
      "Metabolic Syndrome Index Construction"
    ]
  },
  {
    "objectID": "metSyn_index_construction.html#iv.-computational-implementation-the-desirability2-r-package-architecture",
    "href": "metSyn_index_construction.html#iv.-computational-implementation-the-desirability2-r-package-architecture",
    "title": "Metabolic Syndrome Index Construction",
    "section": "",
    "text": "The desirability2 package is designed to modernize the application of the DS methodology, making it accessible and efficient for users familiar with the Tidyverse computational environment in R.\n\n\ndesirability2 is architecturally aligned with the tidymodels framework, requiring R version 4.1.0 or newer and relying heavily on core Tidyverse packages.(5) Key dependencies include cli, stats, and tibble, but most critically, dplyr and purrr for streamlined data manipulation and functional programming, along with rlang for handling non-standard evaluation.(5) This architecture provides a substantial improvement over the original R package implementations of desirability functions.(11) The design prioritizes user experience, transforming a typically procedural multi-step analysis into a concise, chainable set of data transformation operations.(6)\n\n\n\nThe defining feature of desirability2 is its support for in-line computation, which is central to its utility within dplyr pipelines.(5) This approach fundamentally changes how MRO is executed within R environments. Instead of requiring external function calls or the management of temporary objects, the calculation and assignment of individual desirability scores (\\(d_i\\)) occur directly within a data manipulation pipe, typically using the mutate() verb. For instance, if a researcher has a table of tuning results (classification_results) containing ROC AUC values, the calculation of its desirability score (roc_d) is seamless:\nclassification_results |&gt; mutate(roc_d = d_max(roc_auc, low = 0.5, high = 1.0)).(6)\nOnce all individual scores are calculated, the overall desirability \\(D\\) is aggregated in the same pipeline using the d_overall() function in conjunction with the dplyr::across() selector. This permits the calculation of the geometric mean across multiple columns defined by a pattern (e.g., all columns ending with _d).8 The final step, ranking the results, is then accomplished immediately within the same pipe using slice_max(D, n = 1), resulting in a concise, readable, and highly auditable workflow that flows logically from raw data to the optimal result.(6) This cohesion dramatically increases the efficiency of managing complex optimization problems and reduces potential coding errors related to intermediate steps.\n\n\n\nThe package is engineered to support modern data analysis challenges, including those involving responses that change over time. For instance, when analyzing predictive metrics derived from time-dependent data (e.g., the time-dependent ROC curve often used in survival analysis), the function definitions accommodate an eval_time parameter.(7) This parameter allows the user to specify a single numeric time point at which the dynamic metrics should be selected for desirability calculation, ensuring consistency with the original data creation process.(5) This adaptability demonstrates that desirability2 is designed to support not just classical experimental design but also advanced computational problems common in machine learning and data science.\nTable 2 highlights the architectural shift achieved by desirability2 compared to legacy implementations.\n\n\n\n\n\n\n\n\n\n\n\n\nFeature\nTraditional DF Packages (e.g., original desirability)\ndesirability2 R Package\nSignificance\n\n\n\n\nComputation Style\nProcedural; required multiple external function calls or custom wrappers.\nFunctional and In-line. (12)\nDirect integration into data transformation pipelines.\n\n\nData Structure Focus\nVector or matrix input; less emphasis on data frame workflow.\nOptimized for tibble and dplyr. (6)\nMaximized compatibility with the tidymodels ecosystem for model tuning.\n\n\nAggregation Method\nSeparate function call applied to pre-calculated score vectors.\nSeamless aggregation via d_overall(across(...)).(6)\nSingle, readable step from individual score calculation to overall ranking.\n\n\nDesign Philosophy\nFocus on mathematical implementation of core functions.\nFocus on user experience (UX) and modern computational efficiency.(6)\nReduces cognitive load and streamlines iterative optimization tasks.",
    "crumbs": [
      "Sections",
      "Metabolic Syndrome Index Construction"
    ]
  },
  {
    "objectID": "metSyn_index_construction.html#v.-case-studies-and-applications-in-optimization",
    "href": "metSyn_index_construction.html#v.-case-studies-and-applications-in-optimization",
    "title": "Metabolic Syndrome Index Construction",
    "section": "",
    "text": "The desirability function methodology is highly versatile, finding utility in diverse fields that require the negotiation of trade-offs between competing performance indicators.\n\n\nIn computational statistics, particularly within machine learning, desirability functions provide a clear mechanism for balancing model complexity against predictive performance.(6) Optimization often requires selecting hyperparameters that simultaneously maximize a positive metric (e.g., ROC AUC) and minimize negative metrics (e.g., log-loss, model size). For instance, in genetic algorithms used for feature selection, DFs can be used to guide the search process.(12) Kuhn and Johnson (2019) utilized these functions to help select predictors that improved model performance while actively reducing the number of predictors used, effectively balancing the objective of predictive power with the objective of model parsimony.(12) The practical demonstration within the package shows how classification results, including metrics such as multinomial log-loss, ROC AUC, and the number of features, can be ranked. This involves applying d_max() to ROC AUC and d_min() to both log-loss and feature count, and then aggregating these three scale-free scores using the d_overall() function to identify the optimal compromise setting among hundreds of possible model configurations.(6)\n\n\n\nIn industrial and biological sciences, the Desirability Optimization Methodology (DOM) frequently combines desirability functions with Response Surface Methodology (RSM), where the response values (\\(Y_i\\)) are derived from fitted predictive models (\\(\\hat{Y}_i\\)).(3) A compelling example arises in biotechnological systems, specifically the optimization of secondary metabolite production in plants. Research involving Datura stramonium hairy roots required determining optimal elicitation conditions (jasmonate treatments) to maximize the valuable tropane alkaloid, hyoscyamine, while minimizing the inhibition of overall biomass growth.3 These are inherently antagonist responses. The application of DOM successfully addressed this conflict. By maximizing the overall desirability index \\(D\\), the methodology identified an optimal compromise: the application of 0.06 mM jasmonic acid for 24 hours.(3) This treatment resulted in hyoscyamine levels increasing by up to 290% after 24 hours, while biomass growth was only slightly affected (Growth Index, GI = 0.9) 120 hours after elicitation.(3) The efficacy of the geometric mean aggregation is demonstrated here; if the treatment had led to high alkaloid production but completely unacceptable biomass growth (\\(d_{\\text{growth}}=0\\)), the overall index \\(D\\) would have immediately dropped to zero, signaling that the trade-off was a failure. The DF approach guarantees that the selected optimum is a satisfactory compromise across all critical responses.(3)",
    "crumbs": [
      "Sections",
      "Metabolic Syndrome Index Construction"
    ]
  },
  {
    "objectID": "metSyn_index_construction.html#vi.-discussion-of-limitations-and-advanced-considerations",
    "href": "metSyn_index_construction.html#vi.-discussion-of-limitations-and-advanced-considerations",
    "title": "Metabolic Syndrome Index Construction",
    "section": "",
    "text": "While the DS desirability function is a robust and highly utilized tool for MRO, its application in rigorous scientific contexts necessitates an understanding of its inherent limitations, particularly concerning subjectivity and statistical inference.\n\n\nA principal challenge in applying the DS methodology is the sensitivity of the final optimized solution (the maximum \\(D\\) value) to the initial parameters chosen by the decision-maker. The boundaries (\\(L_i, U_i, T_i\\)) and the shape parameters (\\(s, t\\)) define the DM’s utility function and risk tolerance regarding the variability of the response.(8) The determination of these parameters is inherently subjective.(1) For instance, setting \\(L_i\\) slightly higher for a minimization objective can significantly reduce the overall desirability of numerous acceptable process points. If the chosen exponents reflect an overly strict utility function (e.g., \\(s, t &gt; 1\\)), minor deviations from the ideal target will be heavily penalized, potentially excluding viable operating conditions. Therefore, in any formal research or industrial application, thorough sensitivity analysis across a reasonable range of \\(L_i, U_i\\), and exponents is mandatory to ensure the robustness of the identified optimal solution.\n\n\n\nThe conventional framework of the DS method maximizes the point estimate \\(D\\). When attempting to conduct statistical inference—such as constructing confidence or prediction intervals around the estimated optimal \\(D\\) value—a significant methodological gap emerges.(9) The underlying response models (\\(\\hat{Y}_i\\)) in MRO problems are typically derived from experimental designs (e.g., RSM) and exhibit a complex structure of covariance. The responses are often significantly correlated, and frequently exhibit the antagonism that initially necessitated the MRO analysis.(1) However, traditional, simple methods for calculating intervals around the optimal \\(D\\) often rely on the assumption that the response variables are independent, which is fundamentally antithetical to the nature of the problem.(9) Methods that construct simple confidence intervals by examining the best and worst cases for individual responses fail to incorporate this crucial covariance component.(9) This exclusion means that the resulting intervals for the optimal desirability index \\(D\\) are statistically inadequate and may provide misleading estimates of confidence or uncertainty. The literature recognizes this need for novel inference methods that explicitly account for the complex covariance structure among the fitted response variables to ensure statistically rigorous confidence regions are established around the optimum \\(D\\).(9)\n\n\n\nThe piecewise and potentially non-smooth nature of the DS functions, combined with the aforementioned inference challenges, has spurred the development of alternative desirability frameworks. Other optimization strategies, such as those based on minimizing the estimated distance from an ideal design point (Khuri and Conlon, 1981), offer different theoretical bases.(2) Furthermore, alternative functional forms, such as exponential desirability functions, have been proposed to offer different mechanisms for assessing penalty and utility.(2) More recently, researchers have focused on proposing novel desirability functions that are smooth, nonlinear, and fully differentiable. These characteristics are desirable because they make the objective function \\(D\\) more suitable for application within highly efficient, modern gradient-based optimization algorithms, particularly when searching large, complex response surfaces.(1)",
    "crumbs": [
      "Sections",
      "Metabolic Syndrome Index Construction"
    ]
  },
  {
    "objectID": "metSyn_index_construction.html#vii.-conclusions-and-future-work",
    "href": "metSyn_index_construction.html#vii.-conclusions-and-future-work",
    "title": "Metabolic Syndrome Index Construction",
    "section": "",
    "text": "The desirability2 R package successfully translates the influential Derringer and Suich (1980) framework for Multi-Response Optimization into a modern, computationally efficient software architecture. The core function of the package is to provide highly flexible, exponent-controlled transformations that map multi-scale responses (\\(\\hat{Y}_i\\)) to a uniform desirability score (\\(d_i\\)). The subsequent aggregation via the geometric mean, implemented through the d_overall() function, enforces the essential non-compensatory principle, guaranteeing that any chosen optimal solution satisfies a minimum acceptability criterion for every objective simultaneously. The package’s primary architectural contribution is the seamless integration of these desirability calculations into dplyr pipelines via in-line functions. This enables researchers, especially those working within the tidymodels ecosystem, to treat MRO as a routine and auditable data transformation step, significantly streamlining tasks such as hyperparameter tuning and model ranking. Moving forward, future methodological research must focus on overcoming the known limitations of statistical inference within the DS framework. Specifically, effort should be directed toward integrating advanced inference techniques that can accurately account for the covariance structure among the antagonistic response variables.11 Additionally, the incorporation of smooth and fully differentiable desirability functions into the desirability2 architecture would enhance the package’s compatibility with cutting-edge gradient-based optimization methods, thereby extending its utility to handle even larger and more complex optimization challenges.(1)",
    "crumbs": [
      "Sections",
      "Metabolic Syndrome Index Construction"
    ]
  },
  {
    "objectID": "eda2.html",
    "href": "eda2.html",
    "title": "Data Processing & EDA",
    "section": "",
    "text": "Compared to version 1 in this version missing values from the biochemical data have been filled either by correction or missing value imputation. As a result the number of observations has increased from ~123 in version 1 to ~153 in this version i.e. a ~25% increase. The ~ approximation here is to denote the fact that depending on the type of analysis and the data sets involved, the number of observations could change a bit to 120 instead of 123 in version 1, and to 150 in this version.\nClick here for the codiet project’s site.",
    "crumbs": [
      "Sections",
      "Data Processing & EDA"
    ]
  },
  {
    "objectID": "eda2.html#idf-metabolic-syndrome-definition",
    "href": "eda2.html#idf-metabolic-syndrome-definition",
    "title": "Data Processing & EDA",
    "section": "IDF Metabolic Syndrome Definition",
    "text": "IDF Metabolic Syndrome Definition\nNote: Below, the MetS IDF definition is not fully using the imputed biochemical information to decide on whether an individual belongs to the NO or YES groups for having metabolic syndrome.\n\n\n\n\n\n\nMetabolic Syndrome Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\n\nClinical Variable\nN\nOverall\nN = 1531\n\nIDF Metabolic Syndrome\n\np-value2,3\n\n\nNO\nN = 1201\nYES\nN = 331\n\n\n\n\nGender\n153\n\n\n\n\n\n\n0.009**\n\n\n    Female\n\n\n99 (65%)\n84 (70%)\n15 (45%)\n\n\n\n\n    Male\n\n\n54 (35%)\n36 (30%)\n18 (55%)\n\n\n\n\nSite Collection\n153\n\n\n\n\n\n\n0.881\n\n\n    AUTH\n\n\n32 (21%)\n25 (21%)\n7 (21%)\n\n\n\n\n    BILBAO\n\n\n19 (12%)\n16 (13%)\n3 (9.1%)\n\n\n\n\n    CORK\n\n\n50 (33%)\n40 (33%)\n10 (30%)\n\n\n\n\n    ICL\n\n\n24 (16%)\n19 (16%)\n5 (15%)\n\n\n\n\n    UVEG\n\n\n28 (18%)\n20 (17%)\n8 (24%)\n\n\n\n\nBMI\n153\n30.6 (28.5, 34.9)\n29.6 (27.8, 33.2)\n34.9 (32.4, 38.8)\n&lt;0.001***\n\n\nTRIG\n153\n69 (48, 116)\n61 (45, 102)\n93 (66, 136)\n0.007**\n\n\nHDL\n149\n53 (44, 62)\n54 (47, 63)\n43 (38, 51)\n&lt;0.001***\n\n\n    Missing\n\n\n4\n4\n0\n\n\n\n\nGLU\n149\n91 (84, 97)\n90 (83, 95)\n101 (90, 106)\n&lt;0.001***\n\n\n    Missing\n\n\n4\n3\n1\n\n\n\n\nHighBP\n150\n105 (70%)\n75 (64%)\n30 (91%)\n0.003**\n\n\n    Missing\n\n\n3\n3\n0\n\n\n\n\n\nP-values are unadjusted.\n\n\n1 n (%); Median (Q1, Q3)\n\n\n2 Pearson’s Chi-squared test; Fisher’s exact test; Wilcoxon rank sum test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001",
    "crumbs": [
      "Sections",
      "Data Processing & EDA"
    ]
  },
  {
    "objectID": "eda2.html#biochemical-measurements",
    "href": "eda2.html#biochemical-measurements",
    "title": "Data Processing & EDA",
    "section": "Biochemical Measurements",
    "text": "Biochemical Measurements\nNote: Below, the MetS IDF definition is not fully using the imputed biochemical information to decide on whether an individual belongs to the NO or YES groups for having metabolic syndrome.\n\n\n\n\n\n\nBiochemical Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\n\nBiochemical Variable\nN\nOverall\nN = 1531\n\nIDF Metabolic Syndrome\n\np-value2,3\n\n\nNO\nN = 1201\nYES\nN = 331\n\n\n\n\nSite_Collection\n153\n\n\n\n\n\n\n0.881\n\n\n    AUTH\n\n\n32 (21%)\n25 (21%)\n7 (21%)\n\n\n\n\n    BILBAO\n\n\n19 (12%)\n16 (13%)\n3 (9.1%)\n\n\n\n\n    CORK\n\n\n50 (33%)\n40 (33%)\n10 (30%)\n\n\n\n\n    ICL\n\n\n24 (16%)\n19 (16%)\n5 (15%)\n\n\n\n\n    UVEG\n\n\n28 (18%)\n20 (17%)\n8 (24%)\n\n\n\n\nCHOL\n153\n203 (184, 233)\n209 (189, 236)\n193 (173, 217)\n0.018*\n\n\nTRIG\n153\n69 (48, 116)\n61 (45, 102)\n93 (66, 136)\n0.007**\n\n\nHDL\n153\n53 (44, 61)\n54 (48, 63)\n43 (38, 51)\n&lt;0.001***\n\n\nHDL_Detected\n153\n149 (97%)\n116 (97%)\n33 (100%)\n0.578\n\n\nLDL\n153\n139 (113, 158)\n140 (116, 161)\n126 (102, 151)\n0.097\n\n\nLDL_Detected\n153\n149 (97%)\n116 (97%)\n33 (100%)\n0.578\n\n\nHbA1c_Perc\n153\n5.60 (5.35, 5.90)\n5.50 (5.31, 5.75)\n5.85 (5.60, 6.20)\n&lt;0.001***\n\n\nHbA1c_Perc_Detected\n153\n151 (99%)\n118 (98%)\n33 (100%)\n&gt;0.999\n\n\nGLU\n153\n91 (84, 97)\n90 (83, 95)\n101 (91, 105)\n&lt;0.001***\n\n\nGLU_Detected\n153\n149 (97%)\n117 (98%)\n32 (97%)\n&gt;0.999\n\n\nUREA\n153\n29 (24, 34)\n29 (24, 34)\n29 (24, 33)\n0.812\n\n\nUREA_Detected\n153\n\n\n\n\n\n\n\n\n\n\n    Yes\n\n\n153 (100%)\n120 (100%)\n33 (100%)\n\n\n\n\nCREA\n153\n0.79 (0.70, 0.90)\n0.78 (0.70, 0.90)\n0.81 (0.70, 1.00)\n0.189\n\n\n25_OH_Vit_D3\n153\n23 (19, 27)\n23 (20, 27)\n23 (19, 27)\n0.413\n\n\n25_OH_Vit_D3_Detected\n153\n104 (68%)\n82 (68%)\n22 (67%)\n0.856\n\n\nALB\n153\n4.40 (4.10, 4.69)\n4.40 (4.12, 4.70)\n4.37 (4.00, 4.59)\n0.230\n\n\nALB_Detected\n153\n152 (99%)\n119 (99%)\n33 (100%)\n&gt;0.999\n\n\nTBIL\n153\n0.54 (0.41, 0.75)\n0.55 (0.40, 0.76)\n0.53 (0.43, 0.70)\n0.868\n\n\nTBIL_Detected\n153\n149 (97%)\n116 (97%)\n33 (100%)\n0.578\n\n\nNa\n153\n140.00 (139.00, 142.00)\n140.00 (138.40, 141.60)\n141.00 (139.00, 142.00)\n0.079\n\n\nK\n153\n4.47 (4.20, 4.70)\n4.50 (4.20, 4.70)\n4.40 (4.20, 4.66)\n0.582\n\n\nK_Detected\n153\n151 (99%)\n118 (98%)\n33 (100%)\n&gt;0.999\n\n\nCRP\n153\n0.28 (0.12, 0.91)\n0.27 (0.12, 0.79)\n0.58 (0.22, 1.00)\n0.107\n\n\nCRP_Detected\n153\n\n\n\n\n\n\n\n\n\n\n    Yes\n\n\n153 (100%)\n120 (100%)\n33 (100%)\n\n\n\n\nWBC\n153\n6.20 (5.17, 7.66)\n6.04 (5.14, 7.82)\n6.56 (5.31, 7.48)\n0.719\n\n\nRBC\n153\n4.74 (4.48, 5.02)\n4.65 (4.37, 4.93)\n4.92 (4.77, 5.27)\n&lt;0.001***\n\n\nHCT_Perc\n153\n42.7 (40.0, 44.8)\n41.6 (39.7, 44.1)\n44.0 (43.0, 46.0)\n0.005**\n\n\nHGB\n153\n14.10 (13.10, 15.10)\n14.00 (13.00, 15.00)\n14.90 (13.70, 15.50)\n0.020*\n\n\nNEU_Perc\n153\n57 (51, 62)\n57 (50, 62)\n58 (51, 62)\n0.506\n\n\nLYM_Perc\n153\n32 (28, 37)\n32 (28, 37)\n32 (26, 37)\n0.613\n\n\nMONO_Perc\n153\n7.30 (5.90, 9.10)\n7.40 (5.90, 9.12)\n7.20 (5.90, 8.90)\n0.638\n\n\nBASO_Perc\n153\n0.80 (0.60, 1.27)\n0.85 (0.60, 1.31)\n0.80 (0.52, 1.00)\n0.419\n\n\nBASO_Perc_Detected\n153\n142 (93%)\n111 (93%)\n31 (94%)\n&gt;0.999\n\n\nEOS_Perc\n153\n2.80 (1.64, 3.92)\n2.66 (1.63, 3.94)\n3.10 (1.70, 3.85)\n0.837\n\n\nEOS_Perc_Detected\n153\n151 (99%)\n118 (98%)\n33 (100%)\n&gt;0.999\n\n\nMVC\n153\n90.1 (86.5, 93.0)\n90.4 (86.9, 93.2)\n87.5 (85.3, 92.3)\n0.102\n\n\nMCH\n153\n30.00 (29.00, 31.00)\n30.20 (29.00, 31.00)\n29.50 (28.00, 30.40)\n0.028*\n\n\nMCHC\n153\n33.30 (32.50, 34.10)\n33.20 (32.55, 34.20)\n33.60 (32.50, 34.00)\n0.829\n\n\nRDW_CV_Perc\n153\n13.00 (12.30, 13.70)\n12.90 (12.25, 13.70)\n13.20 (12.70, 13.70)\n0.172\n\n\nNEU\n153\n3.41 (2.74, 4.46)\n3.40 (2.74, 4.38)\n3.62 (2.90, 4.55)\n0.536\n\n\nLYM\n153\n1.91 (1.55, 2.38)\n1.91 (1.60, 2.42)\n1.97 (1.52, 2.31)\n0.564\n\n\nMONO\n153\n0.45 (0.39, 0.56)\n0.47 (0.39, 0.56)\n0.43 (0.39, 0.56)\n0.942\n\n\nBASO\n153\n0.050 (0.040, 0.080)\n0.050 (0.040, 0.080)\n0.050 (0.040, 0.060)\n0.571\n\n\nBASO_Detected\n153\n142 (93%)\n111 (93%)\n31 (94%)\n&gt;0.999\n\n\nEOS\n153\n0.17 (0.10, 0.25)\n0.17 (0.10, 0.25)\n0.18 (0.10, 0.25)\n0.986\n\n\nEOS_Detected\n153\n151 (99%)\n118 (98%)\n33 (100%)\n&gt;0.999\n\n\nPLT\n153\n265 (230, 301)\n269 (233, 308)\n252 (193, 292)\n0.062\n\n\nSGOT\n153\n23 (19, 27)\n23 (19, 26)\n25 (20, 29)\n0.076\n\n\nSGOT_Detected\n153\n129 (84%)\n101 (84%)\n28 (85%)\n0.924\n\n\nSGPT\n153\n28 (21, 34)\n28 (19, 34)\n30 (26, 54)\n0.019*\n\n\nALP\n153\n70 (56, 84)\n69 (54, 84)\n72 (58, 86)\n0.316\n\n\nALP_Detected\n153\n152 (99%)\n119 (99%)\n33 (100%)\n&gt;0.999\n\n\nTG_HDL_C_Index\n153\n1.34 (0.86, 2.24)\n1.16 (0.77, 1.90)\n2.16 (1.59, 3.09)\n&lt;0.001***\n\n\nTG_HDL_C_Index_Detected\n153\n149 (97%)\n116 (97%)\n33 (100%)\n0.578\n\n\nTyG_Index\n153\n4.37 (4.16, 4.62)\n4.33 (4.12, 4.58)\n4.58 (4.37, 4.74)\n&lt;0.001***\n\n\nTyG_Index_Detected\n153\n149 (97%)\n117 (98%)\n32 (97%)\n&gt;0.999\n\n\nALT_AST_Ratio\n153\n1.18 (0.93, 1.53)\n1.12 (0.93, 1.48)\n1.33 (1.00, 1.78)\n0.046*\n\n\nALT_AST_Ratio_Detected\n153\n129 (84%)\n101 (84%)\n28 (85%)\n0.924\n\n\nCHOL_HDL_Ratio\n153\n3.89 (3.38, 4.59)\n3.76 (3.26, 4.54)\n4.12 (3.68, 4.98)\n0.016*\n\n\nCHOL_HDL_Ratio_Detected\n153\n149 (97%)\n116 (97%)\n33 (100%)\n0.578\n\n\nAtherogenic_Index\n153\n0.13 (-0.06, 0.35)\n0.06 (-0.11, 0.28)\n0.33 (0.20, 0.49)\n&lt;0.001***\n\n\nAtherogenic_Index_Detected\n153\n149 (97%)\n116 (97%)\n33 (100%)\n0.578\n\n\nAISI\n153\n225 (141, 308)\n223 (146, 298)\n236 (123, 327)\n0.884\n\n\ndNLR\n153\n1.31 (1.02, 1.64)\n1.30 (1.01, 1.66)\n1.37 (1.03, 1.61)\n0.507\n\n\nEBR\n153\n3.00 (2.00, 4.75)\n2.90 (2.00, 4.56)\n3.00 (2.00, 5.25)\n0.643\n\n\nEBR_Detected\n153\n141 (92%)\n110 (92%)\n31 (94%)\n&gt;0.999\n\n\nLMR\n153\n4.27 (3.41, 5.44)\n4.28 (3.45, 5.45)\n4.22 (2.93, 5.36)\n0.564\n\n\nMLR\n153\n0.23 (0.18, 0.29)\n0.23 (0.18, 0.29)\n0.24 (0.19, 0.34)\n0.564\n\n\nNLR\n153\n1.81 (1.36, 2.25)\n1.80 (1.35, 2.24)\n1.88 (1.42, 2.47)\n0.509\n\n\nPLR\n153\n134 (110, 166)\n138 (115, 167)\n127 (100, 165)\n0.228\n\n\nSII\n153\n462 (343, 617)\n464 (347, 619)\n453 (288, 563)\n0.560\n\n\n\nUnits are various: mg/dL, ng/mL, g/dL, mmol/L, 10^3/μL, 10^6/μL, %, 10^9/L and U/L. P-values are unadjusted.\n\n\n1 n (%); Median (Q1, Q3)\n\n\n2 Fisher’s exact test; Wilcoxon rank sum test; NA; Pearson’s Chi-squared test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001",
    "crumbs": [
      "Sections",
      "Data Processing & EDA"
    ]
  },
  {
    "objectID": "eda2.html#metabolic-syndrome-index",
    "href": "eda2.html#metabolic-syndrome-index",
    "title": "Data Processing & EDA",
    "section": "Metabolic Syndrome Index",
    "text": "Metabolic Syndrome Index\nBlood pressure data are imported as seen below:\n\n\n\n  \n\n\n\n\n\n\n\n\n\n\n\nFigure 1: Systolic Vs Diastolic Blood Pressure. The dashed pink lines denote the values above which a case is typically characterized as having metabolic syndrome. The purple line indicates the correlation between the two measurements, which is 55%.\n\n\n\n\n\nUsing the blood pressure data together with other measurements used for defining the metabolic syndrome, a score index can be derived as follows. For each input, a translation function is created to map each biomarker’s values between zero and one where zero is unacceptable and one is most desirable i.e. exceeding a given threshold. The mapping depends on whether high or low values are desirable. Each translation function has a parameter which is carefully selected so that each input threshold corresponds to either the 60% value or the 50% value (risk probability) of the translation function (see plots below for more clarity). The 60% threshold value is applied only to \\(\\geqslant\\) cases. The input thresholds as well as the desirability directions (\\(\\geqslant\\) or &gt; or &lt;) for defining the metabolic syndrome index are:\n\nBody Mass Index (BMI) : \\(\\text{ &gt; 30 }kg/m^2\\)\nTriglycerides (TRIG) : \\(\\text{ $\\geqslant$ 150 mg/dL}\\)\nHigh Density Lipoprotein (HDL) : \\(\\text{ &lt; 45 mg/dL}\\)\nGlucose (GLU) : \\(\\text{ $\\geqslant$ 100 mg/dL}\\)\nSystolic Blood Pressure (SBP) : \\(\\text{  $\\geqslant$ 130 mm Hg}\\)\nDiastolic Blood Pressure (DBP) : \\(\\text{  $\\geqslant$ 85 mm Hg}\\)\n\nThen all the translation function results are combined to form a final score for the metabolic syndrome. The combination is done in a manner that takes into account the varying degrees of each biomarker’s translation function. More details on the algorithm used can be found on the section list to the left of this webpage, section Metabolic Syndrome Index Construction.\nIn the below multi-plot panel the relation of the metabolic syndrome score and of the translation functions are shown for each biomarker.\n\n\n\n\n\n\n\n\n\n\n\n(a) Metabolic syndrome index score Vs Body Mass Index\n\n\n\n\n\n\n\n\n\n\n\n(b) Translation Function Vs Body Mass Index\n\n\n\n\n\n\n\n\n\n\n\n\n\n(c) Metabolic syndrome index score Vs Triglycerides\n\n\n\n\n\n\n\n\n\n\n\n(d) Translation Function Vs Triglycerides\n\n\n\n\n\n\n\n\n\n\n\n\n\n(e) Metabolic syndrome index score Vs High Density Lipoprotein\n\n\n\n\n\n\n\n\n\n\n\n(f) Translation Function Vs High Density Lipoprotein\n\n\n\n\n\n\n\n\n\n\n\n\n\n(g) Metabolic syndrome index score Vs Glucose\n\n\n\n\n\n\n\n\n\n\n\n(h) Translation Function Vs Glucose\n\n\n\n\n\n\n\n\n\n\n\n\n\n(i) Metabolic syndrome index score Vs Systolic Blood Pressure\n\n\n\n\n\n\n\n\n\n\n\n(j) Translation Function Vs Systolic Blood Pressure\n\n\n\n\n\n\n\n\n\n\n\n\n\n(k) Metabolic syndrome index score Vs Diastolic Blood Pressure\n\n\n\n\n\n\n\n\n\n\n\n(l) Translation Function Vs Diastolic Blood Pressure\n\n\n\n\n\n\n\nFigure 2: Metabolic syndrome index score and translation functions for each biomarker.\n\n\n\n\n\n\n\n\n\n\n\nFigure 3: Histogram and density curve of the Metabolic Syndrome Score. The vertical dashed line denotes the median value which separates the higher from lower risk cases.\n\n\n\n\n\nNote: Below, the imputed biochemical information is used for deriving the metabolic syndrome MetS index.\n\n\n\n\n\n\nBiochemical Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\n\nBiochemical Variable\nN\nOverall\nN = 1531\n\nIndex Metabolic Syndrome (Using A Score Cutoff Of ~58.67)\n\np-value2,3\n\n\nNO\nN = 761\nYES\nN = 771\n\n\n\n\nSite_Collection\n153\n\n\n\n\n\n\n0.124\n\n\n    AUTH\n\n\n32 (21%)\n17 (22%)\n15 (19%)\n\n\n\n\n    BILBAO\n\n\n19 (12%)\n7 (9.2%)\n12 (16%)\n\n\n\n\n    CORK\n\n\n50 (33%)\n28 (37%)\n22 (29%)\n\n\n\n\n    ICL\n\n\n24 (16%)\n15 (20%)\n9 (12%)\n\n\n\n\n    UVEG\n\n\n28 (18%)\n9 (12%)\n19 (25%)\n\n\n\n\nCHOL\n153\n203 (184, 233)\n214 (189, 238)\n199 (175, 232)\n0.046*\n\n\nTRIG\n153\n69 (48, 116)\n56 (39, 80)\n93 (56, 130)\n&lt;0.001***\n\n\nHDL\n153\n53 (44, 61)\n60 (52, 73)\n46 (41, 53)\n&lt;0.001***\n\n\nLDL\n153\n139 (113, 158)\n140 (113, 160)\n139 (114, 158)\n0.688\n\n\nHbA1c_Perc\n153\n5.60 (5.35, 5.90)\n5.50 (5.30, 5.70)\n5.72 (5.44, 6.00)\n0.001**\n\n\nGLU\n153\n91 (84, 97)\n90 (81, 95)\n93 (86, 102)\n&lt;0.001***\n\n\nUREA\n153\n29 (24, 34)\n28 (22, 33)\n30 (25, 34)\n0.096\n\n\nCREA\n153\n0.79 (0.70, 0.90)\n0.78 (0.69, 0.86)\n0.80 (0.70, 1.00)\n0.014*\n\n\n25_OH_Vit_D3\n153\n23 (19, 27)\n23 (19, 28)\n23 (19, 26)\n0.357\n\n\nALB\n153\n4.40 (4.10, 4.69)\n4.34 (4.10, 4.70)\n4.40 (4.10, 4.60)\n0.682\n\n\nTBIL\n153\n0.56 (0.41, 0.75)\n0.59 (0.40, 0.73)\n0.53 (0.41, 0.76)\n0.749\n\n\nNa\n153\n140.00 (139.00, 142.00)\n140.00 (139.00, 142.00)\n140.00 (138.90, 141.10)\n0.722\n\n\nK\n153\n4.47 (4.20, 4.70)\n4.50 (4.25, 4.70)\n4.40 (4.20, 4.70)\n0.549\n\n\nCRP\n153\n0.28 (0.12, 0.91)\n0.22 (0.10, 0.55)\n0.39 (0.18, 1.30)\n0.008**\n\n\nWBC\n153\n6.20 (5.17, 7.66)\n5.73 (4.92, 7.45)\n6.56 (5.51, 7.82)\n0.074\n\n\nRBC\n153\n4.74 (4.48, 5.02)\n4.61 (4.30, 4.87)\n4.86 (4.60, 5.09)\n&lt;0.001***\n\n\nHCT_Perc\n153\n42.7 (40.0, 44.8)\n41.1 (38.9, 44.0)\n43.8 (40.5, 45.3)\n0.004**\n\n\nHGB\n153\n14.10 (13.10, 15.10)\n13.70 (12.90, 14.55)\n14.60 (13.70, 15.40)\n&lt;0.001***\n\n\nNEU_Perc\n153\n57 (51, 62)\n56 (49, 61)\n57 (52, 63)\n0.117\n\n\nLYM_Perc\n153\n32 (28, 37)\n32 (28, 37)\n31 (27, 36)\n0.332\n\n\nMONO_Perc\n153\n7.30 (5.90, 9.10)\n7.26 (5.84, 9.29)\n7.40 (6.10, 8.90)\n0.983\n\n\nBASO_Perc\n153\n0.70 (0.50, 1.00)\n0.71 (0.50, 1.30)\n0.70 (0.52, 0.96)\n0.686\n\n\nEOS_Perc\n153\n2.74 (1.61, 3.91)\n2.85 (1.63, 4.40)\n2.72 (1.60, 3.60)\n0.406\n\n\nMVC\n153\n90.1 (86.5, 93.0)\n91.0 (87.1, 94.0)\n89.7 (86.1, 92.5)\n0.063\n\n\nMCH\n153\n30.00 (29.00, 31.00)\n30.05 (29.00, 31.00)\n30.00 (28.70, 31.00)\n0.570\n\n\nMCHC\n153\n33.30 (32.50, 34.10)\n33.10 (32.50, 34.10)\n33.60 (32.60, 34.10)\n0.192\n\n\nRDW_CV_Perc\n153\n13.00 (12.30, 13.70)\n13.00 (12.25, 13.60)\n13.00 (12.40, 13.70)\n0.440\n\n\nNEU\n153\n3.41 (2.74, 4.46)\n3.25 (2.55, 4.06)\n3.69 (2.95, 4.60)\n0.035*\n\n\nLYM\n153\n1.91 (1.55, 2.38)\n1.90 (1.52, 2.36)\n1.96 (1.60, 2.47)\n0.590\n\n\nMONO\n153\n0.45 (0.39, 0.56)\n0.45 (0.39, 0.52)\n0.47 (0.39, 0.59)\n0.185\n\n\nBASO\n153\n0.05 (0.03, 0.07)\n0.05 (0.03, 0.07)\n0.05 (0.04, 0.06)\n0.993\n\n\nEOS\n153\n0.17 (0.10, 0.25)\n0.15 (0.10, 0.26)\n0.18 (0.10, 0.24)\n0.950\n\n\nPLT\n153\n265 (230, 301)\n267 (227, 303)\n263 (234, 301)\n0.997\n\n\nSGOT\n153\n23 (19, 27)\n23 (19, 27)\n23 (19, 27)\n0.891\n\n\nSGPT\n153\n28 (21, 34)\n28 (20, 34)\n29 (21, 42)\n0.201\n\n\nALP\n153\n70 (56, 84)\n69 (54, 86)\n71 (56, 83)\n0.783\n\n\nTG_HDL_C_Index\n153\n1.34 (0.86, 2.24)\n0.91 (0.59, 1.35)\n1.91 (1.34, 2.67)\n&lt;0.001***\n\n\nTyG_Index\n153\n4.37 (4.16, 4.62)\n4.25 (4.05, 4.40)\n4.58 (4.28, 4.70)\n&lt;0.001***\n\n\nALT_AST_Ratio\n153\n1.18 (0.93, 1.53)\n1.09 (0.87, 1.41)\n1.25 (0.95, 1.65)\n0.051\n\n\nCHOL_HDL_Ratio\n153\n3.89 (3.38, 4.59)\n3.58 (2.99, 4.15)\n4.45 (3.68, 4.90)\n&lt;0.001***\n\n\nAtherogenic_Index\n153\n0.13 (-0.06, 0.35)\n-0.04 (-0.23, 0.13)\n0.28 (0.13, 0.43)\n&lt;0.001***\n\n\nAISI\n153\n225 (141, 308)\n214 (127, 280)\n236 (157, 338)\n0.088\n\n\ndNLR\n153\n1.31 (1.02, 1.64)\n1.28 (0.97, 1.55)\n1.32 (1.08, 1.68)\n0.118\n\n\nEBR\n152\n3 (2, 6)\n3 (2, 6)\n4 (2, 5)\n\n\n\n\n    Missing\n\n\n1\n1\n0\n\n\n\n\nLMR\n153\n4.27 (3.41, 5.44)\n4.41 (3.48, 5.61)\n4.22 (3.21, 5.30)\n0.346\n\n\nMLR\n153\n0.23 (0.18, 0.29)\n0.23 (0.18, 0.29)\n0.24 (0.19, 0.31)\n0.346\n\n\nNLR\n153\n1.81 (1.36, 2.25)\n1.72 (1.33, 2.26)\n1.86 (1.46, 2.25)\n0.183\n\n\nPLR\n153\n134 (110, 166)\n138 (117, 162)\n132 (101, 172)\n0.611\n\n\nSII\n153\n462 (343, 617)\n462 (337, 566)\n470 (352, 653)\n0.340\n\n\n\nUnits are various: mg/dL, ng/mL, g/dL, mmol/L, 10^3/μL, 10^6/μL, %, 10^9/L and U/L. P-values are unadjusted.\n\n\n1 n (%); Median (Q1, Q3)\n\n\n2 Pearson’s Chi-squared test; Wilcoxon rank sum test; NA\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001\n\n\n\n\n\n\n\n\nWhen comparing the metabolic syndrome IDF with the Score Index univariate statistics tables for the biochemical data, we see that the Score Index seems to produce results of stronger significance, and with a few notable differences such as the case of CRP.",
    "crumbs": [
      "Sections",
      "Data Processing & EDA"
    ]
  },
  {
    "objectID": "eda2.html#human-body-measurements---devices",
    "href": "eda2.html#human-body-measurements---devices",
    "title": "Data Processing & EDA",
    "section": "Human Body Measurements - Devices",
    "text": "Human Body Measurements - Devices\nNote: Below, the imputed human body device information is used for comparing to the metabolic syndrome index.\n\n\n\n\n\n\nHuman Body Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\n\nHuman Body Data Variable\nN\nOverall\nN = 1531\n\nIndex Metabolic Syndrome (Using A Score Cutoff Of ~58.67)\n\np-value2,3\n\n\nNO\nN = 761\nYES\nN = 771\n\n\n\n\nSite_Collection\n153\n\n\n\n\n\n\n0.124\n\n\n    AUTH\n\n\n32 (21%)\n17 (22%)\n15 (19%)\n\n\n\n\n    CBG\n\n\n19 (12%)\n7 (9.2%)\n12 (16%)\n\n\n\n\n    ICL\n\n\n24 (16%)\n15 (20%)\n9 (12%)\n\n\n\n\n    TEAGASC\n\n\n50 (33%)\n28 (37%)\n22 (29%)\n\n\n\n\n    UVEG\n\n\n28 (18%)\n9 (12%)\n19 (25%)\n\n\n\n\ngender\n153\n\n\n\n\n\n\n0.003**\n\n\n    Female\n\n\n99 (65%)\n58 (76%)\n41 (53%)\n\n\n\n\n    Male\n\n\n54 (35%)\n18 (24%)\n36 (47%)\n\n\n\n\nage_value\n153\n1.93 (1.70, 2.30)\n1.91 (1.70, 2.25)\n2.00 (1.70, 2.30)\n0.846\n\n\nrisk_group_cardiovascular\n153\n\n\n\n\n\n\n0.034*\n\n\n    I\n\n\n58 (38%)\n22 (29%)\n36 (47%)\n\n\n\n\n    II\n\n\n15 (9.8%)\n10 (13%)\n5 (6.5%)\n\n\n\n\n    III\n\n\n3 (2.0%)\n3 (3.9%)\n0 (0%)\n\n\n\n\n    Normal\n\n\n77 (50%)\n41 (54%)\n36 (47%)\n\n\n\n\nai\n153\n-59 (-84, -31)\n-61 (-85, -26)\n-58 (-83, -32)\n0.780\n\n\nae\n153\n-77 (-85, -64)\n-78 (-86, -62)\n-77 (-84, -64)\n0.937\n\n\npe\n153\n-30 (-37, -19)\n-30 (-37, -18)\n-29 (-38, -20)\n0.798\n\n\nans_activity\n153\n107 (93, 126)\n112 (97, 133)\n101 (84, 119)\n0.010*\n\n\nans_balance\n153\n66 (34, 101)\n65 (38, 98)\n69 (34, 103)\n0.694\n\n\nstress_resilience\n153\n107 (90, 131)\n113 (95, 137)\n102 (84, 124)\n0.012*\n\n\nstress_index\n153\n92 (75, 108)\n88 (67, 100)\n96 (83, 114)\n0.003**\n\n\nfatigue_index\n153\n87 (68, 103)\n82 (66, 100)\n91 (74, 107)\n0.039*\n\n\nmean_hrt\n153\n71 (64, 79)\n67 (62, 76)\n74 (67, 83)\n0.002**\n\n\nelectro_cardiac_stability\n153\n108 (97, 128)\n115 (101, 130)\n105 (94, 118)\n0.013*\n\n\nectopic_beat\n153\n0.0 (0.0, 1.0)\n0.0 (0.0, 1.0)\n0.0 (0.0, 0.0)\n0.636\n\n\nsdnn\n153\n35 (25, 47)\n38 (29, 55)\n32 (23, 45)\n0.014*\n\n\npsi\n153\n44 (23, 75)\n35 (19, 62)\n51 (29, 98)\n0.004**\n\n\ntp\n153\n900 (463, 1,765)\n1,046 (658, 2,024)\n669 (330, 1,356)\n0.014*\n\n\nvlf\n153\n286 (165, 661)\n318 (183, 745)\n241 (129, 583)\n0.091\n\n\nlf\n153\n274 (138, 542)\n311 (152, 595)\n230 (105, 438)\n0.059\n\n\nhf\n153\n177 (96, 388)\n269 (110, 490)\n134 (69, 256)\n0.005**\n\n\nlfnorm\n153\n56 (42, 75)\n54 (40, 72)\n61 (46, 76)\n0.252\n\n\nhfnorm\n153\n44 (25, 58)\n46 (28, 60)\n39 (24, 54)\n0.252\n\n\nlf_hf_ratio\n153\n1.28 (0.73, 2.94)\n1.16 (0.68, 2.62)\n1.55 (0.86, 3.14)\n0.252\n\n\nrmssd\n153\n26 (18, 38)\n32 (22, 41)\n21 (14, 30)\n&lt;0.001***\n\n\napen\n153\n0.98 (0.81, 1.08)\n0.93 (0.79, 1.06)\n1.01 (0.86, 1.12)\n0.011*\n\n\nsrd\n153\n0.98 (0.90, 1.07)\n0.99 (0.89, 1.07)\n0.98 (0.91, 1.07)\n0.768\n\n\ntsrd\n153\n119 (88, 152)\n131 (111, 155)\n102 (78, 127)\n&lt;0.001***\n\n\ntp_ln\n153\n6.80 (6.14, 7.48)\n6.95 (6.49, 7.61)\n6.51 (5.80, 7.21)\n0.014*\n\n\nvlf_ln\n153\n5.66 (5.10, 6.49)\n5.76 (5.21, 6.61)\n5.49 (4.86, 6.37)\n0.091\n\n\nlf_ln\n153\n5.61 (4.93, 6.30)\n5.73 (5.02, 6.39)\n5.44 (4.66, 6.08)\n0.059\n\n\nhf_ln\n153\n5.18 (4.57, 5.96)\n5.60 (4.70, 6.19)\n4.90 (4.23, 5.55)\n0.005**\n\n\nage\n153\n51 (44, 58)\n51 (45, 58)\n49 (43, 57)\n0.321\n\n\ntbw\n153\n40 (35, 48)\n37 (32, 43)\n43 (37, 51)\n&lt;0.001***\n\n\nicw\n153\n24.5 (21.3, 29.6)\n22.6 (19.8, 26.6)\n26.4 (23.0, 31.2)\n&lt;0.001***\n\n\necw\n153\n14.9 (13.0, 18.2)\n13.9 (12.2, 16.6)\n16.7 (14.3, 19.3)\n&lt;0.001***\n\n\nprotein\n153\n10.60 (9.20, 12.70)\n9.80 (8.60, 11.55)\n11.40 (10.00, 13.50)\n&lt;0.001***\n\n\nminerals\n153\n3.83 (3.26, 4.57)\n3.55 (3.13, 4.15)\n4.11 (3.51, 4.81)\n&lt;0.001***\n\n\nbfm\n153\n33 (26, 43)\n29 (24, 37)\n38 (29, 49)\n&lt;0.001***\n\n\nslm\n153\n51 (45, 61)\n47 (41, 55)\n55 (48, 65)\n&lt;0.001***\n\n\nffm\n153\n54 (47, 65)\n50 (43, 59)\n59 (51, 69)\n&lt;0.001***\n\n\nsmm\n153\n30 (26, 37)\n28 (24, 33)\n32 (28, 39)\n&lt;0.001***\n\n\nbmi\n153\n30.6 (28.5, 34.9)\n28.8 (27.2, 31.0)\n33.2 (30.2, 38.8)\n&lt;0.001***\n\n\npbf\n153\n39 (33, 44)\n38 (33, 43)\n40 (33, 47)\n0.351\n\n\nlean_mass_of_right_arm\n153\n3.02 (2.45, 3.77)\n2.72 (2.24, 3.23)\n3.35 (2.91, 3.95)\n&lt;0.001***\n\n\nlean_mass_percent_of_right_arm\n153\n109 (102, 117)\n107 (100, 114)\n113 (105, 121)\n0.003**\n\n\nlean_mass_of_left_arm\n153\n2.97 (2.45, 3.72)\n2.69 (2.22, 3.25)\n3.28 (2.82, 3.98)\n&lt;0.001***\n\n\nlean_mass_percent_of_left_arm\n153\n109 (101, 116)\n106 (98, 114)\n112 (104, 118)\n0.003**\n\n\nlean_mass_of_trunk\n153\n24.5 (20.9, 28.8)\n22.9 (19.8, 26.0)\n26.5 (23.6, 30.5)\n&lt;0.001***\n\n\nlean_mass_percent_of_trunk\n153\n103.7 (99.7, 108.0)\n102.6 (98.5, 106.6)\n105.5 (100.4, 109.1)\n0.011*\n\n\nlean_mass_of_right_leg\n153\n7.90 (6.62, 9.80)\n7.42 (6.37, 8.93)\n8.88 (7.41, 10.13)\n&lt;0.001***\n\n\nlean_mass_percent_of_right_leg\n153\n97 (92, 103)\n95 (91, 102)\n99 (93, 103)\n0.090\n\n\nlean_mass_of_left_leg\n153\n7.89 (6.63, 9.81)\n7.38 (6.27, 8.97)\n8.82 (7.40, 10.09)\n&lt;0.001***\n\n\nlean_mass_percent_of_left_leg\n153\n97 (92, 102)\n96 (90, 101)\n98 (93, 103)\n0.069\n\n\ntbw_of_right_arm\n153\n2.34 (1.91, 2.94)\n2.12 (1.74, 2.51)\n2.61 (2.26, 3.07)\n&lt;0.001***\n\n\ntbw_of_left_arm\n153\n2.32 (1.91, 2.90)\n2.10 (1.73, 2.53)\n2.55 (2.20, 3.10)\n&lt;0.001***\n\n\ntbw_of_trunk\n153\n19.0 (16.3, 22.5)\n17.8 (15.4, 20.3)\n20.7 (18.4, 23.7)\n&lt;0.001***\n\n\ntbw_of_right_leg\n153\n6.19 (5.15, 7.65)\n5.78 (4.96, 6.95)\n6.92 (5.77, 7.88)\n&lt;0.001***\n\n\ntbw_of_left_leg\n153\n6.16 (5.16, 7.66)\n5.74 (4.88, 6.98)\n6.87 (5.80, 7.85)\n&lt;0.001***\n\n\nicw_of_right_arm\n153\n1.46 (1.19, 1.82)\n1.32 (1.08, 1.56)\n1.62 (1.40, 1.91)\n&lt;0.001***\n\n\nicw_of_left_arm\n153\n1.43 (1.18, 1.80)\n1.30 (1.06, 1.57)\n1.59 (1.37, 1.93)\n&lt;0.001***\n\n\nicw_of_trunk\n153\n11.80 (10.10, 13.90)\n11.00 (9.55, 12.60)\n12.70 (11.30, 14.80)\n&lt;0.001***\n\n\nicw_of_right_leg\n153\n3.80 (3.21, 4.73)\n3.57 (3.06, 4.33)\n4.27 (3.55, 4.93)\n&lt;0.001***\n\n\nicw_of_left_leg\n153\n3.83 (3.20, 4.73)\n3.57 (3.03, 4.37)\n4.25 (3.55, 4.90)\n&lt;0.001***\n\n\necw_of_right_arm\n153\n0.88 (0.72, 1.12)\n0.80 (0.65, 0.95)\n0.99 (0.83, 1.16)\n&lt;0.001***\n\n\necw_of_left_arm\n153\n0.88 (0.72, 1.09)\n0.79 (0.65, 0.96)\n0.98 (0.83, 1.17)\n&lt;0.001***\n\n\necw_of_trunk\n153\n7.20 (6.20, 8.60)\n6.70 (5.90, 7.85)\n7.80 (7.00, 9.20)\n&lt;0.001***\n\n\necw_of_right_leg\n153\n2.39 (1.98, 2.89)\n2.19 (1.87, 2.64)\n2.61 (2.19, 3.00)\n&lt;0.001***\n\n\necw_of_left_leg\n153\n2.39 (2.00, 2.91)\n2.19 (1.88, 2.64)\n2.63 (2.20, 2.97)\n&lt;0.001***\n\n\necw_tbw_ratio\n153\n0.381 (0.377, 0.386)\n0.381 (0.377, 0.386)\n0.381 (0.377, 0.387)\n0.609\n\n\necw_tbw_ratio_of_right_arm\n153\n0.378 (0.375, 0.381)\n0.378 (0.375, 0.381)\n0.379 (0.376, 0.381)\n0.220\n\n\necw_tbw_ratio_of_left_arm\n153\n0.380 (0.377, 0.382)\n0.379 (0.376, 0.382)\n0.380 (0.378, 0.382)\n0.201\n\n\necw_tbw_ratio_of_trunk\n153\n0.381 (0.377, 0.386)\n0.382 (0.377, 0.386)\n0.381 (0.377, 0.385)\n0.826\n\n\necw_tbw_ratio_of_right_leg\n153\n0.381 (0.376, 0.388)\n0.381 (0.376, 0.387)\n0.382 (0.376, 0.388)\n0.434\n\n\necw_tbw_ratio_of_left_leg\n153\n0.382 (0.377, 0.388)\n0.382 (0.377, 0.387)\n0.383 (0.376, 0.389)\n0.406\n\n\nbfm_of_right_arm\n153\n2.60 (1.90, 3.90)\n2.15 (1.70, 3.20)\n3.20 (2.10, 4.90)\n&lt;0.001***\n\n\nbfm_percent_of_right_arm\n153\n315 (233, 530)\n265 (209, 348)\n432 (292, 647)\n&lt;0.001***\n\n\nbfm_of_left_arm\n153\n2.70 (1.90, 3.90)\n2.15 (1.75, 3.25)\n3.30 (2.10, 5.00)\n&lt;0.001***\n\n\nbfm_percent_of_left_arm\n153\n322 (239, 536)\n271 (209, 351)\n438 (299, 643)\n&lt;0.001***\n\n\nbfm_of_trunk\n153\n17.4 (13.6, 21.9)\n15.1 (12.9, 19.2)\n19.3 (15.7, 24.0)\n&lt;0.001***\n\n\nbfm_percent_of_trunk\n153\n341 (284, 454)\n302 (261, 352)\n400 (330, 488)\n&lt;0.001***\n\n\nbfm_of_right_leg\n153\n4.60 (3.60, 5.90)\n3.90 (3.40, 5.20)\n4.90 (4.10, 6.40)\n0.001**\n\n\nbfm_percent_of_right_leg\n153\n207 (176, 276)\n188 (166, 219)\n242 (197, 304)\n&lt;0.001***\n\n\nbfm_of_left_leg\n153\n4.60 (3.60, 5.90)\n3.90 (3.40, 5.20)\n4.80 (4.10, 6.50)\n0.001**\n\n\nbfm_percent_of_left_leg\n153\n207 (176, 276)\n189 (164, 218)\n242 (195, 305)\n&lt;0.001***\n\n\ninbody_score\n153\n66 (59, 71)\n67 (62, 72)\n65 (56, 71)\n0.061\n\n\ntarget_weight\n153\n69 (61, 78)\n65 (57, 74)\n74 (66, 83)\n&lt;0.001***\n\n\nweight_control\n153\n-20 (-29, -13)\n-15 (-23, -11)\n-24 (-34, -16)\n&lt;0.001***\n\n\nbfm_control\n153\n-20 (-29, -13)\n-15 (-23, -12)\n-24 (-34, -16)\n&lt;0.001***\n\n\nffm_control\n153\n\n\n\n\n\n\n0.250\n\n\n    0\n\n\n143 (93%)\n67 (88%)\n76 (99%)\n\n\n\n\n    0.2\n\n\n2 (1.3%)\n2 (2.6%)\n0 (0%)\n\n\n\n\n    0.3\n\n\n1 (0.7%)\n1 (1.3%)\n0 (0%)\n\n\n\n\n    0.4\n\n\n1 (0.7%)\n1 (1.3%)\n0 (0%)\n\n\n\n\n    0.8\n\n\n2 (1.3%)\n1 (1.3%)\n1 (1.3%)\n\n\n\n\n    1.5\n\n\n1 (0.7%)\n1 (1.3%)\n0 (0%)\n\n\n\n\n    2\n\n\n1 (0.7%)\n1 (1.3%)\n0 (0%)\n\n\n\n\n    3.7\n\n\n1 (0.7%)\n1 (1.3%)\n0 (0%)\n\n\n\n\n    6.3\n\n\n1 (0.7%)\n1 (1.3%)\n0 (0%)\n\n\n\n\nbmr\n153\n1,535 (1,386, 1,766)\n1,453 (1,309, 1,635)\n1,634 (1,465, 1,861)\n&lt;0.001***\n\n\nwhr\n153\n0.99 (0.93, 1.03)\n0.96 (0.92, 1.01)\n1.02 (0.96, 1.07)\n&lt;0.001***\n\n\nvfa\n153\n160 (123, 213)\n142 (115, 189)\n185 (137, 231)\n&lt;0.001***\n\n\nobesity_degree\n153\n145 (132, 164)\n136 (128, 150)\n154 (141, 182)\n&lt;0.001***\n\n\nbcm\n153\n35 (31, 42)\n32 (28, 38)\n38 (33, 45)\n&lt;0.001***\n\n\nac\n153\n35.9 (33.9, 39.3)\n34.3 (32.5, 36.3)\n37.9 (35.6, 42.1)\n&lt;0.001***\n\n\namc\n153\n29.6 (27.8, 32.3)\n28.3 (27.3, 30.0)\n31.4 (29.3, 33.2)\n&lt;0.001***\n\n\nbmc\n153\n3.18 (2.74, 3.77)\n2.98 (2.61, 3.45)\n3.46 (2.88, 3.96)\n&lt;0.001***\n\n\ntbw_ffm_ratio\n153\n73.30 (73.10, 73.50)\n73.20 (73.10, 73.40)\n73.30 (73.20, 73.60)\n0.003**\n\n\nffmi\n153\n19.80 (17.70, 21.40)\n18.40 (16.85, 20.25)\n20.40 (19.50, 22.10)\n&lt;0.001***\n\n\nfmi\n153\n12.0 (9.3, 15.0)\n10.8 (8.8, 13.3)\n12.9 (10.3, 18.1)\n0.005**\n\n\nkhz_ra_5_phase_angle\n153\n2.60 (2.20, 2.80)\n2.40 (2.10, 2.70)\n2.60 (2.40, 2.90)\n0.001**\n\n\nkhz_la_5_phase_angle\n153\n2.40 (2.10, 2.70)\n2.40 (2.10, 2.70)\n2.50 (2.30, 2.80)\n0.018*\n\n\nkhz_tr_5_phase_angle\n153\n3.30 (2.80, 3.80)\n3.30 (2.95, 3.85)\n3.40 (2.70, 3.70)\n0.608\n\n\nkhz_rl_5_phase_angle\n153\n2.60 (2.40, 2.90)\n2.50 (2.30, 2.80)\n2.70 (2.50, 2.90)\n0.044*\n\n\nkhz_ll_5_phase_angle\n153\n2.60 (2.30, 2.80)\n2.50 (2.20, 2.85)\n2.70 (2.40, 2.80)\n0.031*\n\n\nkhz_ra_50_phase_angle\n153\n5.20 (4.90, 5.60)\n5.20 (4.70, 5.50)\n5.30 (5.00, 5.80)\n0.046*\n\n\nkhz_la_50_phase_angle\n153\n5.00 (4.70, 5.40)\n4.90 (4.60, 5.35)\n5.10 (4.80, 5.60)\n0.029*\n\n\nkhz_tr_50_phase_angle\n153\n7.40 (6.80, 8.10)\n7.20 (6.60, 8.10)\n7.50 (7.00, 8.10)\n0.057\n\n\nkhz_rl_50_phase_angle\n153\n5.70 (5.20, 6.30)\n5.65 (5.15, 6.25)\n5.80 (5.30, 6.30)\n0.395\n\n\nkhz_ll_50_phase_angle\n153\n5.60 (5.20, 6.20)\n5.60 (5.05, 6.10)\n5.70 (5.30, 6.30)\n0.214\n\n\nkhz_ra_250_phase_angle\n153\n4.80 (4.50, 5.00)\n4.70 (4.40, 4.90)\n4.80 (4.60, 5.10)\n0.013*\n\n\nkhz_la_250_phase_angle\n153\n4.50 (4.30, 4.80)\n4.45 (4.20, 4.80)\n4.60 (4.40, 4.90)\n0.044*\n\n\nkhz_tr_250_phase_angle\n153\n7.60 (7.00, 8.30)\n7.60 (7.00, 8.25)\n7.60 (6.80, 8.30)\n0.977\n\n\nkhz_rl_250_phase_angle\n153\n4.40 (4.10, 4.60)\n4.35 (4.10, 4.60)\n4.40 (4.20, 4.70)\n0.431\n\n\nkhz_ll_250_phase_angle\n153\n4.60 (4.30, 4.80)\n4.50 (4.30, 4.80)\n4.60 (4.30, 4.90)\n0.360\n\n\nKhz_50_whole_body_phase_angle\n153\n5.50 (5.10, 6.00)\n5.45 (4.90, 5.90)\n5.60 (5.30, 6.10)\n0.086\n\n\nmeasured_circumference_of_neck\n153\n39.4 (37.0, 42.5)\n38.0 (35.8, 40.0)\n41.3 (38.4, 44.3)\n&lt;0.001***\n\n\nmeasured_circumference_of_chest\n153\n106 (101, 114)\n103 (98, 107)\n112 (105, 117)\n&lt;0.001***\n\n\nmeasured_circumference_of_abdomen\n153\n105 (96, 120)\n98 (94, 110)\n113 (103, 124)\n&lt;0.001***\n\n\nmeasured_circumference_of_hip\n153\n107 (103, 114)\n104 (100, 109)\n112 (106, 118)\n&lt;0.001***\n\n\nmeasured_circumference_of_right_arm\n153\n36.1 (34.0, 39.7)\n34.8 (32.7, 36.4)\n38.2 (36.0, 42.5)\n&lt;0.001***\n\n\nmeasured_circumference_of_left_arm\n153\n35.9 (33.9, 39.3)\n34.3 (32.5, 36.3)\n37.9 (35.6, 42.1)\n&lt;0.001***\n\n\nmeasured_circumference_of_right_thigh\n153\n58.6 (55.7, 62.2)\n56.5 (53.5, 60.5)\n60.5 (57.6, 63.4)\n&lt;0.001***\n\n\nmeasured_circumference_of_left_thigh\n153\n58.6 (55.5, 62.4)\n56.4 (53.5, 60.7)\n60.3 (57.5, 63.4)\n&lt;0.001***\n\n\ninbody_type\n153\n\n\n\n\n\n\n\n\n\n\n    970\n\n\n153 (100%)\n76 (100%)\n77 (100%)\n\n\n\n\nsmi\n153\n8.00 (7.10, 8.80)\n7.45 (6.85, 8.20)\n8.50 (7.90, 9.20)\n&lt;0.001***\n\n\nsmi_t_score\n153\n0.30 (-0.30, 1.20)\n-0.05 (-0.65, 0.95)\n0.60 (0.00, 1.40)\n&lt;0.001***\n\n\nsmi_z_score\n153\n0.30 (-0.40, 1.10)\n0.00 (-0.70, 0.80)\n0.50 (0.00, 1.30)\n0.001**\n\n\nwhole_body_ecw_tbw_ratio_t_score\n153\n1.10 (0.30, 2.10)\n1.10 (0.10, 1.90)\n1.10 (0.60, 2.20)\n0.121\n\n\nwhole_body_ecw_tbw_ratio_z_score\n153\n0.20 (-0.40, 1.00)\n0.10 (-0.55, 0.90)\n0.40 (-0.20, 1.20)\n0.047*\n\n\nvfa_t_score\n153\n2.40 (1.40, 3.80)\n1.70 (1.10, 2.95)\n3.20 (1.90, 4.20)\n&lt;0.001***\n\n\nvfa_z_score\n153\n1.20 (0.40, 2.40)\n0.80 (0.30, 1.70)\n2.10 (0.90, 3.00)\n&lt;0.001***\n\n\nbmi_t_score\n153\n1.10 (0.60, 2.20)\n0.70 (0.35, 1.30)\n1.70 (1.00, 2.90)\n&lt;0.001***\n\n\nbmi_z_score\n153\n0.70 (0.10, 1.70)\n0.20 (-0.10, 0.95)\n1.10 (0.60, 2.30)\n&lt;0.001***\n\n\nsubcutaneous_fat\n153\n\n\n\n\n\n\n\n\n\n\n    0\n\n\n153 (100%)\n76 (100%)\n77 (100%)\n\n\n\n\narms_legs_fat_ratio\n153\n15 (11, 20)\n12 (10, 17)\n16 (12, 23)\n&lt;0.001***\n\n\nvisceral_fat\n153\n\n\n\n\n\n\n\n\n\n\n    0\n\n\n153 (100%)\n76 (100%)\n77 (100%)\n\n\n\n\nabdominal_fat\n153\n\n\n\n\n\n\n\n\n\n\n    0\n\n\n153 (100%)\n76 (100%)\n77 (100%)\n\n\n\n\nv_s_ratio\n153\n\n\n\n\n\n\n\n\n\n\n    0\n\n\n153 (100%)\n76 (100%)\n77 (100%)\n\n\n\n\nsfa\n153\n\n\n\n\n\n\n\n\n\n\n    0\n\n\n153 (100%)\n76 (100%)\n77 (100%)\n\n\n\n\nwhtr\n153\n0.63 (0.58, 0.69)\n0.60 (0.57, 0.65)\n0.66 (0.61, 0.73)\n&lt;0.001***\n\n\nbai\n153\n31.4 (28.5, 35.4)\n31.0 (28.1, 33.9)\n31.7 (29.2, 37.0)\n0.077\n\n\nabsi\n153\n0.081 (0.079, 0.084)\n0.081 (0.078, 0.084)\n0.082 (0.079, 0.084)\n0.319\n\n\nconicity_index\n153\n1.35 (1.28, 1.40)\n1.32 (1.27, 1.37)\n1.37 (1.31, 1.41)\n&lt;0.001***\n\n\nsvr\n153\n0.18 (0.14, 0.24)\n0.18 (0.15, 0.24)\n0.18 (0.13, 0.24)\n0.632\n\n\nkhz_50_ab_impedance\n153\n\n\n\n\n\n\n\n\n\n\n    0\n\n\n153 (100%)\n76 (100%)\n77 (100%)\n\n\n\n\nkhz_250_ab_impedance\n153\n\n\n\n\n\n\n\n\n\n\n    0\n\n\n153 (100%)\n76 (100%)\n77 (100%)\n\n\n\n\nwc\n153\n105 (96, 120)\n98 (94, 110)\n113 (103, 124)\n&lt;0.001***\n\n\nangle_r\n153\n\n\n\n\n\n\n\n\n\n\n    0\n\n\n153 (100%)\n76 (100%)\n77 (100%)\n\n\n\n\nangle_l\n153\n\n\n\n\n\n\n\n\n\n\n    0\n\n\n153 (100%)\n76 (100%)\n77 (100%)\n\n\n\n\nsmm_wt_ratio\n153\n33.7 (30.8, 37.2)\n33.8 (31.4, 37.2)\n33.6 (29.4, 37.3)\n0.638\n\n\nbfm_percent_of_whole_body\n153\n333 (266, 429)\n296 (250, 367)\n374 (284, 520)\n&lt;0.001***\n\n\necm_bcm_ratio\n153\n0.538 (0.529, 0.548)\n0.540 (0.529, 0.550)\n0.537 (0.529, 0.547)\n0.599\n\n\ntbw_wt_ratio\n153\n45 (41, 49)\n45 (42, 49)\n44 (39, 49)\n0.379\n\n\nbcm_t_score\n153\n0.10 (-0.50, 0.90)\n-0.10 (-0.65, 0.70)\n0.30 (-0.30, 1.10)\n0.021*\n\n\nbcm_z_score\n153\n0.40 (-0.30, 1.30)\n0.10 (-0.40, 1.15)\n0.60 (0.00, 1.30)\n0.019*\n\n\nffmi_t_score\n153\n0.50 (-0.40, 1.20)\n0.00 (-0.50, 1.00)\n0.80 (0.10, 1.60)\n&lt;0.001***\n\n\nffmi_z_score\n153\n0.50 (-0.40, 1.30)\n0.00 (-0.50, 1.00)\n0.80 (0.10, 1.60)\n0.003**\n\n\nfmi_t_score\n153\n1.30 (0.70, 2.60)\n0.95 (0.50, 1.40)\n1.90 (1.20, 3.10)\n&lt;0.001***\n\n\nfmi_z_score\n153\n0.80 (0.20, 1.90)\n0.40 (0.00, 0.85)\n1.30 (0.50, 2.30)\n&lt;0.001***\n\n\npbf_t_score\n153\n1.40 (0.80, 2.00)\n1.10 (0.65, 1.50)\n1.80 (1.20, 2.30)\n&lt;0.001***\n\n\npbf_z_score\n153\n0.80 (0.30, 1.60)\n0.60 (0.10, 1.00)\n1.20 (0.60, 1.80)\n&lt;0.001***\n\n\nweight_t_score\n153\n1.10 (0.20, 2.00)\n0.60 (0.10, 1.60)\n1.50 (0.70, 2.60)\n&lt;0.001***\n\n\nweight_z_score\n153\n0.60 (0.00, 1.70)\n0.20 (-0.30, 1.15)\n1.10 (0.40, 2.10)\n&lt;0.001***\n\n\nwhr_t_score\n153\n1.10 (0.30, 1.70)\n0.70 (0.20, 1.40)\n1.40 (0.60, 1.90)\n&lt;0.001***\n\n\nwhr_z_score\n153\n0.50 (-0.10, 1.10)\n0.30 (-0.30, 0.80)\n0.80 (0.20, 1.30)\n&lt;0.001***\n\n\nkhz_whole_body_phase_angle_t_score\n153\n-0.70 (-1.50, -0.10)\n-0.80 (-1.50, -0.10)\n-0.70 (-1.50, -0.10)\n0.953\n\n\nkhz_whole_body_phase_angle_z_score\n153\n-0.10 (-1.00, 0.60)\n-0.10 (-1.00, 0.70)\n-0.10 (-1.00, 0.40)\n0.745\n\n\ntbw_wt_ratio_t_score\n153\n-1.40 (-2.00, -0.80)\n-1.10 (-1.50, -0.60)\n-1.80 (-2.30, -1.20)\n&lt;0.001***\n\n\ntbw_wt_ratio_z_score\n153\n-0.80 (-1.50, -0.30)\n-0.60 (-1.00, -0.15)\n-1.20 (-1.80, -0.60)\n&lt;0.001***\n\n\nsmm_wt_ratio_t_score\n153\n-1.40 (-2.00, -0.80)\n-1.10 (-1.50, -0.70)\n-1.70 (-2.20, -1.20)\n&lt;0.001***\n\n\nsmm_wt_ratio_z_score\n153\n-0.80 (-1.60, -0.30)\n-0.60 (-1.00, -0.15)\n-1.30 (-1.80, -0.60)\n&lt;0.001***\n\n\necm_bcm_ratio_t_score\n153\n1.00 (0.10, 1.80)\n1.00 (-0.10, 1.75)\n0.90 (0.20, 1.90)\n0.347\n\n\necm_bcm_ratio_z_score\n153\n0.20 (-0.60, 1.00)\n0.30 (-0.65, 0.75)\n0.10 (-0.50, 1.20)\n0.305\n\n\nr_ht_ratio\n153\n335 (283, 380)\n369 (317, 409)\n306 (271, 340)\n&lt;0.001***\n\n\nxc_ht_ratio\n153\n32.4 (28.6, 35.8)\n34.2 (30.8, 38.2)\n30.8 (26.3, 33.4)\n&lt;0.001***\n\n\n\nP-values are unadjusted.\n\n\n1 n (%); Median (Q1, Q3)\n\n\n2 Pearson’s Chi-squared test; Wilcoxon rank sum test; Fisher’s exact test; NA\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001",
    "crumbs": [
      "Sections",
      "Data Processing & EDA"
    ]
  },
  {
    "objectID": "eda2.html#medication-information",
    "href": "eda2.html#medication-information",
    "title": "Data Processing & EDA",
    "section": "Medication Information",
    "text": "Medication Information\n\n\n\n\n\n\nMedication Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\nMedication Variable\nN\n\nIDF Metabolic Syndrome\n\np-value2,3\n\n\nNO\nN = 1201\nYES\nN = 331\n\n\n\n\nAntihypertensives\n153\n\n\n\n\n0.064\n\n\n    No\n\n\n98 (82%)\n22 (67%)\n\n\n\n\n    Yes\n\n\n22 (18%)\n11 (33%)\n\n\n\n\nHyperlipidemias\n153\n\n\n\n\n0.163\n\n\n    No\n\n\n106 (88%)\n26 (79%)\n\n\n\n\n    Yes\n\n\n14 (12%)\n7 (21%)\n\n\n\n\nAntidepressants\n153\n\n\n\n\n0.735\n\n\n    No\n\n\n108 (90%)\n31 (94%)\n\n\n\n\n    Yes\n\n\n12 (10%)\n2 (6.1%)\n\n\n\n\n\nP-values are unadjusted.\n\n\n1 n (%)\n\n\n2 Pearson’s Chi-squared test; Fisher’s exact test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nMedication Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\nMedication Variable\nN\n\nIndex Metabolic Syndrome (Using A Score Cutoff Of ~58.67)\n\np-value2,3\n\n\nNO\nN = 761\nYES\nN = 771\n\n\n\n\nAntihypertensives\n153\n\n\n\n\n0.034*\n\n\n    No\n\n\n65 (86%)\n55 (71%)\n\n\n\n\n    Yes\n\n\n11 (14%)\n22 (29%)\n\n\n\n\nHyperlipidemias\n153\n\n\n\n\n0.789\n\n\n    No\n\n\n65 (86%)\n67 (87%)\n\n\n\n\n    Yes\n\n\n11 (14%)\n10 (13%)\n\n\n\n\nAntidepressants\n153\n\n\n\n\n0.088\n\n\n    No\n\n\n66 (87%)\n73 (95%)\n\n\n\n\n    Yes\n\n\n10 (13%)\n4 (5.2%)\n\n\n\n\n\nP-values are unadjusted.\n\n\n1 n (%)\n\n\n2 Pearson’s Chi-squared test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001",
    "crumbs": [
      "Sections",
      "Data Processing & EDA"
    ]
  },
  {
    "objectID": "eda2.html#dietary-information",
    "href": "eda2.html#dietary-information",
    "title": "Data Processing & EDA",
    "section": "Dietary Information",
    "text": "Dietary Information\n\nMediterranean Diet Adherence Screener (MEDAS)\n14-item Mediterranean Diet Adherence Screener (MEDAS):\nIt is a short questionnaire used to assess how well someone is following the Mediterranean Diet. It includes 14 questions, each of which gives 1 point if the relevant criterion is met.\n\n0–5 points → Low compliance\n6–9 points → Moderate compliance\n10–14 points → High compliance\n\nThe higher the score, the greater the adherence to the Mediterranean Diet and the more likely its health benefits, especially in cardiovascular prevention.\n\n\n\n\n\n\n\n\nFigure 4: Distribution of MEDAS Score\n\n\n\n\n\n\n\nHealthy Eating Index (HEI)\n\n\n\n\n\n\n\n\nFigure 5: Distribution of HEI Total Scores (Healthy Eating Index)\n\n\n\n\n\n \nAdjustment for Energy Intake (kcal):\n \n\n\n\n\n\n\n\n\nFigure 6: HEI Total Score versus Energy Intake (kcal) at first data collection time.\n\n\n\n\n\n\n\nDietary Inflammatory Index (DII)\n\n\n\n\n\n\n\n\nFigure 7: Distribution of DII Scores (Dietary Inflammatory Index)\n\n\n\n\n\n\n\n\n\n\n\nDietary Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\nDietary Variable\nN\n\nIDF Metabolic Syndrome\n\np-value2,3\n\n\nNO\nN = 1201\nYES\nN = 331\n\n\n\n\nMEDAS_Score\n153\n6.00 (5.00, 7.00)\n6.00 (5.00, 8.00)\n0.746\n\n\nHEI_Total_Score\n150\n63 (40, 68)\n67 (57, 70)\n0.039*\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nDaily_EI\n150\n1,385 (1,314, 1,549)\n1,380 (1,165, 1,629)\n0.712\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nHEI_Total_Score_AdjEI\n150\n66 (39, 67)\n67 (63, 67)\n0.312\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nTotal_DII\n150\n2.28 (2.02, 2.53)\n2.34 (1.91, 2.60)\n0.473\n\n\n    Missing\n\n\n3\n0\n\n\n\n\n\nP-values are unadjusted.\n\n\n1 Median (Q1, Q3)\n\n\n2 Wilcoxon rank sum test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nDietary Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\nDietary Variable\nN\n\nIndex Metabolic Syndrome (Using A Score Cutoff Of ~58.67)\n\np-value2,3\n\n\nNO\nN = 761\nYES\nN = 771\n\n\n\n\nMEDAS_Score\n153\n6.00 (5.00, 7.00)\n6.00 (5.00, 7.00)\n0.331\n\n\nHEI_Total_Score\n150\n61 (40, 67)\n66 (56, 71)\n0.007**\n\n\n    Missing\n\n\n2\n1\n\n\n\n\nDaily_EI\n150\n1,372 (1,282, 1,479)\n1,399 (1,284, 1,638)\n0.134\n\n\n    Missing\n\n\n2\n1\n\n\n\n\nHEI_Total_Score_AdjEI\n150\n65 (39, 67)\n67 (64, 67)\n0.113\n\n\n    Missing\n\n\n2\n1\n\n\n\n\nTotal_DII\n150\n2.29 (2.21, 2.54)\n2.29 (1.85, 2.59)\n0.355\n\n\n    Missing\n\n\n2\n1\n\n\n\n\n\nP-values are unadjusted.\n\n\n1 Median (Q1, Q3)\n\n\n2 Wilcoxon rank sum test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001\n\n\n\n\n\n\n\n\nMissing values are due to IDs existing in the MEDAS score data but not in the other two dietary indices.",
    "crumbs": [
      "Sections",
      "Data Processing & EDA"
    ]
  },
  {
    "objectID": "eda2.html#activity-tracker",
    "href": "eda2.html#activity-tracker",
    "title": "Data Processing & EDA",
    "section": "Activity Tracker",
    "text": "Activity Tracker\n\n\n\n\n\n\nActivity Tracker Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\nActivity Tracker Variable\nN\n\nIDF Metabolic Syndrome\n\np-value2,3\n\n\nNO\nN = 1201\nYES\nN = 331\n\n\n\n\nSteps\n147\n7,248 (5,211, 9,300)\n7,186 (4,557, 10,143)\n0.814\n\n\n    Missing\n\n\n4\n2\n\n\n\n\nSleep\n147\n5.76 (4.82, 6.91)\n5.25 (4.49, 6.61)\n0.138\n\n\n    Missing\n\n\n4\n2\n\n\n\n\nSedentary\n147\n10.09 (8.60, 11.41)\n10.14 (8.42, 12.34)\n0.449\n\n\n    Missing\n\n\n4\n2\n\n\n\n\nLight\n147\n2.38 (1.99, 2.89)\n2.11 (1.86, 2.69)\n0.146\n\n\n    Missing\n\n\n4\n2\n\n\n\n\nModerate\n147\n1.92 (1.43, 2.45)\n1.93 (1.45, 2.48)\n0.907\n\n\n    Missing\n\n\n4\n2\n\n\n\n\nVigorous\n147\n0.01 (0.00, 0.03)\n0.01 (0.00, 0.04)\n0.600\n\n\n    Missing\n\n\n4\n2\n\n\n\n\n\nTimes are in hours. P-values are unadjusted.\n\n\n1 Median (Q1, Q3)\n\n\n2 Wilcoxon rank sum test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nActivity Tracker Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\nActivity Tracker Variable\nN\n\nIndex Metabolic Syndrome (Using A Score Cutoff Of ~58.67)\n\np-value2,3\n\n\nNO\nN = 761\nYES\nN = 771\n\n\n\n\nSteps\n147\n6,982 (5,156, 9,107)\n7,497 (4,969, 9,537)\n0.542\n\n\n    Missing\n\n\n2\n4\n\n\n\n\nSleep\n147\n5.81 (4.83, 6.92)\n5.62 (4.76, 6.88)\n0.552\n\n\n    Missing\n\n\n2\n4\n\n\n\n\nSedentary\n147\n10.13 (8.41, 11.42)\n10.14 (9.10, 11.66)\n0.362\n\n\n    Missing\n\n\n2\n4\n\n\n\n\nLight\n147\n2.40 (2.00, 2.89)\n2.30 (1.96, 2.76)\n0.537\n\n\n    Missing\n\n\n2\n4\n\n\n\n\nModerate\n147\n1.89 (1.38, 2.41)\n1.99 (1.52, 2.48)\n0.360\n\n\n    Missing\n\n\n2\n4\n\n\n\n\nVigorous\n147\n0.01 (0.00, 0.03)\n0.01 (0.00, 0.03)\n0.720\n\n\n    Missing\n\n\n2\n4\n\n\n\n\n\nTimes are in hours. P-values are unadjusted.\n\n\n1 Median (Q1, Q3)\n\n\n2 Wilcoxon rank sum test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001\n\n\n\n\n\n\n\n\nIDs do not fully match other data i.e. missing",
    "crumbs": [
      "Sections",
      "Data Processing & EDA"
    ]
  },
  {
    "objectID": "eda2.html#smoking-status",
    "href": "eda2.html#smoking-status",
    "title": "Data Processing & EDA",
    "section": "Smoking Status",
    "text": "Smoking Status\n\n\n\n\n\n\nSmoking Status (Timepoint 1)\n\n\n\n\n\n\n\n\n\nSmoking Status Variable\nN\n\nIDF Metabolic Syndrome\n\np-value2,3\n\n\nNO\nN = 1181\nYES\nN = 331\n\n\n\n\nSmoking_Status\n151\n\n\n\n\n0.210\n\n\n    Current smoker\n\n\n29 (25%)\n4 (12%)\n\n\n\n\n    Former smoker\n\n\n35 (30%)\n14 (42%)\n\n\n\n\n    Never smoked\n\n\n54 (46%)\n15 (45%)\n\n\n\n\n\nP-values are unadjusted.\n\n\n1 n (%)\n\n\n2 Pearson’s Chi-squared test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSmoking Status (Timepoint 1)\n\n\n\n\n\n\n\n\n\nSmoking Status Variable\nN\n\nIndex Metabolic Syndrome (Using A Score Cutoff Of ~58.67)\n\np-value2,3\n\n\nNO\nN = 741\nYES\nN = 771\n\n\n\n\nSmoking_Status\n151\n\n\n\n\n0.218\n\n\n    Current smoker\n\n\n18 (24%)\n15 (19%)\n\n\n\n\n    Former smoker\n\n\n19 (26%)\n30 (39%)\n\n\n\n\n    Never smoked\n\n\n37 (50%)\n32 (42%)\n\n\n\n\n\nP-values are unadjusted.\n\n\n1 n (%)\n\n\n2 Pearson’s Chi-squared test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001\n\n\n\n\n\n\n\n\nIDs do not fully match other data i.e. missing",
    "crumbs": [
      "Sections",
      "Data Processing & EDA"
    ]
  },
  {
    "objectID": "eda2.html#targeted-metabolites",
    "href": "eda2.html#targeted-metabolites",
    "title": "Data Processing & EDA",
    "section": "Targeted Metabolites",
    "text": "Targeted Metabolites\n\nAmino Acids & Sugars\n\n\n\n\n\n\nSugar & Amino Acid Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\nSugar & Amino Acid Variable\nN\n\nIDF Metabolic Syndrome\n\np-value2,3\n\n\nNO\nN = 1201\nYES\nN = 331\n\n\n\n\nAnhydroglucitol\n153\n99 (75, 128)\n86 (76, 103)\n0.166\n\n\nGlucose\n153\n6,350 (4,904, 7,559)\n7,659 (6,729, 8,296)\n0.001**\n\n\nMannose\n153\n45 (31, 61)\n62 (48, 74)\n0.003**\n\n\nFructose\n153\n20 (6, 28)\n26 (7, 34)\n0.079\n\n\nValine\n153\n228 (161, 285)\n290 (218, 336)\n0.006**\n\n\nLeucine\n153\n192 (148, 241)\n250 (190, 284)\n0.003**\n\n\nIsoleucine\n153\n57 (41, 78)\n70 (59, 89)\n0.005**\n\n\nGlutamine\n153\n563 (388, 695)\n627 (428, 742)\n0.162\n\n\nGlutamic_Acid\n153\n53 (29, 79)\n91 (74, 132)\n&lt;0.001***\n\n\nPhenylalanine\n153\n67 (54, 78)\n69 (61, 85)\n0.102\n\n\nTyrosine\n153\n64 (45, 79)\n80 (67, 92)\n0.002**\n\n\nTryptophan\n153\n50 (35, 60)\n54 (42, 67)\n0.122\n\n\nGlutamine_To_Glutamic_Acid_Ratio\n153\n11 (7, 18)\n7 (5, 9)\n&lt;0.001***\n\n\nBCAA_To_AAA_Ratio\n153\n2.67 (2.32, 2.97)\n2.78 (2.39, 3.12)\n0.178\n\n\n\nUnits are in μΜ. P-values are unadjusted.\n\n\n1 Median (Q1, Q3)\n\n\n2 Wilcoxon rank sum test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSugar & Amino Acid Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\nSugar & Amino Acid Variable\nN\n\nIndex Metabolic Syndrome (Using A Score Cutoff Of ~58.67)\n\np-value2,3\n\n\nNO\nN = 761\nYES\nN = 771\n\n\n\n\nAnhydroglucitol\n153\n100 (78, 134)\n91 (73, 115)\n0.051\n\n\nGlucose\n153\n6,430 (4,757, 7,614)\n7,229 (5,311, 7,887)\n0.115\n\n\nMannose\n153\n45 (31, 59)\n55 (35, 68)\n0.039*\n\n\nFructose\n153\n22 (6, 28)\n21 (6, 32)\n0.418\n\n\nValine\n153\n214 (154, 270)\n251 (184, 325)\n0.010**\n\n\nLeucine\n153\n184 (146, 231)\n226 (177, 270)\n0.006**\n\n\nIsoleucine\n153\n55 (39, 72)\n69 (52, 87)\n0.008**\n\n\nGlutamine\n153\n583 (427, 710)\n566 (388, 692)\n0.692\n\n\nGlutamic_Acid\n153\n46 (28, 73)\n76 (43, 119)\n&lt;0.001***\n\n\nPhenylalanine\n153\n66 (54, 74)\n71 (60, 85)\n0.021*\n\n\nTyrosine\n153\n64 (46, 79)\n70 (49, 88)\n0.072\n\n\nTryptophan\n153\n50 (35, 59)\n53 (38, 63)\n0.480\n\n\nGlutamine_To_Glutamic_Acid_Ratio\n153\n12 (9, 20)\n7 (5, 12)\n&lt;0.001***\n\n\nBCAA_To_AAA_Ratio\n153\n2.67 (2.31, 2.93)\n2.72 (2.39, 3.08)\n0.116\n\n\n\nUnits are in μΜ. P-values are unadjusted.\n\n\n1 Median (Q1, Q3)\n\n\n2 Wilcoxon rank sum test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001\n\n\n\n\n\n\n\n\n\n\nAcylCarnitines\n\n\n\n\n\n\nAcylCarnitines Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\nAcylCarnitines Variable\nN\n\nIDF Metabolic Syndrome\n\np-value2,3\n\n\nNO\nN = 1201\nYES\nN = 331\n\n\n\n\nAcetylcarnitine\n153\n9.9 (6.9, 12.8)\n11.1 (8.2, 13.7)\n0.265\n\n\nPropionylcarnitine\n153\n0.59 (0.45, 0.75)\n0.57 (0.36, 0.76)\n0.575\n\n\nButyrylcarnitine\n153\n0.10 (0.06, 0.13)\n0.08 (0.06, 0.14)\n0.656\n\n\nValerylcarnitine\n153\n0.056 (0.035, 0.070)\n0.055 (0.037, 0.066)\n0.933\n\n\nHexanoylcarnitine\n153\n0.06 (0.04, 0.07)\n0.06 (0.04, 0.09)\n0.540\n\n\nOctanoylcarnitine\n153\n0.14 (0.08, 0.18)\n0.14 (0.10, 0.22)\n0.409\n\n\nDecanoylcarnitine\n153\n0.26 (0.16, 0.34)\n0.24 (0.19, 0.36)\n0.516\n\n\nLauroylcarnitine\n153\n0.04 (0.03, 0.06)\n0.04 (0.03, 0.06)\n0.328\n\n\nMyristoylcarnitine\n153\n0.018 (0.013, 0.024)\n0.021 (0.017, 0.027)\n0.059\n\n\nPalmitoylcarnitine\n153\n0.10 (0.08, 0.11)\n0.11 (0.08, 0.13)\n0.053\n\n\nStearoylcarnitine\n153\n0.019 (0.012, 0.025)\n0.022 (0.014, 0.030)\n0.060\n\n\nLinoleoylcarnitine\n153\n0.07 (0.05, 0.09)\n0.07 (0.05, 0.11)\n0.567\n\n\nOleoylcarnitine\n153\n0.13 (0.10, 0.17)\n0.13 (0.10, 0.18)\n0.797\n\n\n\nUnits are in μΜ. P-values are unadjusted.\n\n\n1 Median (Q1, Q3)\n\n\n2 Wilcoxon rank sum test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nAcylCarnitines Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\nAcylCarnitines Variable\nN\n\nIndex Metabolic Syndrome (Using A Score Cutoff Of ~58.67)\n\np-value2,3\n\n\nNO\nN = 761\nYES\nN = 771\n\n\n\n\nAcetylcarnitine\n153\n10.0 (7.1, 14.9)\n9.9 (7.2, 12.9)\n0.903\n\n\nPropionylcarnitine\n153\n0.59 (0.46, 0.72)\n0.57 (0.40, 0.77)\n0.822\n\n\nButyrylcarnitine\n153\n0.09 (0.07, 0.12)\n0.09 (0.06, 0.14)\n0.964\n\n\nValerylcarnitine\n153\n0.055 (0.036, 0.071)\n0.056 (0.036, 0.065)\n0.758\n\n\nHexanoylcarnitine\n153\n0.06 (0.04, 0.07)\n0.05 (0.04, 0.07)\n0.398\n\n\nOctanoylcarnitine\n153\n0.14 (0.09, 0.18)\n0.14 (0.09, 0.22)\n0.865\n\n\nDecanoylcarnitine\n153\n0.26 (0.18, 0.33)\n0.25 (0.18, 0.36)\n0.881\n\n\nLauroylcarnitine\n153\n0.04 (0.03, 0.06)\n0.04 (0.03, 0.06)\n0.430\n\n\nMyristoylcarnitine\n153\n0.018 (0.014, 0.024)\n0.020 (0.015, 0.027)\n0.398\n\n\nPalmitoylcarnitine\n153\n0.10 (0.08, 0.12)\n0.10 (0.08, 0.12)\n0.874\n\n\nStearoylcarnitine\n153\n0.019 (0.013, 0.025)\n0.020 (0.012, 0.026)\n0.361\n\n\nLinoleoylcarnitine\n153\n0.07 (0.05, 0.09)\n0.08 (0.05, 0.10)\n0.673\n\n\nOleoylcarnitine\n153\n0.13 (0.09, 0.18)\n0.13 (0.10, 0.18)\n0.763\n\n\n\nUnits are in μΜ. P-values are unadjusted.\n\n\n1 Median (Q1, Q3)\n\n\n2 Wilcoxon rank sum test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001",
    "crumbs": [
      "Sections",
      "Data Processing & EDA"
    ]
  },
  {
    "objectID": "eda2.html#urine",
    "href": "eda2.html#urine",
    "title": "Data Processing & EDA",
    "section": "Urine",
    "text": "Urine\n\nHILIC Panel\n\n\n\n\n\n\nHILIC Urine Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\nHILIC Urine Variable\nN\n\nIDF Metabolic Syndrome\n\np-value2,3\n\n\nNO\nN = 1201\nYES\nN = 331\n\n\n\n\n2_Hydroxyisovalericacid\n152\n3,245 (2,371, 4,889)\n2,986 (2,464, 4,076)\n0.668\n\n\n    Missing\n\n\n1\n0\n\n\n\n\n2_Hydroxyisovalericacid_Detected\n152\n\n\n\n\n0.761\n\n\n    No\n\n\n19 (16%)\n6 (18%)\n\n\n\n\n    Yes\n\n\n100 (84%)\n27 (82%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\n3_Methylhistidine\n152\n392,821 (200,436, 792,247)\n275,585 (123,580, 433,552)\n0.040*\n\n\n    Missing\n\n\n1\n0\n\n\n\n\n3_Methylhistidine_Detected\n152\n\n\n\n\n0.685\n\n\n    No\n\n\n8 (6.7%)\n1 (3.0%)\n\n\n\n\n    Yes\n\n\n111 (93%)\n32 (97%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nAcetylcarnitine\n152\n2,019,176 (977,846, 3,992,379)\n2,061,013 (1,154,575, 2,433,283)\n0.505\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nAdenine\n152\n26,812 (19,776, 46,180)\n18,744 (14,676, 24,637)\n&lt;0.001***\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nAdenine_Detected\n152\n\n\n\n\n0.992\n\n\n    No\n\n\n72 (61%)\n20 (61%)\n\n\n\n\n    Yes\n\n\n47 (39%)\n13 (39%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nAlanine\n152\n36,823 (22,142, 78,991)\n37,722 (24,627, 51,062)\n0.964\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nAlanine_Detected\n152\n\n\n\n\n\n\n\n\n    Yes\n\n\n119 (100%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nAllantoin\n152\n9,657 (6,047, 15,475)\n7,466 (4,582, 14,348)\n0.306\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nAscorbic_Acid\n152\n1,672 (1,319, 2,262)\n1,694 (1,467, 1,948)\n0.947\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nAscorbic_Acid_Detected\n152\n\n\n\n\n\n\n\n\n    Yes\n\n\n119 (100%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nAsparagine\n152\n5,997 (4,413, 15,027)\n5,583 (4,254, 8,381)\n0.350\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nBenzoic_Acid\n152\n1,079 (536, 2,075)\n714 (512, 1,271)\n0.157\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nBenzoic_Acid_Detected\n152\n\n\n\n\n0.577\n\n\n    No\n\n\n62 (52%)\n19 (58%)\n\n\n\n\n    Yes\n\n\n57 (48%)\n14 (42%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nBetaine\n152\n1,043,349 (679,074, 2,123,292)\n995,191 (867,436, 1,675,900)\n0.802\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nCaffeine\n152\n24,992 (7,251, 48,149)\n29,827 (13,141, 44,910)\n0.754\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nCaffeine_Detected\n152\n\n\n\n\n\n\n\n\n    Yes\n\n\n119 (100%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nCholine\n152\n223,819 (137,486, 373,539)\n225,075 (160,807, 317,128)\n0.918\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nCotinine\n152\n57,760 (1,214, 311,788)\n83,105 (805, 225,757)\n0.450\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nCotinine_Detected\n152\n\n\n\n\n0.787\n\n\n    No\n\n\n50 (42%)\n13 (39%)\n\n\n\n\n    Yes\n\n\n69 (58%)\n20 (61%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nCreatine\n152\n562,595 (287,258, 1,515,620)\n420,720 (281,003, 1,161,241)\n0.520\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nCreatinine\n152\n47,725,164 (39,296,951, 62,672,929)\n48,990,711 (42,892,934, 55,081,360)\n0.950\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nCytosine\n152\n17,645 (12,456, 43,909)\n15,288 (11,902, 27,662)\n0.323\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nCytosine_Detected\n152\n\n\n\n\n0.882\n\n\n    No\n\n\n23 (19%)\n6 (18%)\n\n\n\n\n    Yes\n\n\n96 (81%)\n27 (82%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nDimethylamine\n152\n35,887 (28,588, 55,720)\n37,009 (31,099, 44,130)\n0.813\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nGlutamic_Acid\n152\n660 (510, 1,241)\n620 (472, 806)\n0.208\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nGlutamic_Acid_Detected\n152\n\n\n\n\n0.121\n\n\n    No\n\n\n54 (45%)\n20 (61%)\n\n\n\n\n    Yes\n\n\n65 (55%)\n13 (39%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nGlutamine\n152\n212,231 (160,633, 374,923)\n205,311 (151,193, 274,505)\n0.270\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nGuanine\n152\n1,660 (928, 2,972)\n1,748 (882, 2,849)\n0.932\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nGuanine_Detected\n152\n\n\n\n\n0.685\n\n\n    No\n\n\n6 (5.0%)\n2 (6.1%)\n\n\n\n\n    Yes\n\n\n113 (95%)\n31 (94%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nHippuric_Acid\n152\n90,452 (44,435, 140,222)\n54,250 (37,750, 102,508)\n0.035*\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nHistamine\n152\n3,144 (2,117, 7,167)\n2,614 (1,947, 4,539)\n0.089\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nHistamine_Detected\n152\n\n\n\n\n0.348\n\n\n    No\n\n\n39 (33%)\n8 (24%)\n\n\n\n\n    Yes\n\n\n80 (67%)\n25 (76%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nHypotaurine\n152\n249 (191, 438)\n230 (185, 273)\n0.337\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nHypotaurine_Detected\n152\n\n\n\n\n0.806\n\n\n    No\n\n\n82 (69%)\n22 (67%)\n\n\n\n\n    Yes\n\n\n37 (31%)\n11 (33%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nHypoxanthine\n152\n84,008 (57,252, 126,316)\n87,173 (60,961, 120,157)\n0.799\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nHypoxanthine_Detected\n152\n\n\n\n\n\n\n\n\n    Yes\n\n\n119 (100%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nIndole_3_Lactic_Acid\n152\n2,725 (2,157, 3,506)\n2,732 (2,200, 3,062)\n0.802\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nInosine\n152\n1,404 (728, 2,752)\n1,134 (722, 1,534)\n0.108\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nInosine_Detected\n152\n\n\n\n\n&gt;0.999\n\n\n    No\n\n\n4 (3.4%)\n1 (3.0%)\n\n\n\n\n    Yes\n\n\n115 (97%)\n32 (97%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nKynurenate\n152\n19,686 (12,712, 29,739)\n14,192 (10,985, 20,488)\n0.064\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nLactose\n152\n1,783 (1,052, 6,823)\n1,263 (878, 3,114)\n0.077\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nLysine\n152\n15,680 (10,614, 63,075)\n23,199 (10,195, 37,618)\n0.961\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nLysine_Detected\n152\n\n\n\n\n0.083\n\n\n    No\n\n\n22 (18%)\n2 (6.1%)\n\n\n\n\n    Yes\n\n\n97 (82%)\n31 (94%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nMannitol\n152\n1,500 (683, 3,638)\n1,400 (838, 3,390)\n0.724\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nMannitol_Detected\n152\n\n\n\n\n0.041*\n\n\n    No\n\n\n14 (12%)\n0 (0%)\n\n\n\n\n    Yes\n\n\n105 (88%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nMethylamine\n152\n6,386 (4,462, 9,421)\n5,329 (4,510, 8,693)\n0.546\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nMethylamine_Detected\n152\n\n\n\n\n&gt;0.999\n\n\n    No\n\n\n1 (0.8%)\n0 (0%)\n\n\n\n\n    Yes\n\n\n118 (99%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nMonoisoamylamine\n152\n15,752 (11,329, 28,060)\n13,493 (10,431, 23,171)\n0.334\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nMonoisoamylamine_Detected\n152\n\n\n\n\n0.348\n\n\n    No\n\n\n7 (5.9%)\n0 (0%)\n\n\n\n\n    Yes\n\n\n112 (94%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nNicotinamide\n152\n1,824 (1,290, 2,373)\n2,262 (1,761, 2,708)\n0.013*\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nNicotinamide_Detected\n152\n\n\n\n\n&gt;0.999\n\n\n    No\n\n\n2 (1.7%)\n0 (0%)\n\n\n\n\n    Yes\n\n\n117 (98%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nPantothenate\n152\n9,098 (4,783, 24,697)\n8,042 (3,944, 16,475)\n0.364\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nPhenylalanine\n152\n46,351 (28,038, 78,775)\n47,823 (38,538, 80,404)\n0.576\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nPyridoxine\n152\n38,543 (24,349, 67,482)\n28,974 (24,816, 59,123)\n0.302\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nPyridoxine_Detected\n152\n\n\n\n\n0.879\n\n\n    No\n\n\n74 (62%)\n21 (64%)\n\n\n\n\n    Yes\n\n\n45 (38%)\n12 (36%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nPyroglutamic\n152\n36,467 (21,864, 75,958)\n33,153 (21,078, 47,637)\n0.266\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nPyroglutamic_Detected\n152\n\n\n\n\n0.004**\n\n\n    No\n\n\n3 (2.5%)\n6 (18%)\n\n\n\n\n    Yes\n\n\n116 (97%)\n27 (82%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nRivoflavine\n152\n1,662 (769, 5,120)\n1,417 (649, 4,252)\n0.472\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nRivoflavine_Detected\n152\n\n\n\n\n0.141\n\n\n    No\n\n\n22 (18%)\n10 (30%)\n\n\n\n\n    Yes\n\n\n97 (82%)\n23 (70%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nSerine\n152\n20,308 (16,235, 62,413)\n20,962 (15,323, 27,687)\n0.704\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nSorbitol\n152\n669 (402, 1,368)\n750 (571, 1,169)\n0.374\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nSorbitol_Detected\n152\n\n\n\n\n\n\n\n\n    Yes\n\n\n119 (100%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nSucrose\n152\n267 (146, 455)\n228 (127, 358)\n0.145\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nSucrose_Detected\n152\n\n\n\n\n0.397\n\n\n    No\n\n\n55 (46%)\n18 (55%)\n\n\n\n\n    Yes\n\n\n64 (54%)\n15 (45%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nTaurine\n152\n8,139 (4,867, 15,166)\n13,052 (3,384, 22,769)\n0.461\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nTaurine_Detected\n152\n\n\n\n\n&gt;0.999\n\n\n    No\n\n\n7 (5.9%)\n2 (6.1%)\n\n\n\n\n    Yes\n\n\n112 (94%)\n31 (94%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nTheobromine\n152\n54,681 (31,327, 90,747)\n39,649 (25,301, 76,404)\n0.240\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nThiamine\n152\n28,398 (16,178, 60,836)\n23,080 (15,430, 42,820)\n0.203\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nThiamine_Detected\n152\n\n\n\n\n&gt;0.999\n\n\n    No\n\n\n3 (2.5%)\n0 (0%)\n\n\n\n\n    Yes\n\n\n116 (97%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nThreonine\n152\n17,420 (12,403, 38,567)\n17,136 (14,076, 28,124)\n0.932\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nThreonine_Detected\n152\n\n\n\n\n\n\n\n\n    Yes\n\n\n119 (100%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nTrimethylamine\n152\n6,874 (5,246, 12,623)\n7,063 (4,855, 14,148)\n0.841\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nTrimethylamine_Detected\n152\n\n\n\n\n0.126\n\n\n    No\n\n\n42 (35%)\n7 (21%)\n\n\n\n\n    Yes\n\n\n77 (65%)\n26 (79%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nTrimethylamine_N_Oxide\n152\n1,684,101 (1,170,555, 2,967,953)\n1,722,838 (1,158,720, 2,477,079)\n0.982\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nTryptamine\n152\n35,537 (22,799, 60,516)\n47,243 (32,180, 74,101)\n0.052\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nTryptamine_Detected\n152\n\n\n\n\n\n\n\n\n    Yes\n\n\n119 (100%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nTryptophan\n152\n17,738 (10,930, 31,330)\n17,906 (13,636, 38,885)\n0.701\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nTyrosine\n152\n6,103 (3,385, 11,765)\n7,087 (4,740, 11,894)\n0.315\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nTyrosine_Detected\n152\n\n\n\n\n&gt;0.999\n\n\n    No\n\n\n7 (5.9%)\n2 (6.1%)\n\n\n\n\n    Yes\n\n\n112 (94%)\n31 (94%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nUracil\n152\n2,985 (2,042, 4,221)\n2,794 (2,272, 3,385)\n0.681\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nUracil_Detected\n152\n\n\n\n\n\n\n\n\n    Yes\n\n\n119 (100%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nUric_Acid\n152\n1,424 (602, 2,860)\n1,335 (968, 2,078)\n0.869\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nUric_Acid_Detected\n152\n\n\n\n\n0.514\n\n\n    No\n\n\n20 (17%)\n4 (12%)\n\n\n\n\n    Yes\n\n\n99 (83%)\n29 (88%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nValine\n152\n29,328 (18,470, 50,389)\n27,418 (20,326, 37,604)\n0.813\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nValine_Detected\n152\n\n\n\n\n0.577\n\n\n    No\n\n\n4 (3.4%)\n0 (0%)\n\n\n\n\n    Yes\n\n\n115 (97%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nXanthine\n152\n14,432 (9,746, 20,331)\n11,352 (9,222, 14,449)\n0.087\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nXanthine_Detected\n152\n\n\n\n\n\n\n\n\n    Yes\n\n\n119 (100%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nA_Ketoglutaric_Acid\n152\n861 (606, 1,518)\n765 (471, 1,159)\n0.146\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nA_Ketoglutaric_Acid_Detected\n152\n\n\n\n\n&gt;0.999\n\n\n    No\n\n\n3 (2.5%)\n0 (0%)\n\n\n\n\n    Yes\n\n\n116 (97%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nG_Aminobutyric\n152\n410 (316, 740)\n382 (345, 588)\n0.782\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nG_Aminobutyric_Detected\n152\n\n\n\n\n0.300\n\n\n    No\n\n\n60 (50%)\n20 (61%)\n\n\n\n\n    Yes\n\n\n59 (50%)\n13 (39%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nLeucine_Isoleucine_Ratio\n152\n34,037 (24,241, 55,137)\n30,751 (22,092, 42,083)\n0.508\n\n\n    Missing\n\n\n1\n0\n\n\n\n\nLeucine_Isoleucine_Ratio_Detected\n152\n\n\n\n\n0.577\n\n\n    No\n\n\n4 (3.4%)\n0 (0%)\n\n\n\n\n    Yes\n\n\n115 (97%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n1\n0\n\n\n\n\n\nUnits are in peak area. P-values are unadjusted.\n\n\n1 Median (Q1, Q3); n (%)\n\n\n2 Wilcoxon rank sum test; Pearson’s Chi-squared test; Fisher’s exact test; NA\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nHILIC Urine Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\nHILIC Urine Variable\nN\n\nIndex Metabolic Syndrome (Using A Score Cutoff Of ~58.67)\n\np-value2,3\n\n\nNO\nN = 751\nYES\nN = 771\n\n\n\n\n2_Hydroxyisovalericacid\n152\n3,185 (2,455, 5,608)\n3,016 (2,399, 4,103)\n0.413\n\n\n2_Hydroxyisovalericacid_Detected\n152\n\n\n\n\n0.883\n\n\n    No\n\n\n12 (16%)\n13 (17%)\n\n\n\n\n    Yes\n\n\n63 (84%)\n64 (83%)\n\n\n\n\n3_Methylhistidine\n152\n348,620 (197,629, 806,731)\n302,983 (186,644, 603,264)\n0.603\n\n\n3_Methylhistidine_Detected\n152\n\n\n\n\n0.096\n\n\n    No\n\n\n7 (9.3%)\n2 (2.6%)\n\n\n\n\n    Yes\n\n\n68 (91%)\n75 (97%)\n\n\n\n\nAcetylcarnitine\n152\n2,204,225 (986,349, 4,752,079)\n2,019,176 (1,067,740, 3,042,715)\n0.221\n\n\nAdenine\n152\n26,812 (19,776, 49,079)\n22,824 (16,797, 31,158)\n0.051\n\n\nAdenine_Detected\n152\n\n\n\n\n0.260\n\n\n    No\n\n\n42 (56%)\n50 (65%)\n\n\n\n\n    Yes\n\n\n33 (44%)\n27 (35%)\n\n\n\n\nAlanine\n152\n37,730 (21,290, 88,226)\n37,226 (23,986, 54,962)\n0.802\n\n\nAlanine_Detected\n152\n\n\n\n\n\n\n\n\n    Yes\n\n\n75 (100%)\n77 (100%)\n\n\n\n\nAllantoin\n152\n10,206 (6,164, 16,144)\n7,824 (4,728, 13,724)\n0.115\n\n\nAscorbic_Acid\n152\n1,681 (1,170, 2,260)\n1,659 (1,456, 2,105)\n0.645\n\n\nAscorbic_Acid_Detected\n152\n\n\n\n\n\n\n\n\n    Yes\n\n\n75 (100%)\n77 (100%)\n\n\n\n\nAsparagine\n152\n6,143 (4,686, 22,452)\n5,498 (3,823, 8,695)\n0.059\n\n\nBenzoic_Acid\n152\n1,033 (466, 1,971)\n1,037 (529, 1,830)\n0.710\n\n\nBenzoic_Acid_Detected\n152\n\n\n\n\n0.335\n\n\n    No\n\n\n37 (49%)\n44 (57%)\n\n\n\n\n    Yes\n\n\n38 (51%)\n33 (43%)\n\n\n\n\nBetaine\n152\n1,084,335 (749,304, 2,106,365)\n995,191 (695,102, 1,849,974)\n0.771\n\n\nCaffeine\n152\n19,918 (7,070, 51,437)\n29,444 (11,627, 45,840)\n0.505\n\n\nCaffeine_Detected\n152\n\n\n\n\n\n\n\n\n    Yes\n\n\n75 (100%)\n77 (100%)\n\n\n\n\nCholine\n152\n233,933 (143,675, 380,375)\n223,304 (148,047, 327,457)\n0.672\n\n\nCotinine\n152\n57,760 (3,080, 311,788)\n83,105 (805, 278,217)\n0.514\n\n\nCotinine_Detected\n152\n\n\n\n\n0.197\n\n\n    No\n\n\n35 (47%)\n28 (36%)\n\n\n\n\n    Yes\n\n\n40 (53%)\n49 (64%)\n\n\n\n\nCreatine\n152\n562,595 (327,032, 1,404,337)\n471,766 (275,121, 1,515,620)\n0.828\n\n\nCreatinine\n152\n46,890,019 (38,750,408, 64,798,358)\n48,216,574 (42,130,912, 55,874,614)\n0.880\n\n\nCytosine\n152\n22,015 (12,702, 45,733)\n15,288 (11,561, 30,337)\n0.070\n\n\nCytosine_Detected\n152\n\n\n\n\n0.485\n\n\n    No\n\n\n16 (21%)\n13 (17%)\n\n\n\n\n    Yes\n\n\n59 (79%)\n64 (83%)\n\n\n\n\nDimethylamine\n152\n35,887 (27,306, 58,679)\n36,599 (30,851, 44,130)\n0.950\n\n\nGlutamic_Acid\n152\n651 (521, 1,516)\n637 (487, 883)\n0.258\n\n\nGlutamic_Acid_Detected\n152\n\n\n\n\n0.143\n\n\n    No\n\n\n32 (43%)\n42 (55%)\n\n\n\n\n    Yes\n\n\n43 (57%)\n35 (45%)\n\n\n\n\nGlutamine\n152\n218,368 (165,371, 383,342)\n195,728 (141,605, 295,039)\n0.078\n\n\nGuanine\n152\n1,626 (912, 2,972)\n1,741 (981, 2,849)\n0.854\n\n\nGuanine_Detected\n152\n\n\n\n\n0.164\n\n\n    No\n\n\n6 (8.0%)\n2 (2.6%)\n\n\n\n\n    Yes\n\n\n69 (92%)\n75 (97%)\n\n\n\n\nHippuric_Acid\n152\n95,381 (45,723, 150,073)\n70,156 (35,912, 118,589)\n0.032*\n\n\nHistamine\n152\n3,539 (2,178, 8,294)\n2,667 (1,950, 4,754)\n0.022*\n\n\nHistamine_Detected\n152\n\n\n\n\n0.676\n\n\n    No\n\n\n22 (29%)\n25 (32%)\n\n\n\n\n    Yes\n\n\n53 (71%)\n52 (68%)\n\n\n\n\nHypotaurine\n152\n248 (186, 618)\n235 (192, 318)\n0.553\n\n\nHypotaurine_Detected\n152\n\n\n\n\n0.646\n\n\n    No\n\n\n50 (67%)\n54 (70%)\n\n\n\n\n    Yes\n\n\n25 (33%)\n23 (30%)\n\n\n\n\nHypoxanthine\n152\n84,144 (57,252, 129,257)\n86,775 (57,836, 123,000)\n0.560\n\n\nHypoxanthine_Detected\n152\n\n\n\n\n\n\n\n\n    Yes\n\n\n75 (100%)\n77 (100%)\n\n\n\n\nIndole_3_Lactic_Acid\n152\n2,695 (2,011, 3,676)\n2,732 (2,233, 3,262)\n0.909\n\n\nInosine\n152\n1,363 (751, 2,847)\n1,190 (710, 2,085)\n0.197\n\n\nInosine_Detected\n152\n\n\n\n\n0.679\n\n\n    No\n\n\n3 (4.0%)\n2 (2.6%)\n\n\n\n\n    Yes\n\n\n72 (96%)\n75 (97%)\n\n\n\n\nKynurenate\n152\n20,024 (12,965, 30,800)\n15,983 (11,157, 24,714)\n0.134\n\n\nLactose\n152\n1,938 (1,168, 6,823)\n1,497 (899, 4,382)\n0.055\n\n\nLysine\n152\n20,792 (11,267, 71,657)\n15,306 (9,869, 36,877)\n0.063\n\n\nLysine_Detected\n152\n\n\n\n\n0.022*\n\n\n    No\n\n\n17 (23%)\n7 (9.1%)\n\n\n\n\n    Yes\n\n\n58 (77%)\n70 (91%)\n\n\n\n\nMannitol\n152\n1,640 (645, 3,638)\n1,400 (837, 3,390)\n0.962\n\n\nMannitol_Detected\n152\n\n\n\n\n0.611\n\n\n    No\n\n\n6 (8.0%)\n8 (10%)\n\n\n\n\n    Yes\n\n\n69 (92%)\n69 (90%)\n\n\n\n\nMethylamine\n152\n6,225 (4,364, 9,510)\n6,885 (4,534, 8,616)\n0.900\n\n\nMethylamine_Detected\n152\n\n\n\n\n0.493\n\n\n    No\n\n\n1 (1.3%)\n0 (0%)\n\n\n\n\n    Yes\n\n\n74 (99%)\n77 (100%)\n\n\n\n\nMonoisoamylamine\n152\n17,860 (11,138, 28,966)\n14,713 (11,073, 22,660)\n0.227\n\n\nMonoisoamylamine_Detected\n152\n\n\n\n\n&gt;0.999\n\n\n    No\n\n\n3 (4.0%)\n4 (5.2%)\n\n\n\n\n    Yes\n\n\n72 (96%)\n73 (95%)\n\n\n\n\nNicotinamide\n152\n1,824 (1,206, 2,467)\n1,984 (1,489, 2,621)\n0.073\n\n\nNicotinamide_Detected\n152\n\n\n\n\n0.242\n\n\n    No\n\n\n2 (2.7%)\n0 (0%)\n\n\n\n\n    Yes\n\n\n73 (97%)\n77 (100%)\n\n\n\n\nPantothenate\n152\n11,335 (6,093, 27,118)\n7,450 (3,593, 16,475)\n0.036*\n\n\nPhenylalanine\n152\n48,848 (24,249, 86,924)\n44,872 (32,768, 75,309)\n0.924\n\n\nPyridoxine\n152\n42,271 (25,182, 84,688)\n31,014 (24,349, 63,323)\n0.166\n\n\nPyridoxine_Detected\n152\n\n\n\n\n0.102\n\n\n    No\n\n\n42 (56%)\n53 (69%)\n\n\n\n\n    Yes\n\n\n33 (44%)\n24 (31%)\n\n\n\n\nPyroglutamic\n152\n36,467 (22,572, 111,137)\n35,772 (20,881, 51,279)\n0.227\n\n\nPyroglutamic_Detected\n152\n\n\n\n\n&gt;0.999\n\n\n    No\n\n\n4 (5.3%)\n5 (6.5%)\n\n\n\n\n    Yes\n\n\n71 (95%)\n72 (94%)\n\n\n\n\nRivoflavine\n152\n2,300 (809, 5,971)\n1,339 (693, 3,181)\n0.128\n\n\nRivoflavine_Detected\n152\n\n\n\n\n0.933\n\n\n    No\n\n\n16 (21%)\n16 (21%)\n\n\n\n\n    Yes\n\n\n59 (79%)\n61 (79%)\n\n\n\n\nSerine\n152\n22,481 (16,681, 75,333)\n20,308 (15,709, 28,845)\n0.180\n\n\nSorbitol\n152\n728 (424, 1,258)\n669 (428, 1,297)\n0.894\n\n\nSorbitol_Detected\n152\n\n\n\n\n\n\n\n\n    Yes\n\n\n75 (100%)\n77 (100%)\n\n\n\n\nSucrose\n152\n301 (170, 478)\n188 (136, 375)\n0.033*\n\n\nSucrose_Detected\n152\n\n\n\n\n0.741\n\n\n    No\n\n\n35 (47%)\n38 (49%)\n\n\n\n\n    Yes\n\n\n40 (53%)\n39 (51%)\n\n\n\n\nTaurine\n152\n8,683 (4,348, 15,166)\n8,361 (4,961, 18,043)\n0.575\n\n\nTaurine_Detected\n152\n\n\n\n\n0.324\n\n\n    No\n\n\n6 (8.0%)\n3 (3.9%)\n\n\n\n\n    Yes\n\n\n69 (92%)\n74 (96%)\n\n\n\n\nTheobromine\n152\n56,260 (31,562, 97,440)\n44,495 (27,195, 83,002)\n0.399\n\n\nThiamine\n152\n29,981 (17,516, 69,874)\n23,791 (15,054, 53,231)\n0.176\n\n\nThiamine_Detected\n152\n\n\n\n\n&gt;0.999\n\n\n    No\n\n\n1 (1.3%)\n2 (2.6%)\n\n\n\n\n    Yes\n\n\n74 (99%)\n75 (97%)\n\n\n\n\nThreonine\n152\n18,376 (12,710, 47,559)\n17,283 (12,037, 28,124)\n0.413\n\n\nThreonine_Detected\n152\n\n\n\n\n\n\n\n\n    Yes\n\n\n75 (100%)\n77 (100%)\n\n\n\n\nTrimethylamine\n152\n6,796 (5,631, 13,068)\n7,063 (4,811, 10,299)\n0.295\n\n\nTrimethylamine_Detected\n152\n\n\n\n\n0.094\n\n\n    No\n\n\n29 (39%)\n20 (26%)\n\n\n\n\n    Yes\n\n\n46 (61%)\n57 (74%)\n\n\n\n\nTrimethylamine_N_Oxide\n152\n1,773,778 (1,192,615, 2,890,172)\n1,514,715 (1,090,219, 2,587,975)\n0.718\n\n\nTryptamine\n152\n39,928 (24,601, 61,038)\n38,902 (24,217, 62,809)\n0.611\n\n\nTryptamine_Detected\n152\n\n\n\n\n\n\n\n\n    Yes\n\n\n75 (100%)\n77 (100%)\n\n\n\n\nTryptophan\n152\n18,310 (8,787, 32,368)\n16,906 (12,142, 30,463)\n0.930\n\n\nTyrosine\n152\n5,716 (3,099, 13,048)\n6,329 (4,596, 9,649)\n0.320\n\n\nTyrosine_Detected\n152\n\n\n\n\n0.744\n\n\n    No\n\n\n5 (6.7%)\n4 (5.2%)\n\n\n\n\n    Yes\n\n\n70 (93%)\n73 (95%)\n\n\n\n\nUracil\n152\n3,050 (2,121, 4,689)\n2,803 (2,082, 3,571)\n0.129\n\n\nUracil_Detected\n152\n\n\n\n\n\n\n\n\n    Yes\n\n\n75 (100%)\n77 (100%)\n\n\n\n\nUric_Acid\n152\n1,424 (548, 3,491)\n1,376 (968, 2,078)\n0.642\n\n\nUric_Acid_Detected\n152\n\n\n\n\n0.337\n\n\n    No\n\n\n14 (19%)\n10 (13%)\n\n\n\n\n    Yes\n\n\n61 (81%)\n67 (87%)\n\n\n\n\nValine\n152\n28,561 (18,677, 55,543)\n29,328 (20,031, 40,656)\n0.748\n\n\nValine_Detected\n152\n\n\n\n\n0.057\n\n\n    No\n\n\n4 (5.3%)\n0 (0%)\n\n\n\n\n    Yes\n\n\n71 (95%)\n77 (100%)\n\n\n\n\nXanthine\n152\n14,320 (10,020, 20,161)\n13,944 (9,222, 17,723)\n0.371\n\n\nXanthine_Detected\n152\n\n\n\n\n\n\n\n\n    Yes\n\n\n75 (100%)\n77 (100%)\n\n\n\n\nA_Ketoglutaric_Acid\n152\n906 (639, 2,006)\n768 (507, 1,183)\n0.073\n\n\nA_Ketoglutaric_Acid_Detected\n152\n\n\n\n\n0.118\n\n\n    No\n\n\n3 (4.0%)\n0 (0%)\n\n\n\n\n    Yes\n\n\n72 (96%)\n77 (100%)\n\n\n\n\nG_Aminobutyric\n152\n430 (319, 793)\n394 (312, 613)\n0.336\n\n\nG_Aminobutyric_Detected\n152\n\n\n\n\n0.422\n\n\n    No\n\n\n37 (49%)\n43 (56%)\n\n\n\n\n    Yes\n\n\n38 (51%)\n34 (44%)\n\n\n\n\nLeucine_Isoleucine_Ratio\n152\n34,037 (22,022, 63,119)\n33,026 (24,933, 48,315)\n0.721\n\n\nLeucine_Isoleucine_Ratio_Detected\n152\n\n\n\n\n&gt;0.999\n\n\n    No\n\n\n2 (2.7%)\n2 (2.6%)\n\n\n\n\n    Yes\n\n\n73 (97%)\n75 (97%)\n\n\n\n\n\nUnits are in peak area. P-values are unadjusted.\n\n\n1 Median (Q1, Q3); n (%)\n\n\n2 Wilcoxon rank sum test; Pearson’s Chi-squared test; Fisher’s exact test; NA\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001\n\n\n\n\n\n\n\n\n\n\nTyrosine–Tryptophan Pathway\n\n\n\n\n\n\nTyrosine–Tryptophan Pathway Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\nTyrosine–Tryptophan Pathway Variable\nN\n\nIDF Metabolic Syndrome\n\np-value2,3\n\n\nNO\nN = 1201\nYES\nN = 331\n\n\n\n\n5HIAA\n150\n1.27 (0.97, 1.63)\n1.18 (0.99, 1.52)\n0.569\n\n\n    Missing\n\n\n3\n0\n\n\n\n\n5HIAA_Detected\n150\n\n\n\n\n&gt;0.999\n\n\n    No\n\n\n3 (2.6%)\n0 (0%)\n\n\n\n\n    Yes\n\n\n114 (97%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n3\n0\n\n\n\n\n5HIAA_Sulfate\n150\n0.08 (0.05, 0.12)\n0.09 (0.04, 0.14)\n0.742\n\n\n    Missing\n\n\n3\n0\n\n\n\n\n5HIAA_Sulfate_Detected\n150\n\n\n\n\n&gt;0.999\n\n\n    No\n\n\n3 (2.6%)\n0 (0%)\n\n\n\n\n    Yes\n\n\n114 (97%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nDopamine\n150\n0.07 (0.05, 0.09)\n0.06 (0.04, 0.10)\n0.926\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nDopamine_Detected\n150\n\n\n\n\n0.118\n\n\n    No\n\n\n10 (8.5%)\n0 (0%)\n\n\n\n\n    Yes\n\n\n107 (91%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nHippuric_Acid\n150\n469 (283, 903)\n331 (214, 634)\n0.013*\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nHippuric_Acid_Detected\n150\n\n\n\n\n0.576\n\n\n    No\n\n\n4 (3.4%)\n0 (0%)\n\n\n\n\n    Yes\n\n\n113 (97%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nHomovanilic_Acid\n150\n1.35 (0.95, 1.89)\n1.22 (0.83, 1.53)\n0.169\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nHomovanilic_Acid_Detected\n150\n\n\n\n\n0.586\n\n\n    No\n\n\n5 (4.3%)\n0 (0%)\n\n\n\n\n    Yes\n\n\n112 (96%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nIndole\n150\n0.87 (0.63, 1.45)\n0.89 (0.65, 1.27)\n&gt;0.999\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nIndole_Detected\n150\n\n\n\n\n&gt;0.999\n\n\n    No\n\n\n12 (10%)\n3 (9.1%)\n\n\n\n\n    Yes\n\n\n105 (90%)\n30 (91%)\n\n\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nIndole3Acetic_Acid\n150\n0.75 (0.37, 1.60)\n0.94 (0.51, 1.30)\n0.911\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nIndole3Acetic_Acid_Detected\n150\n\n\n\n\n0.253\n\n\n    No\n\n\n52 (44%)\n11 (33%)\n\n\n\n\n    Yes\n\n\n65 (56%)\n22 (67%)\n\n\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nIndole3Lactic_Acid\n150\n0.21 (0.14, 0.34)\n0.14 (0.10, 0.22)\n0.018*\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nIndole3Lactic_Acid_Detected\n150\n\n\n\n\n0.707\n\n\n    No\n\n\n35 (30%)\n11 (33%)\n\n\n\n\n    Yes\n\n\n82 (70%)\n22 (67%)\n\n\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nIndoxyl_Sulfate\n150\n42 (24, 58)\n33 (19, 49)\n0.140\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nIndoxyl_Sulfate_Detected\n150\n\n\n\n\n0.586\n\n\n    No\n\n\n5 (4.3%)\n0 (0%)\n\n\n\n\n    Yes\n\n\n112 (96%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nKynurenic_Acid\n150\n1.30 (0.69, 2.13)\n1.36 (0.88, 1.99)\n0.957\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nKynurenic_Acid_Detected\n150\n\n\n\n\n0.665\n\n\n    No\n\n\n31 (26%)\n10 (30%)\n\n\n\n\n    Yes\n\n\n86 (74%)\n23 (70%)\n\n\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nKynurenine\n150\n0.24 (0.15, 0.48)\n0.35 (0.22, 0.49)\n0.085\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nKynurenine_Detected\n150\n\n\n\n\n&gt;0.999\n\n\n    No\n\n\n3 (2.6%)\n0 (0%)\n\n\n\n\n    Yes\n\n\n114 (97%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nP_Coumaric_Acid\n150\n0.06 (0.04, 0.10)\n0.06 (0.03, 0.08)\n0.798\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nP_Coumaric_Acid_Detected\n150\n\n\n\n\n0.484\n\n\n    No\n\n\n9 (7.7%)\n4 (12%)\n\n\n\n\n    Yes\n\n\n108 (92%)\n29 (88%)\n\n\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nP_Coumaric_Acid_Sulfate\n150\n0.04 (0.02, 0.10)\n0.03 (0.02, 0.05)\n0.202\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nP_Coumaric_Acid_Sulfate_Detected\n150\n\n\n\n\n0.466\n\n\n    No\n\n\n11 (9.4%)\n1 (3.0%)\n\n\n\n\n    Yes\n\n\n106 (91%)\n32 (97%)\n\n\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nP_Cresol_Sulfate\n150\n100 (51, 147)\n74 (33, 142)\n0.209\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nP_Cresol_Sulfate_Detected\n150\n\n\n\n\n0.118\n\n\n    No\n\n\n10 (8.5%)\n0 (0%)\n\n\n\n\n    Yes\n\n\n107 (91%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nP_Ethylphenol_Sulfate\n150\n33 (18, 65)\n20 (10, 38)\n0.005**\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nP_Ethylphenol_Sulfate_Detected\n150\n\n\n\n\n0.576\n\n\n    No\n\n\n4 (3.4%)\n0 (0%)\n\n\n\n\n    Yes\n\n\n113 (97%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nP_HBA\n150\n326 (212, 465)\n327 (276, 468)\n0.775\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nP_HBA_Detected\n150\n\n\n\n\n&gt;0.999\n\n\n    No\n\n\n4 (3.4%)\n1 (3.0%)\n\n\n\n\n    Yes\n\n\n113 (97%)\n32 (97%)\n\n\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nP_HBA_Sulfate\n150\n3,264 (1,586, 5,871)\n3,126 (2,036, 5,890)\n0.928\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nP_HBA_Sulfate_Detected\n150\n\n\n\n\n0.372\n\n\n    No\n\n\n34 (29%)\n7 (21%)\n\n\n\n\n    Yes\n\n\n83 (71%)\n26 (79%)\n\n\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nP_Hydroxyphenyl_Acetic_Acid\n150\n10 (7, 15)\n10 (6, 13)\n0.611\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nP_Hydroxyphenyl_Acetic_Acid_Detected\n150\n\n\n\n\n&gt;0.999\n\n\n    No\n\n\n3 (2.6%)\n0 (0%)\n\n\n\n\n    Yes\n\n\n114 (97%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nP_Hydroxyphenyl_Acetic_Acid_Sulfate\n150\n0.43 (0.24, 0.63)\n0.41 (0.23, 0.81)\n0.899\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nP_Hydroxyphenyl_Acetic_Acid_Sulfate_Detected\n150\n\n\n\n\n0.108\n\n\n    No\n\n\n15 (13%)\n8 (24%)\n\n\n\n\n    Yes\n\n\n102 (87%)\n25 (76%)\n\n\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nP_Hydroxyphenyllactic_Acid\n150\n0.04 (0.03, 0.06)\n0.03 (0.02, 0.05)\n0.067\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nP_Hydroxyphenyllactic_Acid_Detected\n150\n\n\n\n\n0.046*\n\n\n    No\n\n\n20 (17%)\n1 (3.0%)\n\n\n\n\n    Yes\n\n\n97 (83%)\n32 (97%)\n\n\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nP_Hydroxyphenyllactic_Acid_Sulfate\n150\n1.66 (1.30, 2.13)\n1.30 (1.13, 1.78)\n0.030*\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nP_Hydroxyphenyllactic_Acid_Sulfate_Detected\n150\n\n\n\n\n&gt;0.999\n\n\n    No\n\n\n3 (2.6%)\n0 (0%)\n\n\n\n\n    Yes\n\n\n114 (97%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nP_Hydroxyphenylpropionic_Acid\n150\n0.19 (0.13, 0.30)\n0.15 (0.14, 0.24)\n0.145\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nP_Hydroxyphenylpropionic_Acid_Detected\n150\n\n\n\n\n0.557\n\n\n    No\n\n\n50 (43%)\n16 (48%)\n\n\n\n\n    Yes\n\n\n67 (57%)\n17 (52%)\n\n\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nP_Hydroxyphenylpropionic_Acid_Sulfate\n150\n0.005 (0.003, 0.009)\n0.006 (0.003, 0.009)\n0.616\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nP_Hydroxyphenylpropionic_Acid_Sulfate_Detected\n150\n\n\n\n\n0.734\n\n\n    No\n\n\n11 (9.4%)\n2 (6.1%)\n\n\n\n\n    Yes\n\n\n106 (91%)\n31 (94%)\n\n\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nPhenol_Sulfate\n150\n6 (3, 12)\n6 (3, 13)\n0.683\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nPhenol_Sulfate_Detected\n150\n\n\n\n\n0.339\n\n\n    No\n\n\n6 (5.1%)\n0 (0%)\n\n\n\n\n    Yes\n\n\n111 (95%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nPhenylalanine\n150\n4.00 (2.75, 6.05)\n4.38 (2.99, 6.43)\n0.381\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nPhenylalanine_Detected\n150\n\n\n\n\n0.348\n\n\n    No\n\n\n7 (6.0%)\n0 (0%)\n\n\n\n\n    Yes\n\n\n110 (94%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nTryptophan\n150\n3.44 (2.33, 4.71)\n3.63 (2.76, 5.03)\n0.240\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nTryptophan_Detected\n150\n\n\n\n\n&gt;0.999\n\n\n    No\n\n\n3 (2.6%)\n0 (0%)\n\n\n\n\n    Yes\n\n\n114 (97%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nTyramine\n150\n0.29 (0.21, 0.37)\n0.30 (0.24, 0.33)\n0.917\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nTyramine_Detected\n150\n\n\n\n\n&gt;0.999\n\n\n    No\n\n\n3 (2.6%)\n0 (0%)\n\n\n\n\n    Yes\n\n\n114 (97%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nTyrosine\n150\n28 (20, 44)\n32 (25, 47)\n0.098\n\n\n    Missing\n\n\n3\n0\n\n\n\n\nTyrosine_Detected\n150\n\n\n\n\n&gt;0.999\n\n\n    No\n\n\n3 (2.6%)\n0 (0%)\n\n\n\n\n    Yes\n\n\n114 (97%)\n33 (100%)\n\n\n\n\n    Missing\n\n\n3\n0\n\n\n\n\n\nUnits are in μg/mmol of creatinine. P-values are unadjusted.\n\n\n1 Median (Q1, Q3); n (%)\n\n\n2 Wilcoxon rank sum test; Fisher’s exact test; Pearson’s Chi-squared test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nTyrosine–Tryptophan Pathway Variables (Timepoint 1)\n\n\n\n\n\n\n\n\n\nTyrosine–Tryptophan Pathway Variable\nN\n\nIndex Metabolic Syndrome (Using A Score Cutoff Of ~58.67)\n\np-value2,3\n\n\nNO\nN = 741\nYES\nN = 761\n\n\n\n\n5HIAA\n150\n1.32 (1.05, 1.82)\n1.19 (0.95, 1.55)\n0.093\n\n\n5HIAA_Detected\n150\n\n\n\n\n0.617\n\n\n    No\n\n\n2 (2.7%)\n1 (1.3%)\n\n\n\n\n    Yes\n\n\n72 (97%)\n75 (99%)\n\n\n\n\n5HIAA_Sulfate\n150\n0.08 (0.05, 0.12)\n0.08 (0.04, 0.12)\n0.321\n\n\n5HIAA_Sulfate_Detected\n150\n\n\n\n\n0.617\n\n\n    No\n\n\n2 (2.7%)\n1 (1.3%)\n\n\n\n\n    Yes\n\n\n72 (97%)\n75 (99%)\n\n\n\n\nDopamine\n150\n0.07 (0.05, 0.09)\n0.06 (0.04, 0.09)\n0.162\n\n\nDopamine_Detected\n150\n\n\n\n\n0.206\n\n\n    No\n\n\n7 (9.5%)\n3 (3.9%)\n\n\n\n\n    Yes\n\n\n67 (91%)\n73 (96%)\n\n\n\n\nHippuric_Acid\n150\n548 (296, 950)\n414 (226, 691)\n0.023*\n\n\nHippuric_Acid_Detected\n150\n\n\n\n\n&gt;0.999\n\n\n    No\n\n\n2 (2.7%)\n2 (2.6%)\n\n\n\n\n    Yes\n\n\n72 (97%)\n74 (97%)\n\n\n\n\nHomovanilic_Acid\n150\n1.33 (0.93, 1.92)\n1.25 (0.89, 1.63)\n0.378\n\n\nHomovanilic_Acid_Detected\n150\n\n\n\n\n0.679\n\n\n    No\n\n\n3 (4.1%)\n2 (2.6%)\n\n\n\n\n    Yes\n\n\n71 (96%)\n74 (97%)\n\n\n\n\nIndole\n150\n0.98 (0.67, 1.50)\n0.76 (0.61, 1.34)\n0.259\n\n\nIndole_Detected\n150\n\n\n\n\n0.157\n\n\n    No\n\n\n10 (14%)\n5 (6.6%)\n\n\n\n\n    Yes\n\n\n64 (86%)\n71 (93%)\n\n\n\n\nIndole3Acetic_Acid\n150\n0.75 (0.39, 1.67)\n0.82 (0.40, 1.31)\n0.597\n\n\nIndole3Acetic_Acid_Detected\n150\n\n\n\n\n0.979\n\n\n    No\n\n\n31 (42%)\n32 (42%)\n\n\n\n\n    Yes\n\n\n43 (58%)\n44 (58%)\n\n\n\n\nIndole3Lactic_Acid\n150\n0.25 (0.16, 0.38)\n0.16 (0.11, 0.23)\n&lt;0.001***\n\n\nIndole3Lactic_Acid_Detected\n150\n\n\n\n\n0.549\n\n\n    No\n\n\n21 (28%)\n25 (33%)\n\n\n\n\n    Yes\n\n\n53 (72%)\n51 (67%)\n\n\n\n\nIndoxyl_Sulfate\n150\n43 (24, 56)\n37 (21, 58)\n0.490\n\n\nIndoxyl_Sulfate_Detected\n150\n\n\n\n\n&gt;0.999\n\n\n    No\n\n\n2 (2.7%)\n3 (3.9%)\n\n\n\n\n    Yes\n\n\n72 (97%)\n73 (96%)\n\n\n\n\nKynurenic_Acid\n150\n1.51 (0.98, 2.13)\n1.23 (0.67, 2.03)\n0.145\n\n\nKynurenic_Acid_Detected\n150\n\n\n\n\n0.777\n\n\n    No\n\n\n21 (28%)\n20 (26%)\n\n\n\n\n    Yes\n\n\n53 (72%)\n56 (74%)\n\n\n\n\nKynurenine\n150\n0.24 (0.16, 0.40)\n0.34 (0.16, 0.55)\n0.230\n\n\nKynurenine_Detected\n150\n\n\n\n\n0.617\n\n\n    No\n\n\n2 (2.7%)\n1 (1.3%)\n\n\n\n\n    Yes\n\n\n72 (97%)\n75 (99%)\n\n\n\n\nP_Coumaric_Acid\n150\n0.07 (0.04, 0.12)\n0.05 (0.03, 0.08)\n0.021*\n\n\nP_Coumaric_Acid_Detected\n150\n\n\n\n\n0.810\n\n\n    No\n\n\n6 (8.1%)\n7 (9.2%)\n\n\n\n\n    Yes\n\n\n68 (92%)\n69 (91%)\n\n\n\n\nP_Coumaric_Acid_Sulfate\n150\n0.06 (0.03, 0.11)\n0.03 (0.02, 0.05)\n0.002**\n\n\nP_Coumaric_Acid_Sulfate_Detected\n150\n\n\n\n\n0.516\n\n\n    No\n\n\n7 (9.5%)\n5 (6.6%)\n\n\n\n\n    Yes\n\n\n67 (91%)\n71 (93%)\n\n\n\n\nP_Cresol_Sulfate\n150\n100 (49, 149)\n89 (45, 146)\n0.624\n\n\nP_Cresol_Sulfate_Detected\n150\n\n\n\n\n0.530\n\n\n    No\n\n\n6 (8.1%)\n4 (5.3%)\n\n\n\n\n    Yes\n\n\n68 (92%)\n72 (95%)\n\n\n\n\nP_Ethylphenol_Sulfate\n150\n35 (22, 84)\n22 (13, 43)\n0.002**\n\n\nP_Ethylphenol_Sulfate_Detected\n150\n\n\n\n\n&gt;0.999\n\n\n    No\n\n\n2 (2.7%)\n2 (2.6%)\n\n\n\n\n    Yes\n\n\n72 (97%)\n74 (97%)\n\n\n\n\nP_HBA\n150\n338 (223, 490)\n314 (203, 448)\n0.287\n\n\nP_HBA_Detected\n150\n\n\n\n\n0.679\n\n\n    No\n\n\n3 (4.1%)\n2 (2.6%)\n\n\n\n\n    Yes\n\n\n71 (96%)\n74 (97%)\n\n\n\n\nP_HBA_Sulfate\n150\n3,353 (1,967, 5,822)\n2,890 (1,303, 6,187)\n0.316\n\n\nP_HBA_Sulfate_Detected\n150\n\n\n\n\n0.516\n\n\n    No\n\n\n22 (30%)\n19 (25%)\n\n\n\n\n    Yes\n\n\n52 (70%)\n57 (75%)\n\n\n\n\nP_Hydroxyphenyl_Acetic_Acid\n150\n11 (7, 16)\n9 (6, 13)\n0.079\n\n\nP_Hydroxyphenyl_Acetic_Acid_Detected\n150\n\n\n\n\n0.617\n\n\n    No\n\n\n2 (2.7%)\n1 (1.3%)\n\n\n\n\n    Yes\n\n\n72 (97%)\n75 (99%)\n\n\n\n\nP_Hydroxyphenyl_Acetic_Acid_Sulfate\n150\n0.42 (0.23, 0.62)\n0.45 (0.23, 0.79)\n0.603\n\n\nP_Hydroxyphenyl_Acetic_Acid_Sulfate_Detected\n150\n\n\n\n\n0.129\n\n\n    No\n\n\n8 (11%)\n15 (20%)\n\n\n\n\n    Yes\n\n\n66 (89%)\n61 (80%)\n\n\n\n\nP_Hydroxyphenyllactic_Acid\n150\n0.05 (0.03, 0.07)\n0.03 (0.02, 0.05)\n&lt;0.001***\n\n\nP_Hydroxyphenyllactic_Acid_Detected\n150\n\n\n\n\n0.440\n\n\n    No\n\n\n12 (16%)\n9 (12%)\n\n\n\n\n    Yes\n\n\n62 (84%)\n67 (88%)\n\n\n\n\nP_Hydroxyphenyllactic_Acid_Sulfate\n150\n1.76 (1.30, 2.17)\n1.51 (1.17, 1.88)\n0.054\n\n\nP_Hydroxyphenyllactic_Acid_Sulfate_Detected\n150\n\n\n\n\n0.617\n\n\n    No\n\n\n2 (2.7%)\n1 (1.3%)\n\n\n\n\n    Yes\n\n\n72 (97%)\n75 (99%)\n\n\n\n\nP_Hydroxyphenylpropionic_Acid\n150\n0.24 (0.13, 0.36)\n0.16 (0.12, 0.25)\n0.012*\n\n\nP_Hydroxyphenylpropionic_Acid_Detected\n150\n\n\n\n\n0.134\n\n\n    No\n\n\n28 (38%)\n38 (50%)\n\n\n\n\n    Yes\n\n\n46 (62%)\n38 (50%)\n\n\n\n\nP_Hydroxyphenylpropionic_Acid_Sulfate\n150\n0.006 (0.003, 0.009)\n0.005 (0.002, 0.008)\n0.298\n\n\nP_Hydroxyphenylpropionic_Acid_Sulfate_Detected\n150\n\n\n\n\n0.810\n\n\n    No\n\n\n6 (8.1%)\n7 (9.2%)\n\n\n\n\n    Yes\n\n\n68 (92%)\n69 (91%)\n\n\n\n\nPhenol_Sulfate\n150\n8 (4, 13)\n4 (3, 10)\n0.023*\n\n\nPhenol_Sulfate_Detected\n150\n\n\n\n\n0.439\n\n\n    No\n\n\n4 (5.4%)\n2 (2.6%)\n\n\n\n\n    Yes\n\n\n70 (95%)\n74 (97%)\n\n\n\n\nPhenylalanine\n150\n3.84 (2.74, 5.94)\n4.30 (2.95, 6.38)\n0.302\n\n\nPhenylalanine_Detected\n150\n\n\n\n\n0.273\n\n\n    No\n\n\n5 (6.8%)\n2 (2.6%)\n\n\n\n\n    Yes\n\n\n69 (93%)\n74 (97%)\n\n\n\n\nTryptophan\n150\n3.15 (2.38, 4.40)\n3.55 (2.51, 5.07)\n0.263\n\n\nTryptophan_Detected\n150\n\n\n\n\n0.617\n\n\n    No\n\n\n2 (2.7%)\n1 (1.3%)\n\n\n\n\n    Yes\n\n\n72 (97%)\n75 (99%)\n\n\n\n\nTyramine\n150\n0.28 (0.21, 0.38)\n0.30 (0.22, 0.35)\n0.725\n\n\nTyramine_Detected\n150\n\n\n\n\n0.617\n\n\n    No\n\n\n2 (2.7%)\n1 (1.3%)\n\n\n\n\n    Yes\n\n\n72 (97%)\n75 (99%)\n\n\n\n\nTyrosine\n150\n27 (19, 43)\n31 (22, 47)\n0.076\n\n\nTyrosine_Detected\n150\n\n\n\n\n0.617\n\n\n    No\n\n\n2 (2.7%)\n1 (1.3%)\n\n\n\n\n    Yes\n\n\n72 (97%)\n75 (99%)\n\n\n\n\n\nUnits are in μg/mmol of creatinine. P-values are unadjusted.\n\n\n1 Median (Q1, Q3); n (%)\n\n\n2 Wilcoxon rank sum test; Fisher’s exact test; Pearson’s Chi-squared test\n\n\n3 p&lt;0.05; p&lt;0.01; p&lt;0.001",
    "crumbs": [
      "Sections",
      "Data Processing & EDA"
    ]
  },
  {
    "objectID": "modeling2.html#forest-plot-explanation",
    "href": "modeling2.html#forest-plot-explanation",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "Forest Plot Explanation",
    "text": "Forest Plot Explanation\n\nGoal and Structure\n\nGoal: To determine how the change in a predictor variable’s value affects the odds of having a MetS Index \\(\\ge 58.67\\).\nOdds Ratio (OR): This is the key metric on the X-axis. An OR is a ratio of two odds: the odds of the event occurring at one level of the predictor versus the odds of the event occurring at a reference level.\n\nOR &gt; 1 (Red Bar): The variable increases the odds (risk) of the event.\nOR &lt; 1 (Green Bar): The variable decreases the odds (risk) of the event.\nOR = 1 (Vertical Line): The variable has no association with the odds of the event.\n\n\\(90\\%\\) Confidence Intervals (CI): The horizontal lines extending from the OR box represent the \\(90\\%\\) CI. If this interval does not cross the vertical line at \\(\\text{OR}=1\\), the association is considered statistically significant (at \\(\\alpha = 0.10\\)).\n\n\n\nKey Risk-Increasing Predictors (OR &gt; 1)\nVariables that significantly increase the odds of having a high MetS Index (red bars crossing the \\(\\text{OR}=1\\) line and extending to the right):\n\nHbA1c_Perc (\\(\\text{OR} = 2.01\\)): The strongest predictor, showing that higher long-term blood sugar control dramatically increases the odds of high MetS Index.\nSGPT (\\(\\text{OR} = 1.35\\)): Elevated levels of this liver enzyme (a marker of liver function/NAFLD) significantly increase the odds.\nSkeletal Muscle Mass (\\(\\text{OR} = 1.91\\)) and Glucose (\\(\\text{OR} = 1.43\\)): Consistent with HbA1c, higher levels of these measurements significantly increase the odds.\nwhr (\\(\\text{OR} = 1.33\\)): A higher Waist-to-Hip Ratio, a key measure of central obesity, strongly increases the odds.\nAntihypertensives (\\(\\text{OR} = 1.58\\)): Taking antihypertensive medication significantly increases the odds of a high MetS Index. This is a marker for the underlying condition of hypertension, a major component of Metabolic Syndrome, as illustrated in the box plot where the median MetS Index is higher for the “Yes” group.\nGender (Male) (\\(\\text{OR} = 1.47\\)): Being male significantly increases the odds of a high MetS Index compared to the reference gender (Female).\n\n\n\nKey Protective Predictors (OR &lt; 1)\nVariables that significantly decrease the odds of having a high MetS Index (green bars not crossing the \\(\\text{OR}=1\\) line):\n\nMEDAS_Score (\\(\\text{OR} = 0.86\\)): A higher Mediterranean Diet Adherence Score is associated with lower odds of a high MetS Index, highlighting a protective lifestyle factor.\nTBIL (\\(\\text{OR} = 0.77\\)): Total Bilirubin (TBIL) is associated with a protective effect, as it is a known antioxidant.\nRiboflavine (\\(\\text{OR} = 0.79\\)): Riboflavin (Vitamin B2) is significantly associated with lower odds.\nAnhydroglucitol (\\(\\text{OR} = 0.63\\)): A higher Anhydroglucitol concentration (i.e., less glucose competition in the kidneys) is protective against high MetS risk. Good glycemic control (high Anhydroglucitol) is associated with significantly lower odds of MetS risk.\n\n\n\nAcylcarnitine Interpretation\nAcylcarnitines which are biomarkers often linked to mitochondrial dysfunction in metabolic syndrome (MetS).\nHere is an explanation of their individual effects on the odds of having a high MetS Index (\\(\\text{MetS} \\ge 58.67\\)), based on the model’s OR estimates.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#propionylcarnitine-textor-0.81",
    "href": "modeling2.html#propionylcarnitine-textor-0.81",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "Propionylcarnitine (\\(\\text{OR} = 0.81\\))",
    "text": "Propionylcarnitine (\\(\\text{OR} = 0.81\\))\n\nDirection of Effect (Green Bar): The model shows a significant decrease in risk, as the OR bar is green and its confidence interval does not cross \\(\\text{OR}=1\\).\nInterpretation: An increase in Propionylcarnitine (C3) by its reference unit is associated with a \\(19\\%\\) lower odds (\\(1 - 0.81 = 0.19\\)) of having a MetS Index \\(\\ge 58.67\\).\n\nThis \\(\\text{OR} = 0.81\\) suggests a protective effect for Propionylcarnitine, which is somewhat counter-intuitive because elevated short-chain acylcarnitines are often associated with mitochondrial stress and disease. However, there are a few possible explanations for this protective finding in the multivariable model:\n\nDetoxification Effect: Propionylcarnitine is formed to remove excess Propionyl-CoA, which arises from the breakdown of certain amino acids. In a stressed metabolic state, the ability to generate C3 for detoxification and subsequent excretion might reflect a preserved buffering capacity of the mitochondria, which is protective compared to individuals whose mitochondria are completely unable to cope.\nAnaplerotic Role: Propionyl-L-carnitine can enter the tricarboxylic acid (TCA) cycle via conversion to succinate, which can help replenish energy cycle intermediates, especially during stress or limited fatty acid oxidation, potentially offering a metabolic benefit.\nReverse Causality/Complexity: Because this is a multivariable model, the protective effect of Propionylcarnitine is dependent of other strongly confounding variables like HbA1c and Glucose. Its dependent role might be protective, when its presence is part of a generally stressed system.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#lauroylcarnitine-textor-0.99",
    "href": "modeling2.html#lauroylcarnitine-textor-0.99",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "Lauroylcarnitine (\\(\\text{OR} = 0.99\\))",
    "text": "Lauroylcarnitine (\\(\\text{OR} = 0.99\\))\n\nDirection of Effect (Bar Crossing OR=1): The OR bar for Lauroylcarnitine (C12, a medium-chain acylcarnitine) crosses the vertical \\(\\text{OR}=1\\) line. The confidence interval includes \\(1.0\\), meaning this variable has no statistically significant association with the odds of having a MetS Index \\(\\ge 58.67\\) in this multivariable model.\n\nLauroylcarnitine is an intermediate in mitochondrial fatty acid oxidation (beta-oxidation).\n\nLack of Significance: The result confirms the finding from the variable importance plot, where Lauroylcarnitine had a zero (0) contribution to the explained variation. While its scatter plot showed an inverted U-shaped trend with the MetS Index, that relationship is either too weak or is entirely accounted for by other variables (like HbA1c or whr) in the full model.\nMulticollinearity: It is highly likely that the metabolic stress signaled by Lauroylcarnitine is redundantly captured by other, more potent predictors in the model (e.g., Anhydroglucitol or SGPT), causing its independent contribution to drop to zero/non-significant.\n\nIn essence, while the acylcarnitines are biologically relevant markers of mitochondrial function, only Propionylcarnitine retained a significant (and somewhat protective) association, while Lauroylcarnitine’s effect was non-significant in the final model.\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nEffects Table of clinical parameters on risk for the metabolic syndrome as captured by the MetS index. The further away the central estimate and its corresponding intervals from unity the higher the variable’s effect.\n\n\n\n\nReference\n\n\nOdds Ratio\n\n\n% Change From Unity\n\n\n\nFrom\nTo\nCentral1,2\nLower1,3\nUpper1,3\nCentral1,2\nLower1,3\nUpper1,3\n\n\n\n\nMEDAS_Score\n5\n7\n0.98\n0.82\n1.18\n−2.02\n−19.85\n16.55\n\n\nbcm_t_score\n-0.5\n0.98\n1.08\n0.81\n1.46\n7.70\n−21.07\n37.84\n\n\nwhr\n0.93\n1.04\n1.33\n1.04\n1.68\n28.52\n3.92\n51.88\n\n\nsmm\n25.58\n36.53\n1.91\n1.51\n2.41\n64.71\n41.21\n87.96\n\n\nfatigue_index\n68.05\n102.9\n1.26\n0.89\n1.78\n23.11\n−11.65\n57.66\n\n\nHbA1c_Perc\n5.35\n5.9\n2.01\n1.49\n2.71\n69.81\n39.88\n99.69\n\n\nSGPT\n20.48\n34.15\n1.35\n1.13\n1.60\n30.01\n12.22\n47.00\n\n\nTBIL\n0.41\n0.73\n0.77\n0.63\n0.95\n−26.14\n−46.20\n−5.13\n\n\nAnhydroglucitol\n75.75\n127.03\n0.63\n0.50\n0.81\n−46.20\n−69.31\n−21.07\n\n\nGlucose\n5072.62\n7720.5\n1.43\n1.07\n1.92\n35.77\n6.77\n65.23\n\n\nGlutamine_To_Glutamic_Acid_Ratio\n6.64\n15.84\n0.85\n0.76\n0.95\n−16.25\n−27.44\n−5.13\n\n\nPropionylcarnitine\n0.44\n0.75\n0.81\n0.68\n0.97\n−21.07\n−38.57\n−3.05\n\n\nLauroylcarnitine\n0.03\n0.06\n0.99\n0.85\n1.17\n−1.01\n−16.25\n15.70\n\n\nRivoflavine\n743.81\n5072.79\n0.89\n0.66\n1.19\n−11.65\n−41.55\n17.40\n\n\nUracil\n2102.35\n3932.48\n0.79\n0.61\n1.02\n−23.57\n−49.43\n1.98\n\n\nHIAA\n0.98\n1.63\n0.72\n0.57\n0.90\n−32.85\n−56.21\n−10.54\n\n\nIndole3Lactic_Acid\n0.12\n0.31\n0.70\n0.57\n0.86\n−35.67\n−56.21\n−15.08\n\n\nIndole\n0.64\n1.44\n1.03\n0.82\n1.29\n2.96\n−19.85\n25.46\n\n\nHippuric_Acid\n247.79\n849.21\n0.64\n0.46\n0.89\n−44.63\n−77.65\n−11.65\n\n\nP_Coumaric_Acid_Sulfate\n0.02\n0.09\n0.73\n0.53\n1.02\n−31.47\n−63.49\n1.98\n\n\nDopamine\n0.05\n0.09\n1.02\n0.82\n1.25\n1.98\n−19.85\n22.31\n\n\nKynurenic_Acid\n0.7\n2.1\n0.80\n0.65\n0.97\n−22.31\n−43.08\n−3.05\n\n\nP_Coumaric_Acid\n0.03\n0.1\n1.02\n0.78\n1.34\n1.98\n−24.85\n29.27\n\n\nP_HBA_Sulfate\n1643.94\n5885.58\n1.01\n0.79\n1.30\n1.00\n−23.57\n26.24\n\n\nP_Hydroxyphenyl_Acetic_Acid\n6.66\n14.99\n1.10\n0.83\n1.47\n9.53\n−18.63\n38.53\n\n\ngender\nFemale\nMale\n1.47\n1.22\n1.78\n38.53\n19.89\n57.66\n\n\nAntihypertensives\nNo\nYes\n1.58\n1.25\n1.98\n45.74\n22.31\n68.31\n\n\nAntidepressants\nNo\nYes\n0.72\n0.56\n0.92\n−32.85\n−57.98\n−8.34\n\n\nSite_Collection\nAUTH\nCBG\n1.14\n0.87\n1.50\n13.10\n−13.93\n40.55\n\n\nSite_Collection\nAUTH\nICL\n0.96\n0.75\n1.21\n−4.08\n−28.77\n19.06\n\n\nSite_Collection\nAUTH\nTEAGASC\n0.92\n0.71\n1.19\n−8.34\n−34.25\n17.40\n\n\nSite_Collection\nAUTH\nUVEG\n1.21\n0.95\n1.55\n19.06\n−5.13\n43.83\n\n\n\n1 Adjusted to: gender=Female, MEDAS_Score=6, bcm_t_score=0.15, smm=30, Site_Collection=AUTH\n\n\n2 Mean estimate of effect\n\n\n3 90% confidence interval of mean estimate\n\n\n\n\n\n\n\n\nFigure 30: Effects table (i.e. odds ratios) of clinical parameters on risk for the metabolic syndrome as captured by the MetS index. The % Change From Unity is an interesting way of viewing the results.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#some-aspects-of-the-forest-plot",
    "href": "modeling2.html#some-aspects-of-the-forest-plot",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "Some Aspects Of The Forest Plot",
    "text": "Some Aspects Of The Forest Plot\n\nGoal and Structure\n\nGoal: To determine how the change in a predictor variable’s value affects the odds of having a MetS Index \\(\\ge 58.67\\).\nOdds Ratio (OR): This is the key metric on the X-axis. An OR is a ratio of two odds: the odds of the event occurring at one level of the predictor versus the odds of the event occurring at a reference level.\n\nOR &gt; 1 (Red Bar): The variable increases the odds (risk) of the event.\nOR &lt; 1 (Green Bar): The variable decreases the odds (risk) of the event.\nOR = 1 (Vertical Line): The variable has no association with the odds of the event.\n\n\\(90\\%\\) Confidence Intervals (CI): The horizontal lines extending from the OR box represent the \\(90\\%\\) CI. If this interval does not cross the vertical line at \\(\\text{OR}=1\\), the association is considered statistically significant (at \\(\\alpha = 0.10\\)).\n\n\n\nKey Risk-Increasing Predictors (OR &gt; 1)\nVariables that significantly increase the odds of having a high MetS Index (red bars crossing the \\(\\text{OR}=1\\) line and extending to the right):\n\nHbA1c_Perc (\\(\\text{OR} = 2.01\\)): The strongest predictor, showing that higher long-term blood sugar control dramatically increases the odds of high MetS Index.\nSGPT (\\(\\text{OR} = 1.35\\)): Elevated levels of this liver enzyme (a marker of liver function/NAFLD) significantly increase the odds.\nSkeletal Muscle Mass (\\(\\text{OR} = 1.91\\)) and Glucose (\\(\\text{OR} = 1.43\\)): Consistent with HbA1c, higher levels of these measurements significantly increase the odds.\nwhr (\\(\\text{OR} = 1.33\\)): A higher Waist-to-Hip Ratio, a key measure of central obesity, strongly increases the odds.\nAntihypertensives (\\(\\text{OR} = 1.58\\)): Taking antihypertensive medication significantly increases the odds of a high MetS Index. This is a marker for the underlying condition of hypertension, a major component of Metabolic Syndrome, as illustrated in the box plot where the median MetS Index is higher for the “Yes” group.\nGender (Male) (\\(\\text{OR} = 1.47\\)): Being male significantly increases the odds of a high MetS Index compared to the reference gender (Female).\n\n\n\nKey Protective Predictors (OR &lt; 1)\nVariables that significantly decrease the odds of having a high MetS Index (green bars not crossing the \\(\\text{OR}=1\\) line):\n\nMEDAS_Score (\\(\\text{OR} = 0.86\\)): A higher Mediterranean Diet Adherence Score is associated with lower odds of a high MetS Index, highlighting a protective lifestyle factor.\nTBIL (\\(\\text{OR} = 0.77\\)): Total Bilirubin (TBIL) is associated with a protective effect, as it is a known antioxidant.\nRiboflavine (\\(\\text{OR} = 0.79\\)): Riboflavin (Vitamin B2) is significantly associated with lower odds.\nAnhydroglucitol (\\(\\text{OR} = 0.63\\)): A higher Anhydroglucitol concentration (i.e., less glucose competition in the kidneys) is protective against high MetS risk. Good glycemic control (high Anhydroglucitol) is associated with significantly lower odds of MetS risk.\n\n\n\nAcylcarnitine Interpretation\nAcylcarnitines which are biomarkers often linked to mitochondrial dysfunction in metabolic syndrome (MetS).\nHere is an explanation of their individual effects on the odds of having a high MetS Index (\\(\\text{MetS} \\ge 58.67\\)), based on the model’s OR estimates.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#partial-dependence-plots-pdps",
    "href": "modeling2.html#partial-dependence-plots-pdps",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "Partial Dependence Plots (PDPs)",
    "text": "Partial Dependence Plots (PDPs)\nA PDP will show how the predicted probability of the event (\\(\\text{MetS} \\ge 58.67\\)) changes as one specific variable changes, with all other variables held constant at the values listed in the model’s Adjusted to: caption. Here is the list of these values for each predictor in the model, where the median is used for continuous variables and the reference for categorical ones.\n\n\n[1] \"gender=Female  MEDAS_Score=6  Antihypertensives=No  Antidepressants=No  bcm_t_score=0.15  whr=0.99  smm=30  fatigue_index=87.25  Site_Collection=AUTH  SGPT=28  TBIL=0.54  Anhydroglucitol=97.16  Glucose=6857  Glutamine_To_Glutamic_Acid_Ratio=9.671  Propionylcarnitine=0.5859  Lauroylcarnitine=0.04275  Rivoflavine=1611  Uracil=2937  HIAA=1.233  Indole3Lactic_Acid=0.1824  Indole=0.878  Hippuric_Acid=447  P_Coumaric_Acid_Sulfate=0.03505  Dopamine=0.06525  Kynurenic_Acid=1.304  P_Coumaric_Acid=0.05905  P_HBA_Sulfate=3182  P_Hydroxyphenyl_Acetic_Acid=9.698 \"\n\n\nNote: PDPs can be constructed for any combination of these variables.\n \n\n\n\n\n\n\n\n\nFigure 31: PDP of % of Total Hemoglobin (mg/dL) in modeling the MetS index. Demonstrates the steep, continuous increase in the predicted probability of high MetS risk as long-term blood glucose control worsens (i.e., as HbA1c levels rise). See Figure 8 for comparison to the unadjusted case.\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nFigure 32: PDP of Anhydroglucitol (μM) in modeling the MetS index. Confirms the strong protective effect of high Anhydroglucitol levels (which signal good short-term glucose control). The predicted probability of MetS decreases sharply as Anhydroglucitol concentration increases. See Figure 11 for comparison to the unadjusted case.\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nFigure 33: PDP of Hippuric Acid (μg/mmol of creatinine) in modeling the MetS index. See Figure 18 for comparison to the unadjusted case.\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nFigure 34: PDP of Skeletal Muscle Mass in modeling the MetS index. See Figure 6 for comparison to the unadjusted case.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#added-value-of-metabolites",
    "href": "modeling2.html#added-value-of-metabolites",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "Added Value Of Metabolites",
    "text": "Added Value Of Metabolites\n\n\n\n\n\n\n\n\nApproximate Wald Statistics of the metabolites in the model. Response: Metabolic Syndrome Index\n\n\nFactor\nChi Square Statistic\nDegrees of Freedom\np-value1\n\n\n\n\nAnhydroglucitol\n11.0280\n2.0000\n0.0040**\n\n\nNonlinear\n1.7137\n1.0000\n0.1905\n\n\nGlucose\n4.1937\n2.0000\n0.1228\n\n\nNonlinear\n2.6733\n1.0000\n0.1020\n\n\nGlutamine_To_Glutamic_Acid_Ratio\n13.5271\n2.0000\n0.0012**\n\n\nNonlinear\n0.0418\n1.0000\n0.8380\n\n\nPropionylcarnitine\n4.1398\n2.0000\n0.1262\n\n\nNonlinear\n2.4394\n1.0000\n0.1183\n\n\nLauroylcarnitine\n0.2109\n2.0000\n0.8999\n\n\nNonlinear\n0.0960\n1.0000\n0.7567\n\n\nRivoflavine\n3.9156\n2.0000\n0.1412\n\n\nNonlinear\n3.5184\n1.0000\n0.0607\n\n\nUracil\n2.9481\n2.0000\n0.2290\n\n\nNonlinear\n2.2635\n1.0000\n0.1325\n\n\nHIAA\n7.3213\n2.0000\n0.0257*\n\n\nNonlinear\n7.2259\n1.0000\n0.0072**\n\n\nIndole3Lactic_Acid\n9.4809\n2.0000\n0.0087**\n\n\nNonlinear\n1.8097\n1.0000\n0.1785\n\n\nIndole\n0.5691\n2.0000\n0.7524\n\n\nNonlinear\n0.4296\n1.0000\n0.5122\n\n\nHippuric_Acid\n5.1009\n2.0000\n0.0780\n\n\nNonlinear\n2.4235\n1.0000\n0.1195\n\n\nP_Coumaric_Acid_Sulfate\n3.2177\n2.0000\n0.2001\n\n\nNonlinear\n0.0843\n1.0000\n0.7715\n\n\nDopamine\n0.6223\n2.0000\n0.7326\n\n\nNonlinear\n0.3720\n1.0000\n0.5419\n\n\nKynurenic_Acid\n4.3217\n2.0000\n0.1152\n\n\nNonlinear\n0.0324\n1.0000\n0.8573\n\n\nP_Coumaric_Acid\n0.0166\n2.0000\n0.9917\n\n\nNonlinear\n0.0139\n1.0000\n0.9060\n\n\nP_HBA_Sulfate\n0.0277\n2.0000\n0.9862\n\n\nNonlinear\n0.0275\n1.0000\n0.8683\n\n\nP_Hydroxyphenyl_Acetic_Acid\n0.3059\n2.0000\n0.8582\n\n\nNonlinear\n0.0020\n1.0000\n0.9643\n\n\nTOTAL NONLINEAR\n26.6730\n17.0000\n0.0630\n\n\nTOTAL\n141.8952\n34.0000\n0.0000***\n\n\n\n1 p&lt;0.05; p&lt;0.01; p&lt;0.001\n\n\n\n\n\n\n\n\nThe last entry in the table TOTAL indicates a significant contribution of the metabolites when added to the model.",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#model-changes-based-on-po",
    "href": "modeling2.html#model-changes-based-on-po",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "Model Changes Based On PO",
    "text": "Model Changes Based On PO",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "modeling2.html#model-changes-based-on-po-assumption",
    "href": "modeling2.html#model-changes-based-on-po-assumption",
    "title": "Modeling & Assessing Metabolite Added Value",
    "section": "Model Changes Based On PO Assumption",
    "text": "Model Changes Based On PO Assumption\nTO DO",
    "crumbs": [
      "Sections",
      "Modeling"
    ]
  },
  {
    "objectID": "metSyn_index_construction.html#interpretation-of-strictness-exponents-in-desirability-functions",
    "href": "metSyn_index_construction.html#interpretation-of-strictness-exponents-in-desirability-functions",
    "title": "Metabolic Syndrome Index Construction",
    "section": "",
    "text": "Exponent Value\nCurve Shape\nImplication for Penalty Assessment\nDM Preference\n\n\n\n\n\\(s=1\\) or \\(t=1\\)\nLinear\nProportional change in desirability with response value.\nNeutral or standard compromise.\n\n\n\\(s &gt; 1\\) or \\(t &gt; 1\\)\nConcave\nHigh desirability (near 1) is achieved only very close to the ideal point.\nExtreme sensitivity; heavily penalizes minor deviations from the ideal.\n\n\n\\(s &lt; 1\\) or \\(t &lt; 1\\)\nConvex\nDesirability increases quickly, allowing moderate performance to retain high \\(d_i\\).\nTolerance for variability; allows slight penalty for small deviations.",
    "crumbs": [
      "Sections",
      "Metabolic Syndrome Index Construction"
    ]
  },
  {
    "objectID": "metSyn_index_construction.html#table1-interpretation-of-strictness-exponents-in-desirability-functions",
    "href": "metSyn_index_construction.html#table1-interpretation-of-strictness-exponents-in-desirability-functions",
    "title": "Metabolic Syndrome Index Construction",
    "section": "",
    "text": "Exponent Value\nCurve Shape\nImplication for Penalty Assessment\nDM Preference\n\n\n\n\n\\(s=1\\) or \\(t=1\\)\nLinear\nProportional change in desirability with response value.\nNeutral or standard compromise.\n\n\n\\(s &gt; 1\\) or \\(t &gt; 1\\)\nConcave\nHigh desirability (near 1) is achieved only very close to the ideal point.\nExtreme sensitivity; heavily penalizes minor deviations from the ideal.\n\n\n\\(s &lt; 1\\) or \\(t &lt; 1\\)\nConvex\nDesirability increases quickly, allowing moderate performance to retain high \\(d_i\\).\nTolerance for variability; allows slight penalty for small deviations.",
    "crumbs": [
      "Sections",
      "Metabolic Syndrome Index Construction"
    ]
  }
]